

# WEST Search History

DATE: Tuesday, November 26, 2002

<u>Set Name</u> side by side	<u>Query</u>	<u>Hit Count</u>	<u>Set Name</u> result set
<i>DB=USPT,PGPB,JPAB,EPAB,DWPI; THES=ASSIGNEE; PLUR=YES; OP=ADJ</i>			
L4	allergy and L3	30	L4
L3	antagonist and L2	46	L3
L2	Chemokine and L1	66	L2
L1	tarc	212	L1

END OF SEARCH HISTORY

Welcome to STN International! Enter x:x

LOGINID:SSSPTA1648BQL

PASSWORD:

TERMINAL (ENTER 1, 2, 3, OR ?):2

\* \* \* \* \* Welcome to STN International \* \* \* \* \*

NEWS 1 Web Page URLs for STN Seminar Schedule - N. America  
NEWS 2 Apr 08 "Ask CAS" for self-help around the clock  
NEWS 3 Apr 09 BEILSTEIN: Reload and Implementation of a New Subject Area  
NEWS 4 Apr 09 ZDB will be removed from STN  
NEWS 5 Apr 19 US Patent Applications available in IFICDB, IFIPAT, and  
IFIUDB  
NEWS 6 Apr 22 Records from IP.com available in CAPLUS, HCAPLUS, and  
ZCAPLUS  
NEWS 7 Apr 22 BIOSIS Gene Names now available in TOXCENTER  
NEWS 8 Apr 22 Federal Research in Progress (FEDRIP) now available  
NEWS 9 Jun 03 New e-mail delivery for search results now available  
NEWS 10 Jun 10 MEDLINE Reload  
NEWS 11 Jun 10 PCTFULL has been reloaded  
NEWS 12 Jul 02 FOREGE no longer contains STANDARDS file segment  
NEWS 13 Jul 22 USAN to be reloaded July 28, 2002;  
saved answer sets no longer valid  
NEWS 14 Jul 29 Enhanced polymer searching in REGISTRY  
NEWS 15 Jul 30 NETFIRST to be removed from STN  
NEWS 16 Aug 08 CANCERLIT reload  
NEWS 17 Aug 08 PHARMAMarketLetter(PHARMAML) - new on STN  
NEWS 18 Aug 08 NTIS has been reloaded and enhanced  
NEWS 19 Aug 19 Aquatic Toxicity Information Retrieval (AQUIRE)  
now available on STN  
NEWS 20 Aug 19 IFIPAT, IFICDB, and IFIUDB have been reloaded  
NEWS 21 Aug 19 The MEDLINE file segment of TOXCENTER has been reloaded  
NEWS 22 Aug 26 Sequence searching in REGISTRY enhanced  
NEWS 23 Sep 03 JAPIO has been reloaded and enhanced  
NEWS 24 Sep 16 Experimental properties added to the REGISTRY file  
NEWS 25 Sep 16 Indexing added to some pre-1967 records in CA/CAPLUS  
NEWS 26 Sep 16 CA Section Thesaurus available in CAPLUS and CA  
NEWS 27 Oct 01 CASREACT Enriched with Reactions from 1907 to 1985  
NEWS 28 Oct 21 EVENTLINE has been reloaded  
NEWS 29 Oct 24 BEILSTEIN adds new search fields  
NEWS 30 Oct 24 Nutraceuticals International (NUTRACEUT) now available on  
STN  
NEWS 31 Oct 25 MEDLINE SDI run of October 8, 2002  
NEWS 32 Nov 18 DKILIT has been renamed APOLLIT  
  
NEWS EXPRESS October 14 CURRENT WINDOWS VERSION IS V6.01,  
CURRENT MACINTOSH VERSION IS V6.0a(ENG) AND V6.0Ja(JP),  
AND CURRENT DISCOVER FILE IS DATED 01 OCTOBER 2002  
NEWS HOURS STN Operating Hours Plus Help Desk Availability  
NEWS INTER General Internet Information  
NEWS LOGIN Welcome Banner and News Items  
NEWS PHONE Direct Dial and Telecommunication Network Access to STN  
NEWS WWW CAS World Wide Web Site (general information)

Enter NEWS followed by the item number or name to see news on that

specific topic.

All use of STN is subject to the provisions of the STN Customer agreement. Please note that this agreement limits use to scientific research. Use for software development or design or implementation of commercial gateways or other similar uses is prohibited and may result in loss of user privileges and other penalties.

\* \* \* \* \* STN Columbus \* \* \* \* \*

FILE 'HOME' ENTERED AT 13:43:34 ON 22 NOV 2002

=> file caplus biosis

COST IN U.S. DOLLARS

SINCE FILE

ENTRY

TOTAL

SESSION

FULL ESTIMATED COST

0.21

0.21

FILE 'CAPLUS' ENTERED AT 13:43:42 ON 22 NOV 2002

USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.

PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

COPYRIGHT (C) 2002 AMERICAN CHEMICAL SOCIETY (ACS)

FILE 'BIOSIS' ENTERED AT 13:43:42 ON 22 NOV 2002

COPYRIGHT (C) 2002 BIOLOGICAL ABSTRACTS INC.(R)

=> "macrophage derived chemokine"

L1 291 "MACROPHAGE DERIVED CHEMOKINE"

=> MDC or L1

L2 1118 MDC OR L1

=> antagonist and L1

L3 12 ANTAGONIST AND L1

=> antibody and L1

L4 59 ANTIBODY AND L1

=> "thymus and activation-regulated chemokine" or TARC

L5 369 "THYMUS AND ACTIVATION-REGULATED CHEMOKINE" OR TARC

=> chemokine (W) TARC

L6 179 CHEMOKINE (W) TARC

=> antagonist and L6

L7 9 ANTAGONIST AND L6

=> allergy and L3

L8 0 ALLERGY AND L3

=> treatment and L3

L9 1 TREATMENT AND L3

=> treatment and L4

L10 12 TREATMENT AND L4

=> treatment and L6

L11 26 TREATMENT AND L6

=> treatment and L7  
L12 1 TREATMENT AND L7

=> CCR4 and treatment  
L13 62 CCR4 AND TREATMENT

=> allergy and L13  
L14 7 ALLERGY AND L13

=> D L14 IBIB TI SO AU ABS 1-7

L14 ANSWER 1 OF 7 CAPLUS COPYRIGHT 2002 ACS

ACCESSION NUMBER: 2002:832576 CAPLUS

TITLE: **Treatment** of respiratory and lung diseases  
with antisense oligonucleotides and a bronchodilating  
agent

INVENTOR(S): Nyce, Jonathan W.; Li, Yukui; Sandrasagra, Anthony;  
Katz, Evan; Pabalan, Jonathan; Aguilar, Douglas;  
Miller, Shoreh; Tang, Lei; Shahabuddin, Syed

PATENT ASSIGNEE(S): Epigenesis Pharmaceuticals, Inc., USA

SOURCE: PCT Int. Appl., 764 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2002085309	A2	20021031	WO 2002-US13143	20020423
W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM			
RW:	GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG			

PRIORITY APPLN. INFO.: US 2001-286036P P 20010424

TI **Treatment** of respiratory and lung diseases with antisense  
oligonucleotides and a bronchodilating agent

SO PCT Int. Appl., 764 pp.

CODEN: PIXXD2

IN Nyce, Jonathan W.; Li, Yukui; Sandrasagra, Anthony; Katz, Evan; Pabalan,  
Jonathan; Aguilar, Douglas; Miller, Shoreh; Tang, Lei; Shahabuddin, Syed

AB This patent relates to a compn. comprising a carrier, oligonucleotides  
(oligos) that are antisense to adenosine receptors, and contain low amts.  
of or no adenosine (A), plus bronchodilating agents. All antisense  
oligonucleotides designed in accordance with the invention were highly  
effective at countering or reducing effects mediated by the receptors to  
which they are targeted. Two antisense phosphorothioated oligos  
targeting

human adenosine A1 receptor mRNA, one targeting adenosine A2b receptor,  
and two targeting an A3 receptor are capable of countering the effect of  
exogenously administered adenosine which is mediated by the specific  
receptor they are targeted to. The activity of the antisense oligos are  
specific to the target and substitutively fail to inhibit another target.

An oligonucleotide wherein the phosphodiester bonds are substituted with phosphorothioate bonds evidenced an unexpected superiority over the phosphodiester antisense oligo. In addn., they result in extremely low or non-existent deleterious side effects or toxicity. This represents 100% success in providing agents that are highly effective and specific in the **treatment** of bronchoconstriction and/or inflammation. These agents and the compn. and formulations provided are suitable for the **treatment** of respiratory tract, pulmonary and malignant diseases assocd. with bronchoconstriction, respiratory tract inflammation and **allergies**, impaired airways, including lung disease and diseases whose secondary effects afflict the lungs of a subject, such as **allergies**, asthma, impeded respiration, allergic rhinitis, pain, cystic fibrosis, pulmonary fibrosis, RDA, COPD, and cancers, among others.

The present agents and compn. may be administered preventatively, prophylactically or therapeutically in conjunction with other therapies, or may be utilized as a substitute for therapies that have significant, neg. side effects. The method of the present invention is also practiced with antisense oligonucleotides targeted to many genes, mRNAs and their corresponding proteins in essential the same manner.

L14 ANSWER 2 OF 7 CAPLUS COPYRIGHT 2002 ACS

ACCESSION NUMBER: 2002:832575 CAPLUS  
 TITLE: **Treatment** of respiratory and lung diseases with antisense oligonucleotides and a bronchodilating agent  
 INVENTOR(S): Nyce, Jonathan W.; Li, Yukui; Sandrasagra, Anthony; Katz, Evan; Pabalan, Jonathan; Aguilar, Douglas; Miller, Shoreh; Tang, Lei; Shahabuddin, Syed  
 PATENT ASSIGNEE(S): Epigenesis Pharmaceuticals, Inc., USA  
 SOURCE: PCT Int. Appl., 872 pp.  
 CODEN: PIXXD2  
 DOCUMENT TYPE: Patent  
 LANGUAGE: English  
 FAMILY ACC. NUM. COUNT: 4  
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2002085308	A2	20021031	WO 2002-US13135	20020423
W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM			
RW:	GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG			
WO 2002085308	A2	20021031	WO 2002-XA13135	20020423
W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM			
RW:	GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, CH,			

CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR,  
 BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG  
 WO 2002085308 A2 20021031 WO 2002-XB13135 20020423  
 W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN,  
 CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH,  
 GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR,  
 LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH,  
 PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ,  
 UA, UG, US, UZ, VN, YU, ZA, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU,  
 TJ, TM  
 RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, CH,  
 CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR,  
 BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG  
 WO 2002085308 A2 20021031 WO 2002-XC13135 20020423  
 W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN,  
 CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH,  
 GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR,  
 LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH,  
 PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ,  
 UA, UG, US, UZ, VN, YU, ZA, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU,  
 TJ, TM  
 RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, CH,  
 CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR,  
 BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG  
 PRIORITY APPLN. INFO.: US 2001-286137P P 20010424  
 WO 2002-US13135 A 20020423  
 TI **Treatment** of respiratory and lung diseases with antisense  
 oligonucleotides and a bronchodilating agent  
 SO PCT Int. Appl., 872 pp.  
 CODEN: PIXXD2  
 IN Nyce, Jonathan W.; Li, Yukui; Sandrasagra, Anthony; Katz, Evan; Pabalan,  
 Jonathan; Aguilar, Douglas; Miller, Shoreh; Tang, Lei; Shahabuddin, Syed  
 AB This patent relates to a compn. comprising a carrier, oligonucleotides  
 (oligos) that are antisense to adenosine receptors, and contain low amts.  
 of or no adenosine (A), plus bronchodilating agents. All antisense  
 oligonucleotides designed in accordance with the invention were highly  
 effective at countering or reducing effects mediated by the receptors to  
 which they are targeted. Two antisense phosphorothioated oligos  
 targeting  
 human adenosine A1 receptor mRNA, one targeting adenosine A2b receptor,  
 and two targeting an A3 receptor are capable of countering the effect of  
 exogenously administered adenosine which is mediated by the specific  
 receptor they are targeted to. The activity of the antisense oligos are  
 specific to the target and substitutively fail to inhibit another target.  
 An oligonucleotide wherein the phosphodiester bonds are substituted with  
 phosphorothioate bonds evidenced an unexpected superiority over the  
 phosphodiester antisense oligo. In addn., they result in extremely low  
 or  
 non-existent deleterious side effects or toxicity. This represents 100%  
 success in providing agents that are highly effective and specific in the  
**treatment** of bronchoconstriction and/or inflammation.  
**Treatment** with antisense oligonucleotides in combination with  
 anti-inflammatory steroid and/or ubiquinones is also provided. These  
 agents and the compn. and formulations provided are suitable for the  
**treatment** of respiratory tract, pulmonary and malignant diseases  
 assocd. with bronchoconstriction, respiratory tract inflammation and  
**allergies**, impaired airways, including lung disease and diseases  
 whose secondary effects afflict the lungs of a subject, such as  
**allergies**, asthma, impeded respiration, allergic rhinitis, pain,  
 cystic fibrosis, pulmonary fibrosis, RDA, COPD, and cancers, among  
 others.

The present agents and compn. may be administered preventatively, prophylactically or therapeutically in conjunction with other therapies, or may be utilized as a substitute for therapies that have significant, neg. side effects. The method of the present invention is also practiced with antisense oligonucleotides targeted to many genes, mRNAs and their corresponding proteins in essential the same manner.

L14 ANSWER 3 OF 7 CAPLUS COPYRIGHT 2002 ACS

ACCESSION NUMBER: 2000:756484 CAPLUS  
DOCUMENT NUMBER: 133:329593  
TITLE: Low adenosine anti-sense oligonucleotide, compositions, kit and method for **treatment** of airway disorders associated with bronchoconstriction, lung inflammation, **allergy**(ies) and surfactant depletion  
INVENTOR(S): Nyce, Jonathan W.  
PATENT ASSIGNEE(S): East Carolina University, USA  
SOURCE: PCT Int. Appl., 1592 pp.  
CODEN: PIXXD2  
DOCUMENT TYPE: Patent  
LANGUAGE: English  
FAMILY ACC. NUM. COUNT: 1  
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2000062736	A2	20001026	WO 2000-US8020	20000324
WO 2000062736	A3	20011011		
W: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: GH, GM, KE, LS, MW, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
BR 2000006019	A	20010313	BR 2000-6019	20000324
EP 1168919	A2	20020109	EP 2000-919668	20000324
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO				

PRIORITY APPLN. INFO.: US 1999-127958P P 19990406  
WO 2000-US8020 W 20000324

OTHER SOURCE(S): MARPAT 133:329593

TI Low adenosine anti-sense oligonucleotide, compositions, kit and method for

**treatment** of airway disorders associated with bronchoconstriction, lung inflammation, **allergy**(ies) and surfactant depletion

SO PCT Int. Appl., 1592 pp.

CODEN: PIXXD2

IN Nyce, Jonathan W.

AB An in vivo method of selectively delivering a nucleic acid to a target gene or mRNA, comprises the topical administration, e.g. to the respiratory system, of a subject of a therapeutic amt. of an oligonucleotide (oligo) that is antisense to the initiation codon region, the coding region, the 5' or 3' intron-exon junctions or regions within 2 to 10 nucleotides of the junctions of the gene or antisense to a mRNA complementary to the gene in an amt. effective to reach the target polynucleotide and reducing or inhibiting expression. In addn. a method of treating an adenosine-mediated effect comprises topically administering

to a subject an antisense oligo in an amt. effective to treat the respiratory, pulmonary, or airway disease. In order to minimize triggering adenosine receptors by their metab., the administered oligos have a low content of or are essentially free of adenosine. A pharmaceutical compn. and formulations comprise the oligo antisense to an adenosine receptor, genes and mRNAs encoding them, genomic and mRNA flanking regions, intron and exon borders and all regulatory and functionally related segments of the genes and mRNAs encoding the polypeptides, their salts and mixts. Various formulations contain a requisite carrier, and optionally other additives and biol. active agents.

The low-adenosine or adenosine-free (des-A) agent for practicing the method of the invention may be prepd. by selecting a target gene(s), genomic flanking region(s), RNA(s) and/or polypeptide(s) assocd. with a disease(s) or condition(s) afflicting lung airways, obtaining the sequence

of the mRNA(s) corresponding to the target gene(s) and/or genomic flanking

region(s), and/or RNAs encoding the target polypeptide(s), selecting at least one segment of the mRNA which may be up to 60 % free of thymidine (T) and synthesizing one or more anti-sense oligonucleotide(s) to the

mRNA

segments which are free of adenosine (A) by substituting a universal base for A when present in the oligonucleotide. The agent may be prepd. by selection of target nucleic acid sequences with GC running stretches, which have low T content, and by optionally replacing A in the antisense oligonucleotides with a "Universal or alternative base". The agent, compn. and formulations are used for prophylactic, preventive and therapeutic **treatment** of ailments assocd. with impaired respiration, lung **allergy**(ies) and/or inflammation and depletion lung surfactant or surfactant hypoprodn., such as pulmonary vasoconstriction, inflammation, **allergies**, allergic rhinitis, asthma, impeded respiration, lung pain, cystic fibrosis, bronchoconstriction. The present **treatment** is suitable for administration in combination with other **treatments**, e.g. before, during and after other **treatments**, including radiation, chemotherapy, antibody therapy and surgery, among others. Alternatively, the present agent is effectively administered prophylactically or therapeutically by itself for conditions without known therapies or as a substitute for therapies exhibiting undesirable side effects. The **treatment** of this invention may be administered directly into the respiratory system of a subject so that the agent has direct access to

the

lungs, or by other effective routes of administration, e.g. topically, transdermally, by implantation, etc., in an amt. effective to reduce or inhibit the symptoms of the ailment.

L14 ANSWER 4 OF 7 CAPLUS COPYRIGHT 2002 ACS

ACCESSION NUMBER: 2000:628006 CAPLUS

DOCUMENT NUMBER: 133:217723

TITLE: Method for validating/invalidating target(s) and pathways

INVENTOR(S): Nyce, Jonathan W.

PATENT ASSIGNEE(S): Epigenesis Pharmaceuticals, Inc., USA

SOURCE: PCT Int. Appl., 53 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:



PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2000051621	A1	20000908	WO 2000-US5643	20000302
W: AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM RW: GH, GM, KE, LS, MW, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
BR 2000009247	A	20011120	BR 2000-9247	20000302
EP 1165093	A1	20020102	EP 2000-913730	20000302
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO				
JP 2002537792	T2	20021112	JP 2000-602288	20000302
PRIORITY APPLN. INFO.:			US 1999-122950P	P 19990305
			WO 2000-US5643	W 20000302
OTHER SOURCE(S): MARPAT 133:217723				
TI	Method for validating/invalidating target(s) and pathways			
SO	PCT Int. Appl., 53 pp.			
	CODEN: PIXXD2			
IN	Nyce, Jonathan W.			
AB	<p>A method of detg. the existence of a correlation between a function of a disease or condition and a gene or mRNA encoding a target polypeptide suspected of being assocd. with a disease or condition, comprises obtaining oligonucleotides (oligos) consisting of up to about 15 % adenosine (A), preferably having no adenosine content, and which is anti-sense to a target selected from the group consisting of target genes and their corresponding mRNAs, genomic and mRNA flanking regions selected from the group consisting of 3' and 5' intron-exon borders and the juxta-section between coding and non-coding regions, and all mRNA segments encoding polypeptides assocd. with a pre-selected disease or condition; selecting amongst the oligos one that significantly inhibits or ablates expression of the polypeptide encoded by the mRNA upon in vitro hybridization to the target mRNA; administering to a subject an amt. of the selected oligo effective for in vivo hybridization to the target mRNA;</p> <p>and assessing a subject's function that is assocd. with the disease or condition before and after administration of the oligo; wherein a change in the function's value greater than about 70% indicates a pos. correlation, between about 40 and about 70% a possible correlation, and below about 30% a lack of correlation. The present method preferably administers the oligos in situ where the target is located, e.g. into the subject's respiration when validating targets assocd. with malignant and other pulmonary and respiratory functions, so that the agent has direct access to the lungs. Alternatively, such desAdenosine oligos may be delivered directly to the CNS or other organs, tissues and organ systems, by known delivery formulations. This invention provides a rapid, reliable method for drug target validation/invalidation in various biol. systems that utilize proprietary low or desAdenosine antisense oligonucleotides. Using desAdenosine antisense oligonucleotides, the present method may validate/invalidate potential gene targets with a level of speed and accuracy that has heretofore been impossible using traditional techniques.</p> <p>The use of antisense oligonucleotides to target adenosine receptors is</p>			

described. Adenosine A1 receptor antisense oligonucleotides had bronchodilator activity in rabbits and adenosine A3 receptor antisense oligonucleotides had anti-inflammatory activity in asthmatic rabbits.

REFERENCE COUNT: 3 THERE ARE 3 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE

# FORMAT

L14 ANSWER 5 OF 7 CAPLUS COPYRIGHT 2002 ACS

ACCESSION NUMBER: 1999:223049 CAPLUS  
DOCUMENT NUMBER: 130:251233  
TITLE: Macrophage-derived chemokine (MDC), MDC analogs, MDC inhibitor substances, and their therapeutic applications  
INVENTOR(S): Gray, Patrick W.; Chantry, David H.; Deeley, Michael C.; Raport, Carol J.; Godiska, Ronald  
PATENT ASSIGNEE(S): Icos Corporation, USA  
SOURCE: PCT Int. Appl., 159 pp.  
CODEN: PIXXD2  
DOCUMENT TYPE: Patent  
LANGUAGE: English  
FAMILY ACC. NUM. COUNT: 3  
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9915666	A2	19990401	WO 1998-US20270	19980928
WO 9915666	A3	19990916		
W: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, US, US, US, US, US, UZ, VN, YU, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: GH, GM, KE, LS, MW, SD, SZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
CN 1163635	A	19971029	CN 1996-190875	19960607
US 5932703	A	19990803	US 1996-660542	19960607
CA 2302806	AA	19990401	CA 1998-2302806	19980928
AU 9897778	A1	19990412	AU 1998-97778	19980928
EP 1017818	A2	20000712	EP 1998-951961	19980928
R: AT, BE, CH, DE, ES, FR, GB, IT, LI, SE, IE				
PRIORITY APPLN. INFO.:			US 1995-479620	A2 19950607
			US 1995-558658	A2 19951116
			US 1996-660542	A2 19960607
			US 1997-939107	A2 19970926
			US 1998-67447	A2 19980428
			WO 1998-US20270	W 19980928
TI	Macrophage-derived chemokine (MDC), MDC analogs, MDC inhibitor substances, and their therapeutic applications			
SO	PCT Int. Appl., 159 pp. CODEN: PIXXD2			
IN	Gray, Patrick W.; Chantry, David H.; Deeley, Michael C.; Raport, Carol J.; Godiska, Ronald			
AB	The present invention provides purified and isolated polynucleotide sequences encoding a novel macrophage-derived C-C chemokine designated "Macrophage Derived Chemokine" (MDC), and polypeptide fragments and analogs thereof. MDC cDNA sequences and their deduced amino acid sequences are provided from human, mouse, rat, and macaque. Also provided			

are materials and methods for the recombinant or synthetic prodn. of the chemokine, fragments, and analogs; and purified and isolated chemokine protein, and polypeptide fragments and analogs thereof. Also provided are antibodies reactive with the chemokine and methods of making and using all of the foregoing. Also provided are assays for identifying modulators of MDC chemokine activity. MDC possesses antiproliferative activity against HIV-1 virus, stimulates fibroblast proliferation, inhibits tumor growth, induces chemotaxis of TH2 helper T cells, and modulates platelet aggregation, and is shown to be a high-affinity ligand for **CCR4**.

L14 ANSWER 6 OF 7 CAPLUS COPYRIGHT 2002 ACS

ACCESSION NUMBER: 1999:219995 CAPLUS

DOCUMENT NUMBER: 130:306599

TITLE: Antisense oligonucleotides capable of binding to multiple targets and their use in the **treatment** of respiratory disease

INVENTOR(S): Nyce, Jonathan W.

PATENT ASSIGNEE(S): East Carolina University, USA

SOURCE: PCT Int. Appl., 120 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 2

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9913886	A1	19990325	WO 1998-US19419	19980917
W: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, GH, GM, HR, HU, ID, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: GH, GM, KE, LS, MW, SD, SZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
CA 2304312	AA	19990325	CA 1998-2304312	19980917
AU 9893951	A1	19990405	AU 1998-93951	19980917
AU 752531	B2	20020919		
EP 1019065	A1	20000719	EP 1998-947089	19980917
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, PT, IE,				
FI				
BR 9812650	A	20000822	BR 1998-12650	19980917
PRIORITY APPLN. INFO.:			US 1997-59160P	P 19970917
			US 1998-93972	A 19980609
			WO 1998-US19419	W 19980917
TI	Antisense oligonucleotides capable of binding to multiple targets and their use in the <b>treatment</b> of respiratory disease			
SO	PCT Int. Appl., 120 pp.			
	CODEN: PIXXD2			
IN	Nyce, Jonathan W.			
AB	Antisense oligonucleotides carrying sequences that will allow them to bind			

to more than one mRNA in a target cell are described. Such oligonucleotides can be used as a single **treatment** for diseases having more than one contributing pathway. In particular, oligonucleotides effective against genes involved in the etiol. of respiratory disease are targeted. Preferably, the oligonucleotides are

low in adenosine (<15%) and may have adenosines substituted with analogs. These oligonucleotides are targeted to high (G+C) sequences within mRNAs. Thus, phosphorothioate antisense oligonucleotide (HAdA1AS, 5'-gatggagggcgccatggcggg-3') designed for the adenosine A1 receptor is provided. HAdA1AS significantly and specifically reduces the in vivo response to adenosine challenge in a dose-dependent manner, is effective in protection against aeroallergen-induced bronchoconstriction (house dust mite), has an unexpected long-term duration of effect (8.3 days for both PC50 adenosine and resistance), and is free of side effects that might be toxic to the recipient. Such oligonucleotides may be used for treating a disease or condition assocd. with lung airway, such as bronchoconstriction, inflammation, or **allergies**.

REFERENCE COUNT: 2 THERE ARE 2 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE

FORMAT

L14 ANSWER 7 OF 7 BIOSIS COPYRIGHT 2002 BIOLOGICAL ABSTRACTS INC.

ACCESSION NUMBER: 2002:449998 BIOSIS

DOCUMENT NUMBER: PREV200200449998

TITLE: IFN-gamma-inducible expression of thymus and activation-regulated chemokine/CCL17 and

macrophage-derived

chemokine/CCL22 in epidermal keratinocytes and their roles in atopic dermatitis.

AUTHOR(S): Horikawa, Tatsuya; Nakayama, Takashi; Hikita, Ichiro; Yamada, Hidekazu; Fujisawa, Ryuichi; Bito, Toshinori; Harada, Susumu; Fukunaga, Atsushi; Chantry, David; Gray, Patrick W.; Morita, Atsushi; Suzuki, Ryuji; Tezuka, Tadashi; Ichihashi, Masamitsu; Yoshie, Osamu (1)

CORPORATE SOURCE: (1) Department of Microbiology, Kinki University School of Medicine, Osaka, 589-8511: o.yoshie@med.kindai.ac.jp Japan

SOURCE: International Immunology, (July, 2002) Vol. 14, No. 7, pp. 767-773. <http://www.intimm.oupjournals.org>. print. ISSN: 0953-8178.

DOCUMENT TYPE: Article

LANGUAGE: English

TI IFN-gamma-inducible expression of thymus and activation-regulated chemokine/CCL17 and macrophage-derived chemokine/CCL22 in epidermal keratinocytes and their roles in atopic dermatitis.

SO International Immunology, (July, 2002) Vol. 14, No. 7, pp. 767-773. <http://www.intimm.oupjournals.org>. print. ISSN: 0953-8178.

AU Horikawa, Tatsuya; Nakayama, Takashi; Hikita, Ichiro; Yamada, Hidekazu; Fujisawa, Ryuichi; Bito, Toshinori; Harada, Susumu; Fukunaga, Atsushi; Chantry, David; Gray, Patrick W.; Morita, Atsushi; Suzuki, Ryuji; Tezuka, Tadashi; Ichihashi, Masamitsu; Yoshie, Osamu (1)

AB Thymus and activation-regulated chemokine (TARC)/CCL17 and macrophage-derived chemokine (MDC)/CCL22 are a pair of CC chemokines known

to selectively attract Th2 type memory T cells via CCR4. Here we examined circulating levels of TARC and MDC in patients with atopic dermatitis (AD) and control subjects by using plasma samples, which reflect blood contents of chemokines more accurately than serum samples. The plasma levels of TARC and MDC were significantly elevated in AD patients. These values also strongly correlated with disease severity and serum lactate dehydrogenase levels, and weakly correlated with serum

total IgE levels and blood eosinophilia. Previous studies demonstrated TARC immunoreactivity in the epidermal layer of AD lesional skin and production

of TARC by a human keratinocytic cell line HaCaT upon stimulation with IFN-gamma. Here we demonstrated MDC immunoreactivity in the epidermal layer of AD skin at levels stronger than that of TARC. Furthermore, primary epidermal keratinocytes expressed both TARC and MDC mRNA upon stimulation with IFN-gamma, but efficiently secreted only MDC. These results suggest a post-transcriptional regulation in TARC production. IFN-gamma also induced TARC and MDC mRNA in mouse skin. Collectively, both TARC and MDC play important roles in the local accumulation of Th2 cells in AD lesional skin. Production of Th2-attracting chemokines by epidermal keratinocytes upon **treatment** with IFN-gamma, which is also the potent inducer of Th1-attracting chemokines, may underline the pivotal role of IFN-gamma in the chronic phase of AD where both Th1 and Th2 responses are mixed.

=> D L12 IBIB TI SO AU ABS 1-12

L12 ANSWER 1 OF 1 CAPLUS COPYRIGHT 2002 ACS

ACCESSION NUMBER: 2002:57331 CAPLUS

DOCUMENT NUMBER: 136:319540

TITLE: Gene profiling reveals unknown enhancing and suppressive actions of glucocorticoids on immune cells

AUTHOR(S): Galon, Jerome; Franchimont, Denis; Hiroi, Naoki; Frey, Gregory; Boettner, Antje; Ehrhart-Bornstein, Monika; O'Shea, John J.; Chrousos, George P.; Bornstein, Stefan R.

CORPORATE SOURCE: Lymphocyte Cell Biology Section, NIAMS, National Institutes of Health, Bethesda, MD, 20892, USA

SOURCE: FASEB Journal (2002), 16(1), 61-71

CODEN: FAJOEC; ISSN: 0892-6638

PUBLISHER: Federation of American Societies for Experimental Biology

DOCUMENT TYPE: Journal

LANGUAGE: English

TI Gene profiling reveals unknown enhancing and suppressive actions of glucocorticoids on immune cells

SO FASEB Journal (2002), 16(1), 61-71

CODEN: FAJOEC; ISSN: 0892-6638

AU Galon, Jerome; Franchimont, Denis; Hiroi, Naoki; Frey, Gregory; Boettner, Antje; Ehrhart-Bornstein, Monika; O'Shea, John J.; Chrousos, George P.; Bornstein, Stefan R.

AB Glucocorticoids continue to be the major immunomodulatory agents used in clin. medicine today. However, their actions as anti-inflammatory and immunosuppressive drugs are both beneficial and deleterious. We analyzed the effect of glucocorticoids on the gene expression profile of peripheral

blood mononuclear cells from healthy donors. DNA microarray anal. combined with quant. TaqMan PCR and flow cytometry revealed that glucocorticoids induced the expression of chemokine, cytokine, and complement family members as well as of newly discovered innate immune-related genes, including scavenger and Toll-like receptors. In contrast, glucocorticoids repressed the expression of adaptive immune-related genes. Simultaneous inhibitory and stimulatory effects of glucocorticoids were found on inflammatory T helper subsets and apoptosis-related gene clusters. In cells activated by T cell receptor crosslinking, glucocorticoids down-regulated the expression of specific genes that were previously up-regulated in resting cells, suggesting a

potential new mechanism by which they exert pos. and neg. effects.  
Considering the broad and continuously renewed interest in glucocorticoid therapy, the profiles we describe here will be useful in designing more specific and efficient **treatment** strategies.

REFERENCE COUNT: 42 THERE ARE 42 CITED REFERENCES AVAILABLE FOR THIS

FORMAT RECORD. ALL CITATIONS AVAILABLE IN THE RE

=> D L10 IBIB TI SO AU ABS all

L10 ANSWER 1 OF 12 CAPLUS COPYRIGHT 2002 ACS

ACCESSION NUMBER: 2002:393356 CAPLUS

DOCUMENT NUMBER: 137:31858

TITLE: Pivotal role of dendritic cell-derived CXCL10 in the retention of T helper cell 1 lymphocytes in secondary lymph nodes

AUTHOR(S): Yoneyama, Hiroyuki; Narumi, Shosaku; Zhang, Yanyun; Murai, Masako; Baggiolini, Marco; Lanzavecchia, Antonio; Ichida, Takafumi; Asakura, Hitoshi; Matsushima, Kouji

CORPORATE SOURCE: Department of Molecular Preventive Medicine, School of

and Medicine and Core Research and Evolutional Science

Technology (CREST), The University of Tokyo, Tokyo, 113-0033, Japan

SOURCE: Journal of Experimental Medicine (2002), 195(10), 1257-1266

CODEN: JEMEAV; ISSN: 0022-1007

PUBLISHER: Rockefeller University Press

DOCUMENT TYPE: Journal

LANGUAGE: English

TI Pivotal role of dendritic cell-derived CXCL10 in the retention of T helper

cell 1 lymphocytes in secondary lymph nodes

SO Journal of Experimental Medicine (2002), 195(10), 1257-1266

CODEN: JEMEAV; ISSN: 0022-1007

AU Yoneyama, Hiroyuki; Narumi, Shosaku; Zhang, Yanyun; Murai, Masako; Baggiolini, Marco; Lanzavecchia, Antonio; Ichida, Takafumi; Asakura, Hitoshi; Matsushima, Kouji

AB Various immune diseases are considered to be regulated by the balance of T

helper (Th)1 and Th2 subsets. Although Th lymphocytes are believed to be generated in draining lymph nodes (LNs), in vivo Th cell behaviors during Th1/Th2 polarization are largely unexplored. Using a murine

granulomatous

liver disease model induced by Propionibacterium acnes, the authors show that retention of Th1 cells in the LNs is controlled by a chemokine, CXCL10/interferon (IFN) inducible protein 10 produced by mature dendritic cells (DCs). Hepatic LN DCs preferentially produced CXCL10 to attract 5'-bromo-2'-deoxyuridine (BrdU)+CD4+ T cells and form clusters with IFN- $\gamma$ -producing CD4+ T cells by day 7 after antigen challenge. Blockade of CXCL10 dramatically altered the distribution of cluster-forming BrdU+CD4+ T cells. BrdU+CD4+ T cells in the hepatic LNs were selectively diminished while those in the circulation were significantly increased by **treatment** with anti-CXCL10 monoclonal **antibody**. This was accompanied by accelerated infiltration of memory T cells into the periphery of hepatic granuloma sites, most of

them

were in cell cycle and further produced higher amt. of IFN-.gamma.  
leading  
to exacerbation of liver injury. Thus, mature DC-derived CXCL10 is pivotal to retain Th1 lymphocytes within T cell areas of draining LNs and optimize the Th1-mediated immune responses.

AN 2002:393356 CAPLUS  
DN 137:31858  
TI Pivotal role of dendritic cell-derived CXCL10 in the retention of T helper cell 1 lymphocytes in secondary lymph nodes

AU Yoneyama, Hiroyuki; Narumi, Shosaku; Zhang, Yanyun; Murai, Masako; Baggiolini, Marco; Lanzavecchia, Antonio; Ichida, Takafumi; Asakura, Hitoshi; Matsushima, Kouji  
CS Department of Molecular Preventive Medicine, School of Medicine and Core Research and Evolutional Science and Technology (CREST), The University of Tokyo, Tokyo, 113-0033, Japan  
SO Journal of Experimental Medicine (2002), 195(10), 1257-1266  
CODEN: JEMEAV; ISSN: 0022-1007  
PB Rockefeller University Press  
DT Journal  
LA English  
CC 15-5 (Immunochemistry)  
Section cross-reference(s): 14

AB Various immune diseases are considered to be regulated by the balance of T helper (Th)1 and Th2 subsets. Although Th lymphocytes are believed to be generated in draining lymph nodes (LNs), in vivo Th cell behaviors during Th1/Th2 polarization are largely unexplored. Using a murine granulomatous liver disease model induced by Propionibacterium acnes, the authors show that retention of Th1 cells in the LNs is controlled by a chemokine, CXCL10/interferon (IFN) inducible protein 10 produced by mature dendritic cells (DCs). Hepatic LN DCs preferentially produced CXCL10 to attract 5'-bromo-2'-deoxyuridine (BrdU)+CD4+ T cells and form clusters with IFN-.gamma.-producing CD4+ T cells by day 7 after antigen challenge. Blockade of CXCL10 dramatically altered the distribution of cluster-forming BrdU+CD4+ T cells. BrdU+CD4+ T cells in the hepatic LNs were selectively diminished while those in the circulation were significantly increased by **treatment** with anti-CXCL10 monoclonal **antibody**. This was accompanied by accelerated infiltration of memory T cells into the periphery of hepatic granuloma sites, most of them

were in cell cycle and further produced higher amt. of IFN-.gamma.  
leading  
to exacerbation of liver injury. Thus, mature DC-derived CXCL10 is pivotal to retain Th1 lymphocytes within T cell areas of draining LNs and optimize the Th1-mediated immune responses.

ST dendritic cell CXCL10 Th1 lymphocyte lymph node  
IT Chemokine receptors  
RL: BSU (Biological study, unclassified); BIOL (Biological study)  
(CXCR3; expression by paracortical T-cells in relation to chemotactic retention response to dendritic cell-derived CXCL10)

IT Chemokines  
RL: BSU (Biological study, unclassified); BIOL (Biological study)  
(MDC (**macrophage-derived chemokine**);  
expression by hepatic lymph node dendritic cells in relation to retention of CD4+ T-cells)

IT Cell migration  
(T cell infiltration; of Propionibacterium acnes-induced granuloma is

regulated by CXCL10 of secondary lymph node dendritic cells)

IT Dendritic cell  
(dendritic cell-derived CXCL10 mediates retention of Th1 cells in secondary lymph nodes)

IT Sarcoidosis  
(dendritic cell-derived CXCL10 mediates retention of Th1 cells in secondary lymph nodes in Propionibacterium acnes-induced granuloma in relation to)

IT Propionibacterium acnes  
(dendritic cell-derived CXCL10 mediates retention of Th1 cells in secondary lymph nodes in response to)

IT Liver, disease  
(granuloma; dendritic cell-derived CXCL10 mediates retention of Th1 cells in secondary lymph nodes in)

IT T cell (lymphocyte)  
(helper cell/inducer, TH1; dendritic cell-derived CXCL10 mediates retention of Th1 cells in secondary lymph nodes)

IT Lymph node  
(hepatic; dendritic cell-derived CXCL10 mediates retention of Th1 cells in)

IT T cell (lymphocyte)  
(infiltration; of Propionibacterium acnes-induced granuloma is regulated by CXCL10 of secondary lymph node dendritic cells)

IT Liver, disease  
(injury; dendritic cell-derived CXCL10 mediates retention of Th1 cells in secondary lymph nodes in relation to memory T-cell role in)

IT Chemokines  
RL: BSU (Biological study, unclassified); BIOL (Biological study)  
(interferon-inducible protein-10; dendritic cell-derived CXCL10 mediates retention of Th1 cells in secondary lymph nodes)

IT T cell (lymphocyte)  
(memory; infiltration of Propionibacterium acnes-induced granuloma is regulated by CXCL10 of secondary lymph node dendritic cells)

RE.CNT 39 THERE ARE 39 CITED REFERENCES AVAILABLE FOR THIS RECORD

RE

- (1) Banchereau, J; Nature 1998, V392, P245 CAPLUS
- (2) Breitfield, D; J Exp Med 2000, V192, P1545
- (3) Butcher, E; Science 1996, V272, P60 CAPLUS
- (4) Cyster, J; Science 1999, V286, P2098 CAPLUS
- (5) Forster, R; Cell 1999, V99, P23 CAPLUS
- (6) Garside, P; Science 1998, V281, P96 CAPLUS
- (7) Grogan, J; Immunity 2001, V14, P205 CAPLUS
- (8) Gunzer, M; Immunity 2000, V13, P323 CAPLUS
- (9) Hancock, W; J Exp Med 2000, V192, P1515 CAPLUS
- (10) Hancock, W; J Exp Med 2001, V193, P975 CAPLUS
- (11) Hashimoto, S; Blood 1999, V94, P845 CAPLUS
- (12) Iezzi, G; J Exp Med 2001, V193, P987 CAPLUS
- (13) Ingulli, E; J Exp Med 1997, V185, P2133 CAPLUS
- (14) Ishige, I; Lancet 1999, V354, P120 CAPLUS
- (15) Itakura, M; J Immunol 2001, V166, P2071 CAPLUS
- (16) Kedl, R; J Exp Med 2000, V192, P1105 CAPLUS
- (17) Khan, I; Immunity 2000, V12, P483 CAPLUS
- (18) Kourilsky, P; Trends Immunol 2001, V22, P502 CAPLUS
- (19) Kudo, S; J Exp Med 1997, V185, P777 CAPLUS
- (20) Lanenkamp, A; Nat Immunol 2000, V1, P311
- (21) Lanzavecchia, A; Science 2000, V290, P92 CAPLUS
- (22) Liu, M; J Immunol 2000, V165, P2327 CAPLUS
- (23) Luther, S; Nat Immunol 2001, V2, P102 CAPLUS
- (24) Narumi, S; Cytokine 2000, V12, P1007 CAPLUS



- (25) Narumi, S; J Leukoc Biol 1992, V52, P27 CAPLUS
- (26) Randolph, D; Science 1999, V286, P2159 CAPLUS
- (27) Reinhardt, R; Nature 2001, V410, P101 CAPLUS
- (28) Sallusto, F; Eur J Immunol 1999, V29, P1617 CAPLUS
- (29) Suriki, H; Clin Immunol 2000, V97, P33 CAPLUS
- (30) Tamaru, M; Biochem Biophys Res Commun 1998, V251, P41 CAPLUS
- (31) Tamaru, M; Cytokine 2000, V12, P299 CAPLUS
- (32) Tang, H; Science 1999, V284, P819 CAPLUS
- (33) Ushiki, T; Anat Rec 1995, V241, P113 MEDLINE
- (34) Vanbervliet, B; Eur J Immunol 2002, V32, P231 CAPLUS
- (35) Westermann, J; Immunol Today 1996, V17, P278 CAPLUS
- (36) Wu, M; J Immunol 2001, V167, P4791 CAPLUS
- (37) Yoneyama, H; J Clin Invest 1998, V102, P1933 CAPLUS
- (38) Yoneyama, H; J Exp Med 2001, V193, P35 CAPLUS
- (39) Yoneyama, H; Springer Semin Immunopathol 2000, V22, P329 CAPLUS

=> D L10 IBIB TI SO AU ABS 2-12

L10 ANSWER 2 OF 12 CAPLUS COPYRIGHT 2002 ACS

ACCESSION NUMBER: 2002:291218 CAPLUS

DOCUMENT NUMBER: 136:384549

TITLE: Multiplexed protein profiling on microarrays by rolling-circle amplification

AUTHOR(S): Schweitzer, Barry; Roberts, Scott; Grimwade, Brian; Shao, Weiping; Wang, Minjuan; Fu, Qin; Shu, Quiping; Laroche, Isabelle; Zhou, Zhimin; Tchernev, Velizar

T.; Christiansen, Jason; Velleca, Mark; Kingsmore, Stephen F.

CORPORATE SOURCE: Molecular Staging, Inc., New Haven, CT, 06511, USA

SOURCE: Nature Biotechnology (2002), 20(4), 359-365

CODEN: NABIF9; ISSN: 1087-0156

PUBLISHER: Nature America Inc.

DOCUMENT TYPE: Journal

LANGUAGE: English

TI Multiplexed protein profiling on microarrays by rolling-circle amplification

SO Nature Biotechnology (2002), 20(4), 359-365

CODEN: NABIF9; ISSN: 1087-0156

AU Schweitzer, Barry; Roberts, Scott; Grimwade, Brian; Shao, Weiping; Wang, Minjuan; Fu, Qin; Shu, Quiping; Laroche, Isabelle; Zhou, Zhimin; Tchernev,

Velizar T.; Christiansen, Jason; Velleca, Mark; Kingsmore, Stephen F.

AB Fluorescent-sandwich immunoassays on microarrays hold appeal for proteomics studies, because equipment and **antibodies** are readily available, and assays are simple, scalable, and reproducible. The achievement of adequate sensitivity and specificity, however, requires a general method of immunoassay amplification. We describe coupling of isothermal rolling-circle amplification (RCA) to universal **antibodies** for this purpose. A total of 75 cytokines were measured simultaneously on glass arrays with signal amplification by RCA with high specificity, femtomolar sensitivity, 3 log quant. range, and economy of sample consumption. A 51-feature RCA cytokine glass array was used to measure secretion from human dendritic cells (DCs) induced by lipopolysaccharide (LPS) or tumor necrosis factor-.alpha. (TNF-.alpha.). As expected, LPS induced rapid secretion of inflammatory cytokines such

as macrophage inflammatory protein (MIP)-1 .beta., interleukin (IL)-8, and

interferon- inducible protein (IP)-10. We found that eotaxin-2 and 1-309 were induced by LPS; in addn., **macrophage- derived chemokine** (MDC), thymus and activation-regulated chemokine (TARC), sol. interleukin 6 receptor (sIL-6R), and sol. tumor necrosis factor receptor I (sTNF-RI) were induced by TNF-.alpha. **treatment**. Because microarrays can accommodate .apprx.1,000 sandwich immunoassays of this type, a relatively small no. of RCA microarrays seem to offer a tractable approach for proteomic surveys.

REFERENCE COUNT: 52 THERE ARE 52 CITED REFERENCES AVAILABLE FOR THIS

RECORD. ALL CITATIONS AVAILABLE IN THE RE

FORMAT

L10 ANSWER 3 OF 12 CAPLUS COPYRIGHT 2002 ACS

ACCESSION NUMBER: 2002:220660 CAPLUS

DOCUMENT NUMBER: 136:246391

TITLE: Fusion proteins comprising defensin and human tumor antigen or viral antigen for treating cancer and

viral

infection

INVENTOR(S): Kwak, Larry W.; Biragyn, Arya

PATENT ASSIGNEE(S): United States of America, Department of Health and Human Services, USA

SOURCE: PCT Int. Appl., 154 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2002022686	A2	20020321	WO 2001-US29074	20010917
W:			AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM	
RW:			GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG	
AU 2001091049	A5	20020326	AU 2001-91049	20010917
PRIORITY APPLN. INFO.:			US 2000-233074P	P 20000915
			WO 2001-US29074	W 20010917
TI			Fusion proteins comprising defensin and human tumor antigen or viral antigen for treating cancer and viral infection	
SO			PCT Int. Appl., 154 pp. CODEN: PIXXD2	
IN			Kwak, Larry W.; Biragyn, Arya	
AB			The present invention relates to a vaccine for increasing the immunogenicity of a tumor antigen thus allowing <b>treatment</b> of cancer, as well as a vaccine that increases the immunogenicity of a viral antigen, thus allowing <b>treatment</b> of viral infection, including immunodeficiency virus (HIV) infection. In particular, the present invention provides a fusion protein comprising a defensin fused to either a tumor antigen or viral antigen which is administered as either a protein or nucleic acid vaccine to elicit an immune response effective in treating	

cancer or effective in treating or preventing viral infection. The defensin is human .beta.-defensin 1, human .beta.-defensin 2, human neutrophil peptide 1 (HNP-1), HNP-2, HNP-3, murine .beta.-defensin 2, murine .beta.-defensin 3, etc.; the tumor antigen is B cell lymphoma antigen, MUC-1, etc.; and the viral antigen is HIV-1 gp120, gp160, gp41, etc. The fusion proteins may also comprise immunostimulatory cytokine or chemokine.

L10 ANSWER 4 OF 12 CAPLUS COPYRIGHT 2002 ACS

ACCESSION NUMBER: 2002:54705 CAPLUS

DOCUMENT NUMBER: 136:230952

TITLE: MCP-1 causes leukocyte recruitment and subsequently endotoxemic ileus in rat

AUTHOR(S): Turler, Andreas; Schwarz, Nicolas T.; Turler, Esther; Kalff, Jorg C.; Bauer, Anthony J.

CORPORATE SOURCE: Department of Medicine, Division of Gastroenterology, University of Pittsburgh Medical Center, Pittsburgh, PA, 15261, USA

SOURCE: American Journal of Physiology (2002), 282(1, Pt. 1), G145-G155

CODEN: AJPHAP; ISSN: 0002-9513

PUBLISHER: American Physiological Society

DOCUMENT TYPE: Journal

LANGUAGE: English

TI MCP-1 causes leukocyte recruitment and subsequently endotoxemic ileus in rat

SO American Journal of Physiology (2002), 282(1, Pt. 1), G145-G155

CODEN: AJPHAP; ISSN: 0002-9513

AU Turler, Andreas; Schwarz, Nicolas T.; Turler, Esther; Kalff, Jorg C.; Bauer, Anthony J.

AB Endotoxemia causes an inflammatory response within the intestinal muscularis and gastrointestinal dysmotility. We hypothesize that the resident **macrophage-derived chemokine**

monocyte chemoattractant protein-1 (MCP-1) plays a significant role in

the recruitment of leukocytes into the lipopolysaccharide (LPS)-stimulated

rat

intestinal muscularis. MCP-1 mRNA expression was investigated by RT-PCR. Leukocyte extravasation and MCP-1 protein localization were detd. by immunohistochem. Contractile activity was assessed by using a std. organ bath in rats that were treated with saline, recombinant MCP-1, LPS, LPS + nonspecific **antibody**, or LPS + MCP-1 **antibody**.

Endotoxemia caused a significant 280-fold increase in MCP-1 mRNA expression in the muscularis, peaking at 3 h. MCP-1 protein was immunohistochem. located to muscularis macrophages. LPS application caused significant leukocyte recruitment into the muscularis and a 51% decrease in muscle contractility. MCP-1 **antibody**

**treatment** significantly averted leukocyte recruitment and significantly prevented muscle dysfunction. These parameters were not significantly altered by the nonspecific **antibody**. Results show that resident muscularis macrophage-derived MCP-1 plays a major role in the recruitment of monocytes during endotoxemia, which then subsequently secrete kinetically active substances that cause ileus.

REFERENCE COUNT: 57 THERE ARE 57 CITED REFERENCES AVAILABLE FOR THIS

RECORD. ALL CITATIONS AVAILABLE IN THE RE

FORMAT

L10 ANSWER 5 OF 12 CAPLUS COPYRIGHT 2002 ACS

ACCESSION NUMBER: 2001:489619 CAPLUS

DOCUMENT NUMBER: 135:71268  
 TITLE: Use of locked nucleic acid-modified oligonucleotides for **treatment** of cancer and inflammation  
 INVENTOR(S): Orum, Henrik; Koch, Troel; Skouv, Jan; Jakobsen, Mogen  
 PATENT ASSIGNEE(S): Havsteen  
 SOURCE: Exiqon A/S, Den.  
 PCT Int. Appl., 50 pp.  
 CODEN: PIXXD2  
 DOCUMENT TYPE: Patent  
 LANGUAGE: English  
 FAMILY ACC. NUM. COUNT: 1  
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2001048190	A2	20010705	WO 2000-IB2043	20001222
WO 2001048190	A3	20020510		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
US 2002068709	A1	20020606	US 2000-747913	20001222
EP 1240322	A2	20020918	EP 2000-990866	20001222
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR				
PRIORITY APPLN. INFO.:			US 1999-171873P	P 19991223
			WO 2000-IB2043	W 20001222
TI	Use of locked nucleic acid-modified oligonucleotides for <b>treatment</b> of cancer and inflammation			
SO	PCT Int. Appl., 50 pp. CODEN: PIXXD2			
IN	Orum, Henrik; Koch, Troel; Skouv, Jan; Jakobsen, Mogen Havsteen			
AB	The invention relates to therapeutic applications of LNA-modified oligonucleotides. In particular, the invention provides methods for <b>treatment</b> of undesired cell growth as well as <b>treatment</b> of inflammatory related diseases and disorders. Preferably, administration of an LNA-modified oligonucleotide modulates expression of a targeted gene assocd. with the undesired cell growth or an inflammatory related disease or disorder. Thus, the peritoneal cells of rats injected i.p. with LNA-contg. oligonucleotides directed to Fc.epsilon.R1.alpha. mRNA produced less Fc.epsilon.R1.alpha. and released less histamine than did rats given unmodified oligonucleotides.			
L10 ANSWER 6 OF 12 CAPLUS COPYRIGHT 2002 ACS				
ACCESSION NUMBER:	2001:181821 CAPLUS			
DOCUMENT NUMBER:	134:339404			
TITLE:	The CC Chemokines MDC and TARC Induce Platelet Activation Via CCR4			
AUTHOR(S):	Abi-Younes, S.; Si-Tahar, M.; Luster, A. D.			
CORPORATE SOURCE:	Division of Rheumatology, Allergy and Immunology, Center for Immunology and Inflammatory Diseases, Massachusetts General Hospital and Harvard Medical School, Boston, MA, USA			
SOURCE:	Thrombosis Research (2001), 101(4), 279-289			

CODEN: THBRAA; ISSN: 0049-3848  
PUBLISHER: Elsevier Science Inc.  
DOCUMENT TYPE: Journal  
LANGUAGE: English  
TI The CC Chemokines MDC and TARC Induce Platelet Activation Via CCR4  
SO Thrombosis Research (2001), 101(4), 279-289  
CODEN: THBRAA; ISSN: 0049-3848  
AU Abi-Younes, S.; Si-Tahar, M.; Luster, A. D.  
AB While chemokines have received considerable attention for their role in leukocyte chemotaxis, their effects on platelets have not been well described. The authors found that CC chemokine receptor 4 (CCR4) ligands, **macrophage-derived chemokine** (MDC) and thymus and activation-regulated chemokine (TARC) induce concn.-dependent platelet aggregation and calcium flux. Flow cytometric anal. revealed the expression of CCR4 on platelets and a monoclonal **antibody** (mAb) to CCR4 inhibited MDC- and TARC-induced platelet aggregation, confirming that this effect is mediated via their common receptor CCR4. MDC fully desensitized TARC-induced calcium mobilization in platelets, while TARC was unable to completely desensitize a subsequent MDC response, which is similar to observations made in Th2 CD4+ lymphocytes and CCR4-transfected cells. Aspirin (ASA) **treatment** of platelets allowed reversible primary aggregation but inhibited irreversible complete aggregation, suggesting that MDC- and TARC-induced full platelet aggregation is dependent on cyclooxygenase metabolites of arachidonic acid. MDC and TARC were unable to induce platelet aggregation and platelet secretion in washed human platelets, even though they induced a calcium flux, suggesting that plasma components are required for MDC- and TARC-induced platelet aggregation. Since Th2-type cytokines induce the release of MDC and TARC from cells and the expression of these chemokines is increased in Th2-type inflammation, the authors hypothesize that MDC and TARC may play a role in platelet activation seen in Th2 diseases, such as asthma and atopic dermatitis.

REFERENCE COUNT: 55 THERE ARE 55 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE REFORMAT

L10 ANSWER 7 OF 12 CAPLUS COPYRIGHT 2002 ACS  
ACCESSION NUMBER: 2000:790144 CAPLUS  
DOCUMENT NUMBER: 133:349154  
TITLE: CCR4 antagonists for **treatment** of septic shock  
INVENTOR(S): Power, Christina A.; Chivatchko, Yolande  
PATENT ASSIGNEE(S): Applied Research Systems ARS Holding N.V., Neth. Antilles  
SOURCE: Eur. Pat. Appl., 20 pp.  
CODEN: EPXXDW  
DOCUMENT TYPE: Patent  
LANGUAGE: English  
FAMILY ACC. NUM. COUNT: 1  
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
EP 1050307	A1	20001108	EP 1999-108954	19990506
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT,				

IE, SI, LT, LV, FI, RO  
WO 2000067791 A1 20001116 WO 2000-EP4018 20000504  
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR,  
CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU,  
ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU,  
LV, MA, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE,  
SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA,  
ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM  
RW: GH, GM, KE, LS, MW, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE,  
DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF,  
CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG  
EP 1176980 A1 20020206 EP 2000-927140 20000504  
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT,  
IE, SI, LT, LV, FI, RO  
PRIORITY APPLN. INFO.: EP 1999-108954 A 19990506  
WO 2000-EP4018 W 20000504  
TI CCR4 antagonists for **treatment** of septic shock  
SO Eur. Pat. Appl., 20 pp.  
CODEN: EPXXDW  
IN Power, Christina A.; Chivatchko, Yolande  
AB The authors disclose the cytokine and cellular responses to  
lipopolysaccharide administration in mice having a targeted disruption of  
the CCR4 gene. CCR4 receptor antagonists (e.g., **antibodies**) are  
proposed for the **treatment** and/or prevention of septic shock.  
REFERENCE COUNT: 9 THERE ARE 9 CITED REFERENCES AVAILABLE FOR THIS  
RECORD. ALL CITATIONS AVAILABLE IN THE RE  
FORMAT

L10 ANSWER 8 OF 12 CAPLUS COPYRIGHT 2002 ACS  
ACCESSION NUMBER: 1999:487126 CAPLUS  
DOCUMENT NUMBER: 131:129056  
TITLE: A C-C chemokine of human macrophage and a cDNA  
encoding it and their uses  
INVENTOR(S): Godiska, Ronald; Gray, Patrick W.  
PATENT ASSIGNEE(S): ICOS Corp., USA  
SOURCE: U.S., 43 pp.  
CODEN: USXXAM  
DOCUMENT TYPE: Patent  
LANGUAGE: English  
FAMILY ACC. NUM. COUNT: 3  
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 5932703	A	19990803	US 1996-660542	19960607
CA 2196691	AA	19961219	CA 1996-2196691	19960607
CN 1163635	A	19971029	CN 1996-190875	19960607
WO 9915666	A2	19990401	WO 1998-US20270	19980928
WO 9915666	A3	19990916		

W: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE,  
DK, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IS, JP, KE,  
KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW,  
MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR,  
TT, UA, UG, US, US, US, US, US, UZ, VN, YU, ZW, AM, AZ, BY, KG,  
KZ, MD, RU, TJ, TM  
RW: GH, GM, KE, LS, MW, SD, SZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES,  
FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI,  
CM, GA, GN, GW, ML, MR, NE, SN, TD, TG  
PRIORITY APPLN. INFO.: US 1995-479620 A2 19950607  
US 1995-558658 A2 19951116

US 1996-660542 A2 19960607  
US 1997-939107 A2 19970926  
US 1998-67447 A2 19980428

TI A C-C chemokine of human macrophage and a cDNA encoding it and their uses  
SO U.S., 43 pp.

CODEN: USXXAM

IN Godiska, Ronald; Gray, Patrick W.

AB A C-C chemokine of human macrophages (**macrophage-derived chemokine** or MDC) is identified and a cDNA encoding it is cloned and expressed. The chemokine or analogs derived from it may be of use in the investigation of chemokine function or in the **treatment** of disease. The cDNA was identified by sequencing of random clones from a macrophage cDNA library by sequence similarity. The gene was expressed strongly in the thymus gland and at a low level in the spleen.

Expression

was found in macrophages, but not in monocytes. Secretory manuf. of the protein in Escherichia coli and accumulation as inclusion bodies are demonstrated.

REFERENCE COUNT: 26 THERE ARE 26 CITED REFERENCES AVAILABLE FOR THIS

RECORD. ALL CITATIONS AVAILABLE IN THE RE

FORMAT

L10 ANSWER 9 OF 12 CAPLUS COPYRIGHT 2002 ACS

ACCESSION NUMBER: 1999:223049 CAPLUS

DOCUMENT NUMBER: 130:251233

TITLE: **Macrophage-derived**

**chemokine** (MDC), MDC analogs, MDC inhibitor substances, and their therapeutic applications

INVENTOR(S): Gray, Patrick W.; Chantry, David H.; Deeley, Michael C.; Raport, Carol J.; Godiska, Ronald

PATENT ASSIGNEE(S): Icos Corporation, USA

SOURCE: PCT Int. Appl., 159 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 3

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9915666	A2	19990401	WO 1998-US20270	19980928
WO 9915666	A3	19990916		

W: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, US, US, US, US, UZ, VN, YU, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM

RW: GH, GM, KE, LS, MW, SD, SZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG

CN 1163635	A	19971029	CN 1996-190875	19960607
US 5932703	A	19990803	US 1996-660542	19960607
CA 2302806	AA	19990401	CA 1998-2302806	19980928
AU 9897778	A1	19990412	AU 1998-97778	19980928
EP 1017818	A2	20000712	EP 1998-951961	19980928

R: AT, BE, CH, DE; ES, FR, GB, IT, LI, SE, IE

PRIORITY APPLN. INFO.: US 1995-479620 A2 19950607  
US 1995-558658 A2 19951116

US 1996-660542 A2 19960607  
US 1997-939107 A2 19970926  
US 1998-67447 A2 19980428  
WO 1998-US20270 W 19980928

TI **Macrophage-derived chemokine** (MDC), MDC  
analogs, MDC inhibitor substances, and their therapeutic applications  
SO PCT Int. Appl., 159 pp.  
CODEN: PIXXD2  
IN Gray, Patrick W.; Chantry, David H.; Deeley, Michael C.; Raport, Carol  
J.;  
Godiska, Ronald  
AB The present invention provides purified and isolated polynucleotide  
sequences encoding a novel macrophage-derived C-C chemokine designated "**Macrophage Derived Chemokine**" (MDC), and  
polypeptide fragments and analogs thereof. MDC cDNA sequences and their  
deduced amino acid sequences are provided from human, mouse, rat, and  
macaque. Also provided are materials and methods for the recombinant or  
synthetic prodn. of the chemokine, fragments, and analogs; and purified  
and isolated chemokine protein, and polypeptide fragments and analogs  
thereof. Also provided are **antibodies** reactive with the  
chemokine and methods of making and using all of the foregoing. Also  
provided are assays for identifying modulators of MDC chemokine activity.  
MDC possesses antiproliferative activity against HIV-1 virus, stimulates  
fibroblast proliferation, inhibits tumor growth, induces chemotaxis of  
TH2 helper T cells, and modulates platelet aggregation, and is shown to be a  
high-affinity ligand for CCR4.

L10 ANSWER 10 OF 12 BIOSIS COPYRIGHT 2002 BIOLOGICAL ABSTRACTS INC.

ACCESSION NUMBER: 2002:251181 BIOSIS

DOCUMENT NUMBER: PREV200200251181

TITLE: Multiplexed protein profiling on microarrays by  
rolling-circle amplification.

AUTHOR(S): Schweitzer, Barry; Roberts, Scott; Grimwade, Brian; Shao,  
Weiping; Wang, Minjuan; Fu, Qin; Shu, Quiping; Laroche,  
Isabelle; Zhou, Zhimin; Tchernev, Velizar T.;

Christiansen,

Jason; Velleca, Mark; Kingsmore, Stephen F. (1)

CORPORATE SOURCE: (1) Molecular Staging, Inc., 300 George Street, Suite 701,  
New Haven, CT, 06511: stephenk@molecularstaging.com USA

SOURCE: Nature Biotechnology, (April, 2002) Vol. 20, No. 4, pp.  
359-365. <http://www.nature.com/nbt/>. print.

ISSN: 1087-0156.

DOCUMENT TYPE: Article

LANGUAGE: English

TI Multiplexed protein profiling on microarrays by rolling-circle  
amplification.

SO Nature Biotechnology, (April, 2002) Vol. 20, No. 4, pp. 359-365.  
<http://www.nature.com/nbt/>. print.  
ISSN: 1087-0156.

AU Schweitzer, Barry; Roberts, Scott; Grimwade, Brian; Shao, Weiping; Wang,  
Minjuan; Fu, Qin; Shu, Quiping; Laroche, Isabelle; Zhou, Zhimin;  
Tchernev,

Velizar T.; Christiansen, Jason; Velleca, Mark; Kingsmore, Stephen F. (1)

AB Fluorescent-sandwich immunoassays on microarrays hold appeal for  
proteomics studies, because equipment and **antibodies** are readily  
available, and assays are simple, scalable, and reproducible. The  
achievement of adequate sensitivity and specificity, however, requires a  
general method of immunoassay amplification. We describe coupling of  
isothermal rolling-circle amplification (RCA) to universal



**antibodies** for this purpose. A total of 75 cytokines were measured simultaneously on glass arrays with signal amplification by RCA with high specificity, femtomolar sensitivity, 3 log quantitative range, and economy of sample consumption. A 51-feature RCA cytokine glass array was used to measure secretion from human dendritic cells (DCs) induced by lipopolysaccharide (LPS) or tumor necrosis factor-alpha (TNF-alpha). As expected, LPS induced rapid secretion of inflammatory cytokines such as macrophage inflammatory protein (MIP)-1beta, interleukin (IL)-8, and interferon-inducible protein (IP)-10. We found that eotaxin-2 and I-309 were induced by LPS; in addition, **macrophage-derived chemokine** (MDC), thymus and activation-regulated chemokine (TARC), soluble interleukin 6 receptor (sIL-6R), and soluble tumor necrosis factor receptor I (sTNF-RI) were induced by TNF-alpha **treatment**. Because microarrays can accommodate approx1,000 sandwich immunoassays of this type, a relatively small number of RCA microarrays seem to offer a tractable approach for proteomic surveys.

L10 ANSWER 11 OF 12 BIOSIS COPYRIGHT 2002 BIOLOGICAL ABSTRACTS INC.

ACCESSION NUMBER: 2001:185996 BIOSIS

DOCUMENT NUMBER: PREV200100185996

TITLE: The CC chemokines MDC and TARC induce platelet activation via CCR4.

AUTHOR(S): Abi-Younes, Sylvie; Si-Tahar, Mustapha; Luster, Andrew D. (1)

CORPORATE SOURCE: (1) Massachusetts General Hospital-East, 13th Street, Building 149, Charlestown, MA, 02129: luster@helix.mgh.harvard.edu USA

SOURCE: Thrombosis Research, (February 15, 2001) Vol. 101, No. 4, pp. 279-289. print. ISSN: 0049-3848.

DOCUMENT TYPE: Article

LANGUAGE: English

SUMMARY LANGUAGE: English

TI The CC chemokines MDC and TARC induce platelet activation via CCR4.

SO Thrombosis Research, (February 15, 2001) Vol. 101, No. 4, pp. 279-289. print. ISSN: 0049-3848.

AU Abi-Younes, Sylvie; Si-Tahar, Mustapha; Luster, Andrew D. (1)

AB While chemokines have received considerable attention for their role in leukocyte chemotaxis, their effects on platelets have not been well described. We found that two CC chemokine receptor 4 (CCR4) ligands, **macrophage-derived chemokine** (MDC) and thymus and activation-regulated chemokine (TARC) induce concentration-dependent platelet aggregation and calcium flux. Flow cytometric analysis revealed the expression of CCR4 on platelets and a monoclonal **antibody** (mAb) to CCR4 inhibited MDC- and TARC-induced platelet aggregation, confirming that this effect is mediated through their common receptor CCR4. MDC fully desensitized TARC-induced calcium mobilization in platelets, while TARC was unable to completely desensitize a subsequent MDC response, which is similar to observations made in Th2 CD4+ lymphocytes and CCR4-transfected cells. Aspirin (ASA) **treatment** of platelets allowed reversible primary aggregation but inhibited irreversible complete aggregation, suggesting that MDC- and TARC-induced full platelet aggregation is dependent on cyclooxygenase metabolites of arachidonic acid. MDC and TARC were unable to induce platelet aggregation and platelet secretion in washed human platelets, even though they induced a calcium flux, suggesting that plasma components are required for MDC-

and TARC-induced platelet aggregation. Since Th2-type cytokines induce the release of MDC and TARC from cells and the expression of these chemokines is increased in Th2-type inflammation, we hypothesize that MDC and TARC may play a role in platelet activation seen in Th2 diseases, such as asthma and atopic dermatitis.

L10 ANSWER 12 OF 12 BIOSIS COPYRIGHT 2002 BIOLOGICAL ABSTRACTS INC.

ACCESSION NUMBER: 2001:115423 BIOSIS

DOCUMENT NUMBER: PREV200100115423

TITLE: Adenosine diphosphate strongly potentiates the ability of the chemokines MDC, TARC, and SDF-1 to stimulate platelet function.

AUTHOR(S): Gear, Adrian R. L. (1); Suttitanamongkol, Sudawadee; Viisoreanu, Delia; Polanowska-Grabowska, Renata K.; Raha, Sanghamitra; Camerini, David

CORPORATE SOURCE: (1) Department of Biochemistry and Molecular Genetics, University of Virginia Health Sciences Center, 1300 Jefferson Park Ave, Charlottesville, VA, 22908: alg4p@virginia.edu USA

SOURCE: Blood, (February 15, 2001) Vol. 97, No. 4, pp. 937-945. print.

ISSN: 0006-4971.

DOCUMENT TYPE: Article

LANGUAGE: English

SUMMARY LANGUAGE: English

TI Adenosine diphosphate strongly potentiates the ability of the chemokines MDC, TARC, and SDF-1 to stimulate platelet function.

SO Blood, (February 15, 2001) Vol. 97, No. 4, pp. 937-945. print. ISSN: 0006-4971.

AU Gear, Adrian R. L. (1); Suttitanamongkol, Sudawadee; Viisoreanu, Delia; Polanowska-Grabowska, Renata K.; Raha, Sanghamitra; Camerini, David

AB Platelet activation is normally induced by primary agonists such as adenosine diphosphate (ADP), thrombin, and collagen, whereas other agonists, such as epinephrine, can play important accessory roles. It is now reported that the **macrophage-derived chemokine** (MDC), thymus activation-regulated chemokine (TARC), and stromal cell-derived factor one (SDF-1) are highly effective activators

of platelet function under a variety of conditions, stimulating platelet shape change, aggregation, and adhesion to collagen or fibrinogen. Chemokine-mediated platelet activation was rapid and maximal (less than 5 seconds) under arterial flow conditions and depended strongly on the presence of low levels of primary agonists such as ADP or thrombin. Concentrations of ADP (0.05-0.25  $\mu$ M) or thrombin (0.005-0.02 U/mL) that induced minimal aggregation caused major aggregation acting in combination

with the chemokines. The ability of apyrase to block chemokine-dependent aggregation or adhesion was consistent with an important role for ADP. Chemokine-stimulated aggregation was also insensitive to indomethacin, suggesting that the activation of cyclo-oxygenase is not involved. TARC, MDC, and SDF-1 increased intracellular calcium concentrations ( $\text{Ca}^{2+}$ )i

when combined with low levels of ADP. The MDC and TARC receptor CCR4 was expressed on platelets, and an anti-CCR4 **antibody** blocked aggregation induced by TARC or MDC. **Treatment** of platelets with SDF-1 and MDC rapidly exposed P-selectin (CD62P) on the cell surface but did not induce the secretion of serotonin. These findings suggest that

the chemokines MDC, TARC, and SDF-1, which may be produced during inflammatory

responses, coupled with low levels of ADP or thrombin, can serve as strong stimuli for activating platelet function.

=> D L9 IBIB TI SO AU ABS

L9 ANSWER 1 OF 1 CAPLUS COPYRIGHT 2002 ACS

ACCESSION NUMBER: 2000:790144 CAPLUS

DOCUMENT NUMBER: 133:349154

TITLE: CCR4 **antagonists** for **treatment** of septic shock

INVENTOR(S): Power, Christina A.; Chivatchko, Yolande

PATENT ASSIGNEE(S): Applied Research Systems ARS Holding N.V., Neth. Antilles

SOURCE: Eur. Pat. Appl., 20 pp.

CODEN: EPXXDW

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
EP 1050307	A1	20001108	EP 1999-108954	19990506
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO				
WO 2000067791	A1	20001116	WO 2000-EP4018	20000504
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: GH, GM, KE, LS, MW, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
EP 1176980	A1	20020206	EP 2000-927140	20000504
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO				

PRIORITY APPLN. INFO.: EP 1999-108954 A 19990506

WO 2000-EP4018 W 20000504

TI CCR4 **antagonists** for **treatment** of septic shock

SO Eur. Pat. Appl., 20 pp.

CODEN: EPXXDW

IN Power, Christina A.; Chivatchko, Yolande

AB The authors disclose the cytokine and cellular responses to lipopolysaccharide administration in mice having a targeted disruption of the CCR4 gene. CCR4 receptor **antagonists** (e.g., antibodies) are proposed for the **treatment** and/or prevention of septic shock.

REFERENCE COUNT: 9 THERE ARE 9 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE

FORMAT

=> D L7 IBIB TI SO AU ABS 1-9

L7 ANSWER 1 OF 9 CAPLUS COPYRIGHT 2002 ACS

ACCESSION NUMBER: 2002:428737 CAPLUS

DOCUMENT NUMBER: 137:1473

TITLE: Chemokine and chemokine receptor gene expression for skin disorder diagnosis and therapy  
 INVENTOR(S): Homey, Bernhard; Zepeda, Monica L.; Zlotnik, Albert  
 PATENT ASSIGNEE(S): Schering Corporation, USA  
 SOURCE: PCT Int. Appl., 17 pp.  
 CODEN: PIXXD2  
 DOCUMENT TYPE: Patent  
 LANGUAGE: English  
 FAMILY ACC. NUM. COUNT: 1  
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2002043758	A2	20020606	WO 2001-US44338	20011127
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, HR, HU, ID, IL, IN, IS, JP, KG, KR, KZ, LC, LK, LR, LT, LU, LV, MA, MD, MG, MK, MN, MX, MZ, NO, NZ, PH, PL, PT, RO, RU, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UZ, VN, YU, ZA, ZM, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
AU 2002025756	A5	20020611	AU 2002-25756	20011127
US 2002111290	A1	20020815	US 2001-995534	20011127
PRIORITY APPLN. INFO.:			US 2000-250782P	P 20001201
			WO 2001-US44338	W 20011127

TI Chemokine and chemokine receptor gene expression for skin disorder diagnosis and therapy  
 SO PCT Int. Appl., 17 pp.  
 CODEN: PIXXD2  
 IN Homey, Bernhard; Zepeda, Monica L.; Zlotnik, Albert  
 AB The present invention is based, in part, upon the recognition of the correlation of chemokine and chemokine receptor agonists and **antagonists** in skin inflammation disorders, and in wound healing. The present invention provides methods of diagnosing or evaluating a skin injury or condition affecting the skin, the method comprising evaluating expression of: a chemokine selected from MCP-2 (CCL8), DC-CK1 (CCL18), TARC (CCL17), RANTES (CCL5), MIP3b (CCL19), I-309 (CCL1), MIG (CXCL9), IP-10 (CXCL10), ITAC (CXCL11), BCA-1 (CXCL13), lymphotactin (XCL1), MDC (CCL22), IL-8 (CXCL8), MCP-3 (CCL7), MCP-1 (CCL2), or SDF-1; or a chemokine receptor selected from CCR5, CCR7, CXCR3, CXCR5, XCR1, CCR2, CCR4, CCR8, or CXCR4. Typically, the condition is selected from lupus erythematosus, atopic dermatitis, cutaneous wound, skin healing, or an inflammatory condition; or the evaluating is: measuring a plurality of the expression levels; measuring mRNA levels; or measuring protein levels. The invention further provides methods of treating a condition affecting the skin, the method comprising administering an **antagonist** of a chemokine. Specific primers and probes for the human and mouse chemokines and chemokine receptors were designed and validated.

L7 ANSWER 2 OF 9 CAPLUS COPYRIGHT 2002 ACS  
 ACCESSION NUMBER: 2002:183334 CAPLUS  
 DOCUMENT NUMBER: 136:308382  
 TITLE: Inflammatory mediators in uveitis: differential induction of cytokines and chemokines in Th1- versus Th2-mediated ocular inflammation  
 AUTHOR(S): Foxman, Ellen F.; Zhang, Meifen; Hurst, Stephen D.;

Muchamuel, Tony; Shen, Defen; Wawrousek, Eric F.;  
 Chan, Chi-Chao; Gery, Igal  
 CORPORATE SOURCE: National Eye Institute, National Institutes of  
 Health,  
 Bethesda, MD, 20892, USA  
 SOURCE: Journal of Immunology (2002), 168(5), 2483-2492  
 CODEN: JOIMA3; ISSN: 0022-1767  
 PUBLISHER: American Association of Immunologists  
 DOCUMENT TYPE: Journal  
 LANGUAGE: English  
 TI Inflammatory mediators in uveitis: differential induction of cytokines  
 and  
 chemokines in Th1- versus Th2-mediated ocular inflammation  
 SO Journal of Immunology (2002), 168(5), 2483-2492  
 CODEN: JOIMA3; ISSN: 0022-1767  
 AU Foxman, Ellen F.; Zhang, Meifen; Hurst, Stephen D.; Muchamuel, Tony;  
 Shen,  
 Defen; Wawrousek, Eric F.; Chan, Chi-Chao; Gery, Igal  
 AB Ocular inflammation leads to vision loss through the destruction and  
 scarring of delicate tissues along the visual axis. To identify  
 inflammatory mediators involved in this process, we used real time RT-PCR  
 to quantify the expression of mRNA transcripts of 34 cytokines, 26  
 chemokines, and 14 chemokine receptors at certain time points during T  
 cell-mediated ocular inflammation. We induced disease by adoptive  
 transfer of Ag-specific Th1 or Th2 cells into recipients expressing the  
 target Ag in their eyes. We also compared the mediator expression  
 patterns seen in adoptive transfer-induced inflammation with that seen in  
 mouse eyes developing exptl. autoimmune uveoretinitis. In addn., we used  
 laser capture microdissection to examine chemokine mRNA prodn. by both  
 retinal pigment epithelium cells and infiltrating leukocytes in inflamed  
 eyes. Major findings included the following: 1) Three patterns of  
 expression of the inflammation-related mols. were seen in recipients of  
 adoptively transferred Th cells: preferential expression in Th1  
 recipients, or in Th2 recipients, or similar expression in both recipient  
 groups. 2) In exptl. autoimmune uveoretinitis, the inflammatory mediator  
 expression pattern largely paralleled that seen in Th1-induced disease.  
 3) Both retinal pigment epithelium and infiltrating leukocytes expressed  
 chemokine transcripts in distinct, but overlapping patterns in inflamed  
 eyes. 4) Interestingly, transcripts of multiple cytokines, chemokines,  
 and chemokine receptors were constitutively expressed in high levels in  
 mouse eyes. Seven of these mols. have not been previously assocd. with  
 the eye. These data underscore the multiplicity of mediators that  
 participate in the pathogenesis of eye inflammation and point to upstream  
 cytokines as potential therapeutic targets.  
 REFERENCE COUNT: 77 THERE ARE 77 CITED REFERENCES AVAILABLE FOR  
 THIS  
 RECORD. ALL CITATIONS AVAILABLE IN THE RE  
 FORMAT  
 L7 ANSWER 3 OF 9 CAPLUS COPYRIGHT 2002 ACS  
 ACCESSION NUMBER: 2002:57331 CAPLUS  
 DOCUMENT NUMBER: 136:319540  
 TITLE: Gene profiling reveals unknown enhancing and  
 suppressive actions of glucocorticoids on immune  
 cells  
 AUTHOR(S): Galon, Jerome; Franchimont, Denis; Hiroi, Naoki;  
 Frey,  
 Gregory; Boettner, Antje; Ehrhart-Bornstein, Monika;  
 O'Shea, John J.; Chrousos, George P.; Bornstein,  
 Stefan R.

CORPORATE SOURCE: Lymphocyte Cell Biology Section, NIAMS, National  
Institutes of Health, Bethesda, MD, 20892, USA  
SOURCE: FASEB Journal (2002), 16(1), 61-71  
CODEN: FAJOEC; ISSN: 0892-6638  
PUBLISHER: Federation of American Societies for Experimental  
Biology  
DOCUMENT TYPE: Journal  
LANGUAGE: English  
TI Gene profiling reveals unknown enhancing and suppressive actions of  
glucocorticoids on immune cells  
SO FASEB Journal (2002), 16(1), 61-71  
CODEN: FAJOEC; ISSN: 0892-6638  
AU Galon, Jerome; Franchimont, Denis; Hiroi, Naoki; Frey, Gregory; Boettner,  
Antje; Ehrhart-Bornstein, Monika; O'Shea, John J.; Chrousos, George P.;  
Bornstein, Stefan R.  
AB Glucocorticoids continue to be the major immunomodulatory agents used in  
clin. medicine today. However, their actions as anti-inflammatory and  
immunosuppressive drugs are both beneficial and deleterious. We analyzed  
the effect of glucocorticoids on the gene expression profile of  
peripheral

blood mononuclear cells from healthy donors. DNA microarray anal.  
combined with quant. TaqMan PCR and flow cytometry revealed that  
glucocorticoids induced the expression of chemokine, cytokine, and  
complement family members as well as of newly discovered innate  
immune-related genes, including scavenger and Toll-like receptors. In  
contrast, glucocorticoids repressed the expression of adaptive  
immune-related genes. Simultaneous inhibitory and stimulatory effects of  
glucocorticoids were found on inflammatory T helper subsets and  
apoptosis-related gene clusters. In cells activated by T cell receptor  
crosslinking, glucocorticoids down-regulated the expression of specific  
genes that were previously up-regulated in resting cells, suggesting a  
potential new mechanism by which they exert pos. and neg. effects.  
Considering the broad and continuously renewed interest in glucocorticoid  
therapy, the profiles we describe here will be useful in designing more  
specific and efficient treatment strategies.

REFERENCE COUNT: 42 THERE ARE 42 CITED REFERENCES AVAILABLE FOR  
THIS

RECORD. ALL CITATIONS AVAILABLE IN THE RE

FORMAT

L7 ANSWER 4 OF 9 CAPLUS COPYRIGHT 2002 ACS

ACCESSION NUMBER: 2002:28942 CAPLUS

DOCUMENT NUMBER: 137:18832

TITLE: TARC: novel mediator for allergic inflammation

AUTHOR(S): Sandoval-Lopez, G.; Teran, L. M.

CORPORATE SOURCE: Inst. Nac. Enfermedades Respiratorias Calzada, Mexico  
City, 14080, Mex.

SOURCE: Clinical and Experimental Allergy (2001), 31(12),  
1809-1812

CODEN: CLEAEN; ISSN: 0954-7894

PUBLISHER: Blackwell Science Ltd.

DOCUMENT TYPE: Journal; General Review

LANGUAGE: English

TI TARC: novel mediator for allergic inflammation

SO Clinical and Experimental Allergy (2001), 31(12), 1809-1812

CODEN: CLEAEN; ISSN: 0954-7894

AU Sandoval-Lopez, G.; Teran, L. M.

review on the potential role of the CC chemokine, called TARC, in  
allergic inflammation. TARC is located on chromosome region 16q13, and

is 2716 base pairs in length, coding a highly basic preprotein of 94 amino acid residues with a cleavage site between Ala 23 and Ala 24. The use of a monoclonal antibody to neutralize TARC in a mouse model of asthma has shown an important contribution for this cytokine in inducing the infiltration of both CD4+ lymphocytes and eosinophils in response to allergen challenge. This observation is further supported by the finding of increased TARC in the airways of asthmatic patients. TARC has also been implicated in other allergic diseases including allergic rhinitis, atopic dermatitis, and allergic contact dermatitis. The use of small

CCR4

**antagonists** with clin. efficacy may have a substantial impact in treating allergic disease.

REFERENCE COUNT: 32 THERE ARE 32 CITED REFERENCES AVAILABLE FOR THIS

RECORD. ALL CITATIONS AVAILABLE IN THE RE

FORMAT

L7 ANSWER 5 OF 9 CAPLUS COPYRIGHT 2002 ACS

ACCESSION NUMBER: 2001:110910 CAPLUS

DOCUMENT NUMBER: 134:290688

TITLE: ADP receptor **antagonists** inhibit platelet aggregation induced by the chemokines SDF-1, MDC and TARC

AUTHOR(S): Suttitanamongkol, S.; Gear, A. R. L.

CORPORATE SOURCE: Department of Biochemistry and Molecular Genetics, University of Virginia, Charlottesville, VA, 22908, USA

SOURCE: FEBS Letters (2001), 490(1,2), 84-87

CODEN: FEBLAL; ISSN: 0014-5793

PUBLISHER: Elsevier Science B.V.

DOCUMENT TYPE: Journal

LANGUAGE: English

TI ADP receptor **antagonists** inhibit platelet aggregation induced by the chemokines SDF-1, MDC and TARC

SO FEBS Letters (2001), 490(1,2), 84-87

CODEN: FEBLAL; ISSN: 0014-5793

AU Suttitanamongkol, S.; Gear, A. R. L.

AB The ability of the chemokines SDF-1, MDC and TARC to induce platelet aggregation depends strongly on low levels of ADP. The ADP receptors involved have now been characterized using the P2Y1 and P2TAC receptor **antagonists**, A2P5P and AR-C69931MX. Stimulation of aggregation by the chemokines at 10 s was not blocked by AR-C69931MX, but was strongly inhibited by A2P5P. Pertussis toxin abolished the chemokine-stimulated aggregation. We conclude that the P2Y1 ADP receptor plays a crit. role

in

the initial phases of SDF-1-, MDC- and TARC-induced platelet aggregation, which involve a pertussis toxin-sensitive G protein.

REFERENCE COUNT: 29 THERE ARE 29 CITED REFERENCES AVAILABLE FOR THIS

RECORD. ALL CITATIONS AVAILABLE IN THE RE

FORMAT

L7 ANSWER 6 OF 9 CAPLUS COPYRIGHT 2002 ACS

ACCESSION NUMBER: 2000:712650 CAPLUS

DOCUMENT NUMBER: 133:277217

TITLE: Serial analysis of gene expression in human monocyte-derived dendritic cells

INVENTOR(S): Hashimoto, Shinichi; Matsushima, Koji; Suzuki, Takuji

PATENT ASSIGNEE(S): Foundation for Scientific Technology Promotion, Japan

SOURCE: Jpn. Kokai Tokkyo Koho, 33 pp.  
CODEN: JKXXAF  
DOCUMENT TYPE: Patent  
LANGUAGE: Japanese  
FAMILY ACC. NUM. COUNT: 1  
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
JP 2000279181	A2	20001010	JP 1999-95481	19990401
CA 2333908	AA	20001012	CA 2000-2333908	20000330
WO 2000060074	A1	20001012	WO 2000-JP2019	20000330
W: CA, CN, KR, SG, US				
RW: AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE				
EP 1087012	A1	20010328	EP 2000-912973	20000330
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, FI				

PRIORITY APPLN. INFO.: JP 1999-95481 A 19990401  
WO 2000-JP2019 W 20000330

TI Serial analysis of gene expression in human monocyte-derived dendritic cells

SO Jpn. Kokai Tokkyo Koho, 33 pp.  
CODEN: JKXXAF

IN Hashimoto, Shinichi; Matsushima, Koji; Suzuki, Takuji

AB Genes expressed in human monocyte-derived dendritic cells (DCs), antibody or **antagonist** for the protein products are disclosed. Dendritic cells (DCs) are professional antigen-presenting cells in the immune system

and can be generated in vitro from hematopoietic progenitor cells in the bone marrow, CD34+ cord blood cells, precursor cells in the peripheral blood, and blood monocytes by culturing with granulocyte-macrophage colony-stimulating factor (GM-CSF), interleukin-4, and tumor necrosis factor-.alpha.. The authors have performed serial anal. of gene expression (SAGE) in DCs derived from human blood monocytes. A total of 58,540 tag sequences from a DC cDNA library represented more than 17,000 different genes, and these data were compared with SAGE anal. of tags

from monocytes (Mo) and GM-CSF-induced macrophages (M.phi.). Many of the genes

that were differentially expressed in DCs were identified as genes encoding proteins related to cell structure (gelsolin, vinculin), lipid metab. (lysosome acid lipase, apolipoprotein C-1), and cell motility. Interestingly, the highly expressed genes in DCs encode chemokines such

as TARC, MDC, and MCP-4, which preferentially chemoattract Th2-type lymphocytes. Some genes had a lower expression in DCs as compared to in monocytes. Although DCs have been considered to be very heterogeneous, the identification of specific genes expressed in human Mo-derived DCs should provide candidate genes to define subsets of, the function of, and the maturation stage of DCs and possibly also to diagnose diseases in which DCs play a significant role, such as autoimmune diseases and neoplasms. This study represents the first extensive gene expression anal. in any type of DCs.

L7 ANSWER 7 OF 9 CAPLUS COPYRIGHT 2002 ACS

ACCESSION NUMBER: 2000:615616 CAPLUS

DOCUMENT NUMBER: 134:188864

TITLE: Maturation of Human Monocyte-Derived Dendritic Cells Studied by Microarray Hybridization



AUTHOR(S): Dietz, Allan B.; Bulur, Peggy A.; Knutson, Gaylord J.;  
CORPORATE SOURCE: Matasic, Richard; Vuk-Pavlovic, Stanimir  
Stem Cell Laboratory, Mayo Clinic Cancer Center, Mayo Clinic, Rochester, MN, 55905, USA  
SOURCE: Biochemical and Biophysical Research Communications (2000), 275(3), 731-738  
CODEN: BBRCA9; ISSN: 0006-291X  
PUBLISHER: Academic Press  
DOCUMENT TYPE: Journal  
LANGUAGE: English  
TI Maturation of Human Monocyte-Derived Dendritic Cells Studied by Microarray

Hybridization  
SO Biochemical and Biophysical Research Communications (2000), 275(3), 731-738  
CODEN: BBRCA9; ISSN: 0006-291X  
AU Dietz, Allan B.; Bulur, Peggy A.; Knutson, Gaylord J.; Matasic, Richard; Vuk-Pavlovic, Stanimir  
AB We compared the transcript profiles of human myeloid immature dendritic (IDC) cells and mature dendritic cells (MDC) by hybridization of cell-derived cDNA to DNA probes immobilized on microarrays. The microarrays contained probes for 4110 known genes. We report maturation-dependent changes in transcription of clusters of differentiation, cytokines, cytokine receptors, chemokines, chemokine receptors, neuropeptides, adhesion mols., and other genes. We identified 1124 transcripts expressed in IDC and 1556 transcripts expressed in MDC. Maturation increased the levels of 291 transcripts twofold or more and reduced the levels of 78 transcripts to one-half or less than in IDC. We identified a concerted maturation-stage-dependent transcription of the variable chains of the members of the .gamma.-chain-cytokine receptor family IL-4R, IL-7R, and IL-15R. Also, we found the reversal of the ratio of transcripts for galectin-3 and galectin-9 upon maturation. We identified maturation-dependent changes in the levels of transcripts for numerous genes encoding proteins previously undetected in dendritic cells such as indoleamine 2,3-deoxygenase, Epstein-Barr virus induced protein 3 and kinesin-2. Moreover, MDC transcribed and translated insulin like growth factor-1 receptor, transforming growth factor .alpha., and neuropeptide Y. Full exptl. details are described in the electronic version of this paper available at [http://www.mayo.edu/research/vuk\\_lab/](http://www.mayo.edu/research/vuk_lab/).  
(c) 2000 Academic Press.

REFERENCE COUNT: 62 THERE ARE 62 CITED REFERENCES AVAILABLE FOR THIS

RECORD. ALL CITATIONS AVAILABLE IN THE RE  
FORMAT

L7 ANSWER 8 OF 9 CAPLUS COPYRIGHT 2002 ACS  
ACCESSION NUMBER: 2000:493413 CAPLUS  
DOCUMENT NUMBER: 133:118952  
TITLE: Modulation of systemic memory T cell trafficking  
INVENTOR(S): Butcher, Eugene C.; Campbell, James J.; Wu, Lijun; Rottman, James B.  
PATENT ASSIGNEE(S): The Board of Trustees of the Leland Stanford Junior University, USA; Leukosite, Inc.  
SOURCE: PCT Int. Appl., 39 pp.  
CODEN: PIXXD2  
DOCUMENT TYPE: Patent  
LANGUAGE: English  
FAMILY ACC. NUM. COUNT: 1  
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
-----	----	-----	-----	-----
WO 2000041724	A1	20000720	WO 2000-US953	20000114
W: AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CU, CZ, DE, DK, DM, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM RW: GH, GM, KE, LS, MW, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
US 6245332	B1	20010612	US 1999-232878	19990115
EP 1144008	A1	20011017	EP 2000-902419	20000114
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO				
JP 2002534482	T2	20021015	JP 2000-593334	20000114
US 2002019341	A1	20020214	US 2001-837446	20010417
PRIORITY APPLN. INFO.:			US 1999-232878	A 19990115
			WO 2000-US953	W 20000114
TI Modulation of systemic memory T cell trafficking SO PCT Int. Appl., 39 pp. CODEN: PIXXD2 IN Butcher, Eugene C.; Campbell, James J.; Wu, Lijun; Rottman, James B. AB Methods are provided to specifically modulate the trafficking of systemic memory T cells, particularly CD4+ T cells, without affecting naive T cells or intestinal memory T cells. It is shown that systemic memory T cells, which are characterized as CD45Ra-, and integrin .alpha.4.beta.7-, express high levels of CCR4. Ligands or CCR4, such as TARC or MDC, act as an adhesion trigger, wherein upon CCR4 binding, these cells undergo integrin-dependent arrest to the appropriate vascular receptor(s). This arrest acts to localize the cells at the target site. The methods of the invention manipulate this triggering, and CCR4 mediated chemotaxis, to affect the localization of T cells in targeted tissues. In one embodiment of the invention, the active agent is a CCR4 agonist, that acts to enhance T cell localization. In an alternative embodiment, the agent is an <b>antagonist</b> that blocks CCR4 biol. activity. An advantage of the invention is the selectivity for systemic memory T cells, without affecting native T cells or intestinal memory T cells.				
REFERENCE COUNT:		3	THERE ARE 3 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE	
FORMAT				
L7 ANSWER 9 OF 9 CAPLUS COPYRIGHT 2002 ACS				
ACCESSION NUMBER:		1999:194178	CAPLUS	
DOCUMENT NUMBER:		130:236476		
TITLE:		Chemokine-derived peptides, peptide variants, derivatives and analogs for modulation of inflammatory responses		
INVENTOR(S):		Grainger, David J.; Tatalick, Lauren Marie; Kanaly, Suzanne T.		
PATENT ASSIGNEE(S):		Neorx Corporation, USA		
SOURCE:		PCT Int. Appl., 208 pp. CODEN: PIXXD2		

DOCUMENT TYPE: Patent  
LANGUAGE: English  
FAMILY ACC. NUM. COUNT: 1  
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9912968	A2	19990318	WO 1998-US19052	19980911
WO 9912968	A3	19990729		
W:	AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, GH, GM, HR, HU, ID, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM			
RW:	GH, GM, KE, LS, MW, SD, SZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG			
US 2001006640	A1	20010705	US 1997-927939	19970911
CA 2303422	AA	19990318	CA 1998-2303422	19980911
AU 9893153	A1	19990329	AU 1998-93153	19980911
EP 1012187	A2	20000628	EP 1998-946057	19980911
R:	AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO			
JP 2001515918	T2	20010925	JP 2000-510773	19980911
PRIORITY APPLN. INFO.:			US 1997-927939 A2 19970911	
			WO 1998-US19052 W 19980911	
TI	Chemokine-derived peptides, peptide variants, derivatives and analogs for modulation of inflammatory responses			
SO	PCT Int. Appl., 208 pp. CODEN: PIXXD2			
IN	Grainger, David J.; Tatalick, Lauren Marie; Kanaly, Suzanne T.			
AB	The authors disclose the identification and characterization of chemokine-derived peptides, substituted variants and isosteres, and peptidic mimics that exhibit agonistic and antagonistic activity for chemokine receptors. In one example, a peptide derived from a conserved region of human monocyte chemoattractant protein-1 (MCP-1) was shown to inhibit the migration of the THP-1 cell line in response to MIP-1.alpha., MCP-1, SDF-1.alpha., and IL-8. Thus, inhibition was both specific and general. In addn., cyclic and reverse D-enantiomeric analogs of the peptide exhibited improved antagonistic activity. In a second example, a peptide derived from a non-conserved portion of MCP-1 was shown to inhibit CXCR4-mediated infection of Jurkat cells by HIV.			

=> D L3 IBIB TI SO AU ABS 1-12

L3 ANSWER 1 OF 12 CAPLUS COPYRIGHT 2002 ACS  
ACCESSION NUMBER: 2002:862739 CAPLUS  
TITLE: Prostaglandin E2 Suppresses Chemokine Production in Human Macrophages through the EP4 Receptor  
AUTHOR(S): Takayama, Kiyoshi; Garcia-Cardena, Guillermo; Sukhova, Galina K.; Comander, Jason; Gimbrone, Michael A., Jr.; Libby, Peter  
CORPORATE SOURCE: Brigham and Women's Hospital, Department of Pathology, and the Center for Excellence in Vascular Biology, Department of Medicine, Leducq Center for

Cardiovascular Research, Harvard Medical School,  
Boston, MA, 02115, USA

SOURCE: Journal of Biological Chemistry (2002), 277(46),  
44147-44154  
CODEN: JBCHA3; ISSN: 0021-9258

PUBLISHER: American Society for Biochemistry and Molecular  
Biology

DOCUMENT TYPE: Journal

LANGUAGE: English

TI Prostaglandin E2 Suppresses Chemokine Production in Human Macrophages  
through the EP4 Receptor

SO Journal of Biological Chemistry (2002), 277(46), 44147-44154  
CODEN: JBCHA3; ISSN: 0021-9258

AU Takayama, Kiyoshi; Garcia-Cardena, Guillermo; Sukhova, Galina K.;  
Comander, Jason; Gimbrone, Michael A., Jr.; Libby, Peter

AB Pro-inflammatory pathways participate in the pathogenesis of  
atherosclerosis. However, the role of endogenous anti-inflammatory  
pathways in atheroma has received much less attention. Therefore, using  
cDNA microarrays, we screened for genes regulated by prostaglandin E2  
(PGE2), a potential endogenous anti-inflammatory mediator, in  
lipopolysaccharide (LPS)-treated human macrophages (M.PHI.). PGE2 (50  
nm)  
attenuated LPS-induced mRNA and protein expression of chemokines  
including  
monocyte chemoattractant protein-1, interleukin-8, macrophage  
inflammatory  
protein-1.alpha. and -1.beta., and interferon-inducible protein-10. PGE2  
also inhibited the tumor necrosis factor-.alpha.-, interferon-.gamma.-,  
and interleukin-1.beta.-mediated expression of these chemokines. In  
contrast to the case of M.PHI., PGE2 did not suppress chemokine  
expression  
in human endothelial and smooth muscle cells (SMC) treated with LPS and  
pro-inflammatory cytokines. To assess the potential paracrine effect of  
endogenous PGE2 on **macrophage-derived**  
**chemokine** prodn., we co-cultured M.PHI. with SMC in the presence  
of LPS. In these co-cultures, cyclooxygenase-2-dependent PGE2 prodn.  
exceeded that in the mono-cultures, and MIP-1.beta. declined  
significantly  
compared with M.PHI. cultured without SMC. We further documented  
prominent expression of the PGE2 receptor EP4 in M.PHI. in both culture  
and human atheroma. Moreover, a selective EP4 **antagonist**  
completely reversed PGE2-mediated suppression of chemokine prodn. Thus,  
endogenous PGE2 may modulate inflammation during atherogenesis and other  
inflammatory diseases by suppressing **macrophage-derived**  
**chemokine** prodn. via the EP4 receptor.

L3 ANSWER 2 OF 12 CAPLUS COPYRIGHT 2002 ACS

ACCESSION NUMBER: 2002:676193 CAPLUS

DOCUMENT NUMBER: 137:215825

TITLE: Protein and cDNA sequences of human cytokine receptor  
complex including IL-7R.alpha. and R.delta.2 subunit  
for cytokine ligand IL-B50

INVENTOR(S): Reche-Gallardo, Pedro A.; De Waal Malefyt, Rene;  
Bazan, J. Fernando; Kastelein, Robert A.; Liu,  
Yong-Jun

PATENT ASSIGNEE(S): Schering Corporation, USA

SOURCE: PCT Int. Appl., 118 pp.  
CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1  
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2002068646	A2	20020906	WO 2001-US50351	20011109
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, HR, HU, ID, IL, IN, IS, JP, KG, KR, KZ, LC, LK, LR, LT, LU, LV, MA, MD, MG, MK, MN, MX, MZ, NO, NZ, PH, PL, PT, RO, RU, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UZ, VN, YU, ZA, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
US 2002173623	A1	20021121	US 2001-8566	20011108
PRIORITY APPLN. INFO.:			US 2000-247218P	P 20001110
			US 2001-298268P	P 20010614
TI	Protein and cDNA sequences of human cytokine receptor complex including IL-7R.alpha. and R.delta.2 subunit for cytokine ligand IL-B50			
SO	PCT Int. Appl., 118 pp. CODEN: PIXXD2			
IN	Reche-Gallardo, Pedro A.; De Waal Malefyt, Rene; Bazan, J. Fernando; Kastelein, Robert A.; Liu, Yong-Jun			
AB	The invention provides protein and cDNA sequences of human cytokine receptor complex including IL-7R.alpha. and R.delta.2 subunit for cytokine ligand IL-B50. The present invention provides methods of producing a ligand : receptor complex, comprising contacting: a substantially pure or recombinant mammalian IL-B50 with a receptor comprising the IL-7R.alpha. or the R.delta.2 subunit; a mammalian IL-B50 with a receptor comprising a substantially pure or recombinant IL-7R.alpha. subunit; or a mammalian IL-B50 with a receptor comprising a substantially pure or recombinant R.delta.2 subunit; which contacting thereby allows the complex to form. In preferred embodiments, the mammalian IL-B50 is primate IL-B50, such as human IL-B50; the complex formation results in signal transduction, STAT activation, or TARC expression; the receptor is on a cell; the receptor comprises both IL-7R.alpha. and R.delta.2 subunit; the complex formation results in a physiol. change in the cell expressing the receptor; the contacting is in combination with a proliferative agent, cytokine, or chemokine; the contacting allows quant. detection of the ligand; or receptor is on a hematopoietic cell, including a lymphoid lineage cell, a myeloid cell such as a monocyte, or dendritic cell. Another method is provided for modulating physiol. or development of an IL-7R.alpha. or R.delta.2 expressing cell comprising contacting the cell to an exogenous agonist or <b>antagonist</b> of a mammalian IL-B50.			
L3	ANSWER 3 OF 12 CAPLUS COPYRIGHT 2002 ACS			
ACCESSION NUMBER:	2002:428737 CAPLUS			
DOCUMENT NUMBER:	137:1473			
TITLE:	Chemokine and chemokine receptor gene expression for skin disorder diagnosis and therapy			
INVENTOR(S):	Homey, Bernhard; Zepeda, Monica L.; Zlotnik, Albert			
PATENT ASSIGNEE(S):	Schering Corporation, USA			
SOURCE:	PCT Int. Appl., 17 pp. CODEN: PIXXD2			
DOCUMENT TYPE:	Patent			
LANGUAGE:	English			
FAMILY ACC. NUM. COUNT:	1			
PATENT INFORMATION:				

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2002043758	A2	20020606	WO 2001-US44338	20011127
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, HR, HU, ID, IL, IN, IS, JP, KG, KR, KZ, LC, LK, LR, LT, LU, LV, MA, MD, MG, MK, MN, MX, MZ, NO, NZ, PH, PL, PT, RO, RU, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UZ, VN, YU, ZA, ZM, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
AU 2002025756	A5	20020611	AU 2002-25756	20011127
US 2002111290	A1	20020815	US 2001-995534	20011127
PRIORITY APPLN. INFO.:			US 2000-250782P	P 20001201
			WO 2001-US44338	W 20011127
TI	Chemokine and chemokine receptor gene expression for skin disorder diagnosis and therapy			
SO	PCT Int. Appl., 17 pp. CODEN: PIXXD2			
IN	Homey, Bernhard; Zepeda, Monica L.; Zlotnik, Albert			
AB	<p>The present invention is based, in part, upon the recognition of the correlation of chemokine and chemokine receptor agonists and <b>antagonists</b> in skin inflammation disorders, and in wound healing. The present invention provides methods of diagnosing or evaluating a skin injury or condition affecting the skin, the method comprising evaluating expression of: a chemokine selected from MCP-2 (CCL8), DC-CK1 (CCL18), TARC (CCL17), RANTES (CCL5), MIP3b (CCL19), I-309 (CCL1), MIG (CXCL9), IP-10 (CXCL10), ITAC (CXCL11), BCA-1 (CXCL13), lymphotactin (XCL1), MDC (CCL22), IL-8 (CXCL8), MCP-3 (CCL7), MCP-1 (CCL2), or SDF-1; or a chemokine receptor selected from CCR5, CCR7, CXCR3, CXCR5, XCR1, CCR2, CCR4, CCR8, or CXCR4. Typically, the condition is selected from lupus erythematosus, atopic dermatitis, cutaneous wound, skin healing, or an inflammatory condition; or the evaluating is: measuring a plurality of</p> <p>the</p> <p>expression levels; measuring mRNA levels; or measuring protein levels. The invention further provides methods of treating a condition affecting the skin, the method comprising administering an <b>antagonist</b> of a chemokine. Specific primers and probes for the human and mouse chemokines</p> <p>and chemokine receptors were designed and validated.</p>			
L3	ANSWER 4 OF 12 CAPLUS COPYRIGHT 2002 ACS			
ACCESSION NUMBER:	2002:183334 CAPLUS			
DOCUMENT NUMBER:	136:308382			
TITLE:	Inflammatory mediators in uveitis: differential induction of cytokines and chemokines in Th1- versus Th2-mediated ocular inflammation			
AUTHOR(S):	Foxman, Ellen F.; Zhang, Meifen; Hurst, Stephen D.; Muchamuel, Tony; Shen, Defen; Wawrousek, Eric F.; Chan, Chi-Chao; Gery, Igal			
CORPORATE SOURCE:	National Eye Institute, National Institutes of Health,			
	Bethesda, MD, 20892, USA			
SOURCE:	Journal of Immunology (2002), 168(5), 2483-2492 CODEN: JOIMA3; ISSN: 0022-1767			
PUBLISHER:	American Association of Immunologists			
DOCUMENT TYPE:	Journal			
LANGUAGE:	English			

TI Inflammatory mediators in uveitis: differential induction of cytokines  
and  
chemokines in Th1- versus Th2-mediated ocular inflammation

SO Journal of Immunology (2002), 168(5), 2483-2492  
CODEN: JOIMA3; ISSN: 0022-1767

AU Foxman, Ellen F.; Zhang, Meifen; Hurst, Stephen D.; Muchamuel, Tony;  
Shen,  
Defen; Wawrousek, Eric F.; Chan, Chi-Chao; Gery, Igal

AB Ocular inflammation leads to vision loss through the destruction and  
scarring of delicate tissues along the visual axis. To identify  
inflammatory mediators involved in this process, we used real time RT-PCR  
to quantify the expression of mRNA transcripts of 34 cytokines, 26  
chemokines, and 14 chemokine receptors at certain time points during T  
cell-mediated ocular inflammation. We induced disease by adoptive  
transfer of Ag-specific Th1 or Th2 cells into recipients expressing the  
target Ag in their eyes. We also compared the mediator expression  
patterns seen in adoptive transfer-induced inflammation with that seen in  
mouse eyes developing exptl. autoimmune uveoretinitis. In addn., we used  
laser capture microdissection to examine chemokine mRNA prodn. by both  
retinal pigment epithelium cells and infiltrating leukocytes in inflamed  
eyes. Major findings included the following: 1) Three patterns of  
expression of the inflammation-related mols. were seen in recipients of  
adoptively transferred Th cells: preferential expression in Th1  
recipients, or in Th2 recipients, or similar expression in both recipient  
groups. 2) In exptl. autoimmune uveoretinitis, the inflammatory mediator  
expression pattern largely paralleled that seen in Th1-induced disease.  
3) Both retinal pigment epithelium and infiltrating leukocytes expressed  
chemokine transcripts in distinct, but overlapping patterns in inflamed  
eyes. 4) Interestingly, transcripts of multiple cytokines, chemokines,  
and chemokine receptors were constitutively expressed in high levels in  
mouse eyes. Seven of these mols. have not been previously assocd. with  
the eye. These data underscore the multiplicity of mediators that  
participate in the pathogenesis of eye inflammation and point to upstream  
cytokines as potential therapeutic targets.

REFERENCE COUNT: 77 THERE ARE 77 CITED REFERENCES AVAILABLE FOR  
THIS

RECORD. ALL CITATIONS AVAILABLE IN THE RE

FORMAT

L3 ANSWER 5 OF 12 CAPLUS COPYRIGHT 2002 ACS

ACCESSION NUMBER: 2001:781079 CAPLUS

DOCUMENT NUMBER: 135:348851

TITLE: Albumin fusion proteins with therapeutic proteins for  
improved shelf-life

INVENTOR(S): Rosen, Craig A.; Haseltine, William A.

PATENT ASSIGNEE(S): Human Genome Sciences, Inc, USA

SOURCE: PCT Int. Appl., 606 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 7

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2001079444	A2	20011025	WO 2001-US12013	20010412
WO 2001079444	A3	20020523		

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN,  
CO, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM,  
HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS,

LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO,  
 RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ,  
 VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM  
 RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY,  
 DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF,  
 BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG

AU 2001074809 A5 20011020 AU 2001-74809 20010412  
 PRIORITY APPLN. INFO.: US 2000-229358P P 20000412  
 US 2000-199384P P 20000425  
 US 2000-256931P P 20001221  
 WO 2001-US12013 W 20010412

TI Albumin fusion proteins with therapeutic proteins for improved shelf-life  
 SO PCT Int. Appl., 606 pp.  
 CODEN: PIXXD2

IN Rosen, Craig A.; Haseltine, William A.

AB The present invention encompasses fusion proteins of albumin with various  
 therapeutic proteins. Therapeutic proteins may be stabilized to extend  
 the shelf-life, and/or to retain the therapeutic protein's activity for  
 extended periods of time in soln., in vitro and/or in vivo, by  
 genetically  
 or chem. fusing or conjugating the therapeutic protein to albumin or a  
 fragment or variant of albumin. Use of albumin fusion proteins may also  
 reduce the need to formulate the protein solns. with large excesses of  
 carrier proteins to prevent loss of therapeutic proteins due to factors  
 such as binding to the container. Nucleic acid mols. encoding the  
 albumin  
 fusion proteins of the invention are also encompassed by the invention,  
 as  
 are vectors contg. these nucleic acids, host cells transformed with these  
 nucleic acids vectors, and methods of making the albumin fusion proteins  
 of the invention and using these nucleic acids, vectors, and/or host  
 cells. Thus, plasmid vectors are constructed in which DNA encoding the  
 desired therapeutic protein may be inserted for expression of the albumin  
 fusion proteins in yeast (pPPC0005) and mammalian cells (pC4:HSA).  
 Yeast-derived signal sequences from *Saccharomyces cerevisiae* invertase  
 SUC2 gene, or the stanniocalcin or native human serum albumin signal  
 peptides, are used for secretion in yeast or mammalian systems, resp.  
 Thus, the fusion product of human growth hormone with residues 1-387 of  
 human serum albumin retains essentially intact biol. activity after 5 wk  
 of incubation in tissue culture media at 37.degree., whereas recombinant  
 human growth hormone used as control lost its biol. activity in the first  
 week. Although the potency of the albumin fusion proteins is slightly  
 lower than the unfused counterparts in rapid bioassays, their biol.  
 stability results in much higher biol. activity in the longer term in  
 vitro assay or in vivo assays. Addnl., the present invention encompasses  
 pharmaceutical compns. comprising albumin fusion proteins and methods of  
 treating, preventing, or ameliorating diseases, disorders or conditions  
 using albumin fusion proteins of the invention.

L3 ANSWER 6 OF 12 CAPLUS COPYRIGHT 2002 ACS

ACCESSION NUMBER: 2001:110910 CAPLUS

DOCUMENT NUMBER: 134:290688

TITLE: ADP receptor **antagonists** inhibit platelet  
 aggregation induced by the chemokines SDF-1, MDC and  
 TARC

AUTHOR(S): Suttitanamongkol, S.; Gear, A. R. L.

CORPORATE SOURCE: Department of Biochemistry and Molecular Genetics,  
 University of Virginia, Charlottesville, VA, 22908,  
 USA

SOURCE: FEBS Letters (2001), 490(1,2), 84-87



CODEN: FEBLAL; ISSN: 0014-5793  
PUBLISHER: Elsevier Science B.V.  
DOCUMENT TYPE: Journal  
LANGUAGE: English  
TI ADP receptor **antagonists** inhibit platelet aggregation induced by  
the chemokines SDF-1, MDC and TARC  
SO FEBS Letters (2001), 490(1,2), 84-87  
CODEN: FEBLAL; ISSN: 0014-5793  
AU Suttitanamongkol, S.; Gear, A. R. L.  
AB The ability of the chemokines SDF-1, MDC and TARC to induce platelet  
aggregation depends strongly on low levels of ADP. The ADP receptors  
involved have now been characterized using the P2Y1 and P2TAC receptor  
**antagonists**, A2P5P and AR-C69931MX. Stimulation of aggregation by  
the chemokines at 10 s was not blocked by AR-C69931MX, but was strongly  
inhibited by A2P5P. Pertussis toxin abolished the chemokine-stimulated  
aggregation. We conclude that the P2Y1 ADP receptor plays a crit. role  
in  
the initial phases of SDF-1-, MDC- and TARC-induced platelet aggregation,  
which involve a pertussis toxin-sensitive G protein.  
REFERENCE COUNT: 29 THERE ARE 29 CITED REFERENCES AVAILABLE FOR  
THIS

RECORD. ALL CITATIONS AVAILABLE IN THE RE  
FORMAT

L3 ANSWER 7 OF 12 CAPLUS COPYRIGHT 2002 ACS  
ACCESSION NUMBER: 2000:790144 CAPLUS  
DOCUMENT NUMBER: 133:349154  
TITLE: CCR4 **antagonists** for treatment of septic  
shock  
INVENTOR(S): Power, Christina A.; Chivatchko, Yolande  
PATENT ASSIGNEE(S): Applied Research Systems ARS Holding N.V., Neth.  
Antilles  
SOURCE: Eur. Pat. Appl., 20 pp.  
CODEN: EPXXDW  
DOCUMENT TYPE: Patent  
LANGUAGE: English  
FAMILY ACC. NUM. COUNT: 1  
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
EP 1050307	A1	20001108	EP 1999-108954	19990506
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO				
WO 2000067791	A1	20001116	WO 2000-EP4018	20000504
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: GH, GM, KE, LS, MW, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
EP 1176980	A1	20020206	EP 2000-927140	20000504
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO				
PRIORITY APPLN. INFO.:			EP 1999-108954	A 19990506
			WO 2000-EP4018	W 20000504
TI CCR4 <b>antagonists</b> for treatment of septic shock				

SO Eur. Pat. Appl., 20 pp.  
 CODEN: EPXXDW  
 IN Power, Christina A.; Chivatchko, Yolande  
 AB The authors disclose the cytokine and cellular responses to lipopolysaccharide administration in mice having a targeted disruption of the CCR4 gene. CCR4 receptor **antagonists** (e.g., antibodies) are proposed for the treatment and/or prevention of septic shock.  
 REFERENCE COUNT: 9 THERE ARE 9 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE  
 FORMAT

L3 ANSWER 8 OF 12 CAPLUS COPYRIGHT 2002 ACS  
 ACCESSION NUMBER: 2000:712650 CAPLUS  
 DOCUMENT NUMBER: 133:277217  
 TITLE: Serial analysis of gene expression in human monocyte-derived dendritic cells  
 INVENTOR(S): Hashimoto, Shinichi; Matsushima, Koji; Suzuki, Takuji  
 PATENT ASSIGNEE(S): Foundation for Scientific Technology Promotion, Japan  
 SOURCE: Jpn. Kokai Tokkyo Koho, 33 pp.  
 CODEN: JKXXAF  
 DOCUMENT TYPE: Patent  
 LANGUAGE: Japanese  
 FAMILY ACC. NUM. COUNT: 1  
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
JP 2000279181	A2	20001010	JP 1999-95481	19990401
CA 2333908	AA	20001012	CA 2000-2333908	20000330
WO 2000060074	A1	20001012	WO 2000-JP2019	20000330
W: CA, CN, KR, SG, US				
RW: AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE				
EP 1087012	A1	20010328	EP 2000-912973	20000330
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, FI				

PRIORITY APPLN. INFO.: JP 1999-95481 A 19990401  
 WO 2000-JP2019 W 20000330

TI Serial analysis of gene expression in human monocyte-derived dendritic cells  
 SO Jpn. Kokai Tokkyo Koho, 33 pp.  
 CODEN: JKXXAF  
 IN Hashimoto, Shinichi; Matsushima, Koji; Suzuki, Takuji  
 AB Genes expressed in human monocyte-derived dendritic cells (DCs), antibody or **antagonist** for the protein products are disclosed. Dendritic cells (DCs) are professional antigen-presenting cells in the immune system  
 and can be generated in vitro from hematopoietic progenitor cells in the bone marrow, CD34+ cord blood cells, precursor cells in the peripheral blood, and blood monocytes by culturing with granulocyte-macrophage colony-stimulating factor (GM-CSF), interleukin-4, and tumor necrosis factor-.alpha.. The authors have performed serial anal. of gene expression (SAGE) in DCs derived from human blood monocytes. A total of 58,540 tag sequences from a DC cDNA library represented more than 17,000 different genes, and these data were compared with SAGE anal. of tags  
 from monocytes (Mo) and GM-CSF-induced macrophages (M.phi.). Many of the genes that were differentially expressed in DCs were identified as genes encoding proteins related to cell structure (gelsolin, vinculin), lipid

metab. (lysosome acid lipase, apolipoprotein C-1), and cell motility. Interestingly, the highly expressed genes in DCs encode chemokines such as TARC, MDC, and MCP-4, which preferentially chemoattract Th2-type lymphocytes. Some genes had a lower expression in DCs as compared to in monocytes. Although DCs have been considered to be very heterogeneous, the identification of specific genes expressed in human Mo-derived DCs should provide candidate genes to define subsets of, the function of, and the maturation stage of DCs and possibly also to diagnose diseases in which DCs play a significant role, such as autoimmune diseases and neoplasms. This study represents the first extensive gene expression anal. in any type of DCs.

L3 ANSWER 9 OF 12 CAPLUS COPYRIGHT 2002 ACS

ACCESSION NUMBER: 2000:446020 CAPLUS

DOCUMENT NUMBER: 133:175944

TITLE: Stromal cell-derived factor-1 and **macrophage-derived chemokine**: 2 chemokines that activate platelets

AUTHOR(S): Kowalska, M. Anna; Ratajczak, Mariusz Z.; Majka, Marcin; Jin, Jianguo; Kunapuli, Satya; Brass, Lawrence; Poncz, Mortimer

CORPORATE SOURCE: Department of Pediatrics, Children's Hospital of Philadelphia, Philadelphia, PA, 19104, USA

SOURCE: Blood (2000), 96(1), 50-57  
CODEN: BLOOAW; ISSN: 0006-4971

PUBLISHER: American Society of Hematology

DOCUMENT TYPE: Journal

LANGUAGE: English

TI Stromal cell-derived factor-1 and **macrophage-derived chemokine**: 2 chemokines that activate platelets

SO Blood (2000), 96(1), 50-57  
CODEN: BLOOAW; ISSN: 0006-4971

AU Kowalska, M. Anna; Ratajczak, Mariusz Z.; Majka, Marcin; Jin, Jianguo; Kunapuli, Satya; Brass, Lawrence; Poncz, Mortimer

AB Platelets play roles in both thrombosis and inflammation, and chemokines that are released at sites of inflammation could potentially activate platelets. Among the chemokine receptors expressed on platelets, the CXCR4 is the receptor for chemokine stromal cell-derived factor-1

(SDF-1), and the CCR4 is the receptor for **macrophage-derived chemokine** (MDC). Of the chemokines tested, SDF-1 and MDC were the only 2 that activated platelets. Both are weak agonists, but they enhanced response to low-dose ADP, epinephrine, or serotonin. When SDF-1 and MDC were added together, full and brisk platelet aggregation occurred.

Platelet activation by these 2 chemokines appears to involve distinct pathways: SDF-1 inhibited an increase in cAMP following prostaglandin

(PG) I2, while MDC had no effect. In contrast, MDC, but not SDF-1, lead to Ca2+ mobilization by platelets. Further, second-wave aggregation induced by MDC in platelet-rich plasma was inhibited by aspirin, ADP scavenger creatine phosphate/creatine phosphokinase (CP/CPK), and ARL-66096, an **antagonist** of the ADP P2TAC receptor involved in adenylyl cyclase inhibition. However, the aggregation was not affected by A3P5PS, an inhibitor of the ADP P2Y receptor. SDF-1-induced aggregation was inhibited by aspirin, but it was only slightly affected by CP/CPK, ARL-66096, or A3P5PS. Finally, the presence of chemokines in platelets was detd. Reverse transcriptase-polymerase chain reaction studies with platelet RNA did not detect the presence of SDF-1 or MDC. Thus, SDF-1

and

MDC are platelet agonists that activate distinct intracellular pathways.  
REFERENCE COUNT: 45 THERE ARE 45 CITED REFERENCES AVAILABLE FOR  
THIS

RECORD. ALL CITATIONS AVAILABLE IN THE RE  
FORMAT

L3 ANSWER 10 OF 12 CAPLUS COPYRIGHT 2002 ACS  
ACCESSION NUMBER: 1999:783948 CAPLUS  
DOCUMENT NUMBER: 132:9042  
TITLE: Receptor ligand **antagonist** complexes and  
their use in treating or preventing receptor-mediated  
diseases  
INVENTOR(S): Devico, Anthony L.; Lewis, George K.; Burns, Jennifer  
M.; Gallo, Robert  
PATENT ASSIGNEE(S): University of Maryland Biotechnology Institute, USA  
SOURCE: PCT Int. Appl., 71 pp.  
CODEN: PIXXD2  
DOCUMENT TYPE: Patent  
LANGUAGE: English  
FAMILY ACC. NUM. COUNT: 1  
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9962535	A2	19991209	WO 1999-US12137	19990601
WO 9962535	A3	20010329		
W:	AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM			
RW:	GH, GM, KE, LS, MW, SD, SL, SZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG			
AU 9943254	A1	19991220	AU 1999-43254	19990601
EP 1100527	A2	20010523	EP 1999-955219	19990601
R:	AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, FI			
US 6399078	B1	20020604	US 1999-323719	19990601
PRIORITY APPLN. INFO.:			US 1998-87436P P	19980601
			WO 1999-US12137 W	19990601
TI	Receptor ligand <b>antagonist</b> complexes and their use in treating or preventing receptor-mediated diseases			
SO	PCT Int. Appl., 71 pp. CODEN: PIXXD2			
IN	Devico, Anthony L.; Lewis, George K.; Burns, Jennifer M.; Gallo, Robert			
AB	The invention provides therapeutic compns. of receptor ligand-contg. <b>antagonist</b> complexes and methods of using them to treat diseases, disorders or conditions assocd. with the function or aberrant function of a cell surface receptor.			

L3 ANSWER 11 OF 12 CAPLUS COPYRIGHT 2002 ACS  
ACCESSION NUMBER: 1998:398418 CAPLUS  
DOCUMENT NUMBER: 129:53370  
TITLE: Human chemokine .beta.-13, recombinant production, antibody and nucleic acid probes, and gene therapy  
INVENTOR(S): Li, Haodong; Seibel, George  
PATENT ASSIGNEE(S): Human Genome Sciences, Inc., USA; Li, Haodong; Seibel,

SOURCE: George  
PCT Int. Appl., 86 pp.  
CODEN: PIXXD2  
DOCUMENT TYPE: Patent  
LANGUAGE: English  
FAMILY ACC. NUM. COUNT: 2  
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9824908	A1	19980611	WO 1997-US23144	19971205
W: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, GH, HU, ID, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: GH, KE, LS, MW, SD, SZ, UG, ZW, AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG				
AU 9853834	A1	19980629	AU 1998-53834	19971205
EP 958366	A1	19991124	EP 1997-950969	19971205
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, FI				
JP 2001506492	T2	20010522	JP 1998-525919	19971205
US 2002055147	A1	20020509	US 2001-908599	20010720
US 2002098545	A1	20020725	US 2001-908600	20010720
PRIORITY APPLN. INFO.:			US 1996-32432P	P 19961205
			US 1995-464594	A2 19950605
			US 1997-986188	B2 19971205
			WO 1997-US23144	W 19971205
			US 1999-432768	B1 19991103
			US 2000-484221	B1 20000118
TI	Human chemokine .beta.-13, recombinant production, antibody and nucleic acid probes, and gene therapy			
SO	PCT Int. Appl., 86 pp. CODEN: PIXXD2			
IN	Li, Haodong; Seibel, George			
AB	The present invention relates to a CKbeta-13 (CK.beta.-13) protein which is a member of the chemokine family. In particular, isolated nucleic acid mols. are provided encoding the human CK.beta.-13 protein. Human CK.beta.-13 cDNA contains an open reading frame encoding a protein 93 amino acids in length; two secreted forms are detected with N-terminal Gly25 or Ala29 residues, resp. CK.beta.-13 polypeptides are also provided as are vectors, host cells and recombinant methods for producing the same.			
The invention further relates to screening methods for identifying agonists and <b>antagonists</b> of CK.beta.-13 activity. Also provided are diagnostic methods for detecting immune system-related disorders and therapeutic methods for treating immune system-related disorders.				
REFERENCE COUNT:	9	THERE ARE 9 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE		
FORMAT				
L3 ANSWER 12 OF 12 BIOSIS COPYRIGHT 2002 BIOLOGICAL ABSTRACTS INC.				
ACCESSION NUMBER:	2000:343420 BIOSIS			
DOCUMENT NUMBER:	PREV200000343420			
TITLE:	Stromal cell-derived factor-1 and <b>macrophage-derived chemokine</b> : 2 chemokines that			

activate platelets.

AUTHOR(S): Kowalska, M. Anna (1); Ratajczak, Mariusz Z.; Majka, Marcin; Jin, Jianguo; Kunapuli, Satya; Brass, Lawrence; Poncz, Mortimer

CORPORATE SOURCE: (1) Children's Hospital of Philadelphia, 34th Street and Civic Center Blvd, ARC, Room 3141, Philadelphia, PA, 19104 USA

SOURCE: Blood, (July 1, 2000) Vol. 96, No. 1, pp. 50-57. print. ISSN: 0006-4971.

DOCUMENT TYPE: Article

LANGUAGE: English

SUMMARY LANGUAGE: English

TI Stromal cell-derived factor-1 and **macrophage-derived chemokine**: 2 chemokines that activate platelets.

SO Blood, (July 1, 2000) Vol. 96, No. 1, pp. 50-57. print. ISSN: 0006-4971.

AU Kowalska, M. Anna (1); Ratajczak, Mariusz Z.; Majka, Marcin; Jin, Jianguo; Kunapuli, Satya; Brass, Lawrence; Poncz, Mortimer

AB Platelets play roles in both thrombosis and inflammation, and chemokines that are released at sites of inflammation could potentially activate platelets. Among the chemokine receptors expressed on platelets, the CXCR4 is the receptor for chemokine stromal cell-derived factor-1 (SDF-1), and the CCR4 is the receptor for **macrophage-derived chemokine** (MDC). Of the chemokines tested, SDF-1 and MDC were the only 2 that activated platelets. Both are weak agonists, but they enhanced response to low-dose adenosine 5'-diphosphate (ADP), epinephrine, or serotonin. When SDF-1 and MDC were added together, full and brisk platelet aggregation occurred. Platelet activation by these 2 chemokines appears to involve distinct pathways: SDF-1 inhibited an increase in cyclic adenosine monophosphate (cAMP) following prostaglandin (PG) I2, while MDC had no effect. In contrast, MDC, but not SDF-1, lead to Ca++ mobilization by platelets. Further, second-wave aggregation induced by MDC in platelet-rich plasma was inhibited by aspirin, ADP scavenger creatine phosphate/creative phosphokinase (CP/CPK), and ARL-66096, an **antagonist** of the ADP P2TAC receptor involved in adenylyl cyclase inhibition. But the aggregation was not affected by A3P5PS, an inhibitor of the ADP P2Y receptor. SDF-1-induced aggregation was inhibited by aspirin, but it was only slightly affected by CP/CPK, ARL-66096, or A3P5PS. Finally, the presence of chemokines in platelets was determined. Reverse transcriptase-polymerase chain reaction studies with platelet RNA did not detect the presence of SDF-1 or MDC. In summary, SDF-1 and MDC are platelet agonists that activate distinct intracellular pathways. Their importance in the development of thrombosis at sites of inflammation needs to be further evaluated.

=> D L4 IBIB TI AU 1-59

L4 ANSWER 1 OF 59 CAPLUS COPYRIGHT 2002 ACS

ACCESSION NUMBER: 2002:832650 CAPLUS

TITLE: Use of dendritic cell-attracting chemokines for augmentation of an immune response

INVENTOR(S): Schall, Thomas J.; Talbot, Dale; Berkovitz, Robert;  
Zheng, Wei; Howard, Maureen; Premack, Brett  
PATENT ASSIGNEE(S): Chemocentryx, USA  
SOURCE: PCT Int. Appl., 80 pp.  
CODEN: PIXXD2  
DOCUMENT TYPE: Patent  
LANGUAGE: English  
FAMILY ACC. NUM. COUNT: 3  
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2002085409	A2	20021031	WO 2001-US45717	20011030

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN,  
CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH,  
GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR,  
LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PH, PL,  
PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG,  
UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM  
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY,  
DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF,  
BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG

PRIORITY APPLN. INFO.: US 2001-834814 A 20010412  
TI Use of dendritic cell-attracting chemokines for augmentation of an immune  
response  
IN Schall, Thomas J.; Talbot, Dale; Berkovitz, Robert; Zheng, Wei; Howard,  
Maureen; Premack, Brett

L4 ANSWER 2 OF 59 CAPLUS COPYRIGHT 2002 ACS

ACCESSION NUMBER: 2002:676193 CAPLUS

DOCUMENT NUMBER: 137:215825

TITLE: Protein and cDNA sequences of human cytokine receptor  
complex including IL-7R.alpha. and R.delta.2 subunit  
for cytokine ligand IL-B50

INVENTOR(S): Reche-Gallardo, Pedro A.; De Waal Malefyt, Rene;  
Bazan, J. Fernando; Kastelein, Robert A.; Liu,  
Yong-Jun

PATENT ASSIGNEE(S): Schering Corporation, USA

SOURCE: PCT Int. Appl., 118 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2002068646	A2	20020906	WO 2001-US50351	20011109

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN,  
CO, CR, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, HR, HU,  
ID, IL, IN, IS, JP, KG, KR, KZ, LC, LK, LR, LT, LU, LV, MA, MD,  
MG, MK, MN, MX, MZ, NO, NZ, PH, PL, PT, RO, RU, SE, SG, SI, SK,  
SL, TJ, TM, TR, TT, TZ, UA, UZ, VN, YU, ZA, AM, AZ, BY, KG, KZ,  
MD, RU, TJ, TM  
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY,  
DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF,  
BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG

US 2002173623 A1 20021121 US 2001-8566 20011108  
PRIORITY APPLN. INFO.: US 2000-247218P P 20001110  
US 2001-298268P P 20010614

TI Protein and cDNA sequences of human cytokine receptor complex including  
IL-7R.alpha. and R.delta.2 subunit for cytokine ligand IL-B50  
IN Reche-Gallardo, Pedro A.; De Waal Malefyt, Rene; Bazan, J. Fernando;  
Kastelein, Robert A.; Liu, Yong-Jun

L4 ANSWER 3 OF 59 CAPLUS COPYRIGHT 2002 ACS

ACCESSION NUMBER: 2002:629149 CAPLUS

DOCUMENT NUMBER: 137:199862

TITLE: DNA vaccines encoding human immunodeficiency virus-1  
glycoprotein 120 fusions with proinflammatory  
chemoattractants induce systemic and mucosal immune  
responses

AUTHOR(S): Biragyn, Arya; Belyakov, Igor M.; Chow, Yen-Hung;  
Dimitrov, Dimitar S.; Berzofsky, Jay A.; Kwak, Larry  
W.

CORPORATE SOURCE: Experimental Transplantation and Immunology Branch,  
Center for Cancer Research, National Cancer  
Institute,

Bethesda, MD, USA  
SOURCE: Blood (2002), 100(4), 1153-1159

CODEN: BLOOAW; ISSN: 0006-4971

PUBLISHER: American Society of Hematology

DOCUMENT TYPE: Journal

LANGUAGE: English

TI DNA vaccines encoding human immunodeficiency virus-1 glycoprotein 120  
fusions with proinflammatory chemoattractants induce systemic and mucosal  
immune responses

AU Biragyn, Arya; Belyakov, Igor M.; Chow, Yen-Hung; Dimitrov, Dimitar S.;  
Berzofsky, Jay A.; Kwak, Larry W.

REFERENCE COUNT: 37 THERE ARE 37 CITED REFERENCES AVAILABLE FOR  
THIS

RECORD. ALL CITATIONS AVAILABLE IN THE RE

FORMAT

L4 ANSWER 4 OF 59 CAPLUS COPYRIGHT 2002 ACS

ACCESSION NUMBER: 2002:429201 CAPLUS

DOCUMENT NUMBER: 137:4997

TITLE: Method for diagnosing allergic diseases using DNA and  
protein microarray technology

INVENTOR(S): Schmidt-Weber, Carsten; Blaser, Kurt; Wohlfahrt, Jan

PATENT ASSIGNEE(S): Genescan Europe Ag, Germany

SOURCE: PCT Int. Appl., 61 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2002044732	A2	20020606	WO 2001-EP13937	20011129
W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM			
RW:	GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG			



EP 1221618 A1 20020710 EP 2000-126117 20001129  
 R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT,  
 IE, SI, LT, LV, FI, RO, MK, CY, AL, TR  
 AU 2002021906 A5 20020611 AU 2002-21906 20011129  
 PRIORITY APPLN. INFO.: EP 2000-126117 A 20001129  
 WO 2001-EP13937 W 20011129  
 TI Method for diagnosing allergic diseases using DNA and protein microarray  
 technology  
 IN Schmidt-Weber, Carsten; Blaser, Kurt; Wohlfahrt, Jan

L4 ANSWER 5 OF 59 CAPLUS COPYRIGHT 2002 ACS  
 ACCESSION NUMBER: 2002:428737 CAPLUS  
 DOCUMENT NUMBER: 137:1473  
 TITLE: Chemokine and chemokine receptor gene expression for  
 skin disorder diagnosis and therapy  
 INVENTOR(S): Homey, Bernhard; Zepeda, Monica L.; Zlotnik, Albert  
 PATENT ASSIGNEE(S): Schering Corporation, USA  
 SOURCE: PCT Int. Appl., 17 pp.  
 CODEN: PIXXD2  
 DOCUMENT TYPE: Patent  
 LANGUAGE: English  
 FAMILY ACC. NUM. COUNT: 1  
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2002043758	A2	20020606	WO 2001-US44338	20011127
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, HR, HU, ID, IL, IN, IS, JP, KG, KR, KZ, LC, LK, LR, LT, LU, LV, MA, MD, MG, MK, MN, MX, MZ, NO, NZ, PH, PL, PT, RO, RU, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UZ, VN, YU, ZA, ZM, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
AU 2002025756	A5	20020611	AU 2002-25756	20011127
US 2002111290	A1	20020815	US 2001-995534	20011127
PRIORITY APPLN. INFO.:			US 2000-250782P	P 20001201
			WO 2001-US44338	W 20011127
TI Chemokine and chemokine receptor gene expression for skin disorder diagnosis and therapy				
IN Homey, Bernhard; Zepeda, Monica L.; Zlotnik, Albert				

L4 ANSWER 6 OF 59 CAPLUS COPYRIGHT 2002 ACS  
 ACCESSION NUMBER: 2002:420603 CAPLUS  
 DOCUMENT NUMBER: 137:45954  
 TITLE: Common and differential chemokine expression patterns  
 in RS cells of NLP, EBV positive and negative  
 classical Hodgkin lymphomas  
 AUTHOR(S): Maggio, Ewerton M.; Van den Berg, Anke; Visser,  
 Lydia;  
 Diepstra, Arjan; Kluiver, Joust; Emmens, Roelke;  
 Poppema, Sibrand  
 CORPORATE SOURCE: Department of Pathology and Laboratory Medicine,  
 University Hospital Groningen, Groningen, Neth.  
 SOURCE: International Journal of Cancer (2002), 99(5),  
 665-672  
 CODEN: IJCNAW; ISSN: 0020-7136  
 PUBLISHER: Wiley-Liss, Inc.

DOCUMENT TYPE: Journal  
LANGUAGE: English  
TI Common and differential chemokine expression patterns in RS cells of NLP,  
EBV positive and negative classical Hodgkin lymphomas  
AU Maggio, Ewerton M.; Van den Berg, Anke; Visser, Lydia; Diepstra, Arjan;  
Kluiver, Joust; Emmens, Roelke; Poppema, Sibrand  
REFERENCE COUNT: 64 THERE ARE 64 CITED REFERENCES AVAILABLE FOR  
THIS  
RECORD. ALL CITATIONS AVAILABLE IN THE RE  
FORMAT

L4 ANSWER 7 OF 59 CAPLUS COPYRIGHT 2002 ACS  
ACCESSION NUMBER: 2002:396033 CAPLUS  
DOCUMENT NUMBER: 137:277426  
TITLE: CD26 is expressed on a restricted subpopulation of  
dendritic cells in vivo  
AUTHOR(S): Gliddon, Daniel R.; Howard, Chris J.  
CORPORATE SOURCE: Institute for Animal Health, Newbury, UK  
SOURCE: European Journal of Immunology (2002), 32(5),  
1472-1481  
CODEN: EJIMAF; ISSN: 0014-2980  
PUBLISHER: Wiley-VCH Verlag GmbH  
DOCUMENT TYPE: Journal  
LANGUAGE: English  
TI CD26 is expressed on a restricted subpopulation of dendritic cells in  
vivo  
AU Gliddon, Daniel R.; Howard, Chris J.  
REFERENCE COUNT: 36 THERE ARE 36 CITED REFERENCES AVAILABLE FOR  
THIS  
RECORD. ALL CITATIONS AVAILABLE IN THE RE  
FORMAT

L4 ANSWER 8 OF 59 CAPLUS COPYRIGHT 2002 ACS  
ACCESSION NUMBER: 2002:396025 CAPLUS  
DOCUMENT NUMBER: 137:31957  
TITLE: Chronic lymphocytic leukemia B cells are endowed with  
the capacity to attract CD4+, CD40L+ T cells by  
producing CCL22  
AUTHOR(S): Ghia, Paolo; Strola, Giuliana; Granziero, Luisa;  
Geuna, Massimo; Guida, Giuseppe; Sallusto, Federica;  
Ruffing, Nancy; Montagna, Licia; Piccoli, Paola;  
Chilosi, Marco; Caligaris-Cappio, Federico  
CORPORATE SOURCE: Department of Oncological Sciences, University of  
Torino, University Division of Clinical Immunology  
and  
Hematology, Ospedale Mauriziano Umberto I.degree.,  
Turin, Italy  
SOURCE: European Journal of Immunology (2002), 32(5),  
1403-1413  
CODEN: EJIMAF; ISSN: 0014-2980  
PUBLISHER: Wiley-VCH Verlag GmbH  
DOCUMENT TYPE: Journal  
LANGUAGE: English  
TI Chronic lymphocytic leukemia B cells are endowed with the capacity to  
attract CD4+, CD40L+ T cells by producing CCL22  
AU Ghia, Paolo; Strola, Giuliana; Granziero, Luisa; Geuna, Massimo; Guida,  
Giuseppe; Sallusto, Federica; Ruffing, Nancy; Montagna, Licia; Piccoli,  
Paola; Chilosi, Marco; Caligaris-Cappio, Federico  
REFERENCE COUNT: 40 THERE ARE 40 CITED REFERENCES AVAILABLE FOR  
THIS

RECORD. ALL CITATIONS AVAILABLE IN THE RE

FORMAT

L4 ANSWER 9 OF 59 CAPLUS COPYRIGHT 2002 ACS  
 ACCESSION NUMBER: 2002:393356 CAPLUS  
 DOCUMENT NUMBER: 137:31858  
 TITLE: Pivotal role of dendritic cell-derived CXCL10 in the retention of T helper cell 1 lymphocytes in secondary lymph nodes  
 AUTHOR(S): Yoneyama, Hiroyuki; Narumi, Shosaku; Zhang, Yanyun; Murai, Masako; Baggiolini, Marco; Lanzavecchia, Antonio; Ichida, Takafumi; Asakura, Hitoshi; Matsushima, Kouji  
 CORPORATE SOURCE: Department of Molecular Preventive Medicine, School of  
 of Medicine and Core Research and Evolutional Science  
 and Technology (CREST), The University of Tokyo, Tokyo, 113-0033, Japan  
 SOURCE: Journal of Experimental Medicine (2002), 195(10), 1257-1266  
 CODEN: JEMEAV; ISSN: 0022-1007  
 PUBLISHER: Rockefeller University Press  
 DOCUMENT TYPE: Journal  
 LANGUAGE: English  
 TI Pivotal role of dendritic cell-derived CXCL10 in the retention of T helper cell 1 lymphocytes in secondary lymph nodes  
 AU Yoneyama, Hiroyuki; Narumi, Shosaku; Zhang, Yanyun; Murai, Masako; Baggiolini, Marco; Lanzavecchia, Antonio; Ichida, Takafumi; Asakura, Hitoshi; Matsushima, Kouji  
 REFERENCE COUNT: 39 THERE ARE 39 CITED REFERENCES AVAILABLE FOR THIS

RECORD. ALL CITATIONS AVAILABLE IN THE RE

FORMAT

L4 ANSWER 10 OF 59 CAPLUS COPYRIGHT 2002 ACS  
 ACCESSION NUMBER: 2002:291218 CAPLUS  
 DOCUMENT NUMBER: 136:384549  
 TITLE: Multiplexed protein profiling on microarrays by rolling-circle amplification  
 AUTHOR(S): Schweitzer, Barry; Roberts, Scott; Grimwade, Brian; Shao, Weiping; Wang, Minjuan; Fu, Qin; Shu, Quiping; Laroche, Isabelle; Zhou, Zhimin; Tchernev, Velizar  
 T.; Christiansen, Jason; Velleca, Mark; Kingsmore, Stephen  
 F.  
 CORPORATE SOURCE: Molecular Staging, Inc., New Haven, CT, 06511, USA  
 SOURCE: Nature Biotechnology (2002), 20(4), 359-365  
 CODEN: NABIF9; ISSN: 1087-0156  
 PUBLISHER: Nature America Inc.  
 DOCUMENT TYPE: Journal  
 LANGUAGE: English  
 TI Multiplexed protein profiling on microarrays by rolling-circle amplification  
 AU Schweitzer, Barry; Roberts, Scott; Grimwade, Brian; Shao, Weiping; Wang, Minjuan; Fu, Qin; Shu, Quiping; Laroche, Isabelle; Zhou, Zhimin; Tchernev, Velizar  
 T.; Christiansen, Jason; Velleca, Mark; Kingsmore, Stephen F.

REFERENCE COUNT: 52 THERE ARE 52 CITED REFERENCES AVAILABLE FOR THIS

RECORD. ALL CITATIONS AVAILABLE IN THE RE

FORMAT

L4 ANSWER 11 OF 59 CAPLUS COPYRIGHT 2002 ACS

ACCESSION NUMBER: 2002:220660 CAPLUS

DOCUMENT NUMBER: 136:246391

TITLE: Fusion proteins comprising defensin and human tumor antigen or viral antigen for treating cancer and viral

infection

INVENTOR(S): Kwak, Larry W.; Biragyn, Arya

PATENT ASSIGNEE(S): United States of America, Department of Health and Human Services, USA

SOURCE: PCT Int. Appl., 154 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2002022686	A2	20020321	WO 2001-US29074	20010917
W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM			
RW:	GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG			
AU 2001091049	A5	20020326	AU 2001-91049	20010917
PRIORITY APPLN. INFO.:			US 2000-233074P	P 20000915
			WO 2001-US29074	W 20010917

TI Fusion proteins comprising defensin and human tumor antigen or viral antigen for treating cancer and viral infection

IN Kwak, Larry W.; Biragyn, Arya

L4 ANSWER 12 OF 59 CAPLUS COPYRIGHT 2002 ACS

ACCESSION NUMBER: 2002:209558 CAPLUS

DOCUMENT NUMBER: 136:323785

TITLE: The identification, characterization, and distribution

of guinea pig CCR4 and epitope mapping of a blocking antibody

AUTHOR(S): Jopling, Louise A.; Sabroe, Ian; Andrew, David P.; Mitchell, Tracey J.; Li, You; Hodge, Martin R.; Williams, Timothy J.; Pease, James E.

CORPORATE SOURCE: Leukocyte Biology Section, Biomedical Sciences Division, Faculty of Medicine, Imperial College of Science, Technology and Medicine, London, SW7 2AZ, UK

SOURCE: Journal of Biological Chemistry (2002), 277(9), 6864-6873

CODEN: JBCHA3; ISSN: 0021-9258

PUBLISHER: American Society for Biochemistry and Molecular Biology

DOCUMENT TYPE: Journal

LANGUAGE: English  
TI The identification, characterization, and distribution of guinea pig CCR4  
and epitope mapping of a blocking **antibody**  
AU Jopling, Louise A.; Sabroe, Ian; Andrew, David P.; Mitchell, Tracey J.;  
Li, You; Hodge, Martin R.; Williams, Timothy J.; Pease, James E.  
REFERENCE COUNT: 54 THERE ARE 54 CITED REFERENCES AVAILABLE FOR  
THIS

RECORD. ALL CITATIONS AVAILABLE IN THE RE

FORMAT

L4 ANSWER 13 OF 59 CAPLUS COPYRIGHT 2002 ACS  
ACCESSION NUMBER: 2002:184856 CAPLUS  
DOCUMENT NUMBER: 136:246373  
TITLE: Genetically engineered co-expression DNA vaccines:  
construction and application  
INVENTOR(S): Hone, David; Lewis, George; Fouts, Timothy; Bagley,  
Ken; Boyson, Michael; Obriecht, Christine; Shata, M.  
T.; Agwale, Simon  
PATENT ASSIGNEE(S): University of Maryland Biotechnology Institute, USA  
SOURCE: PCT Int. Appl., 107 pp.  
CODEN: PIXXD2  
DOCUMENT TYPE: Patent  
LANGUAGE: English  
FAMILY ACC. NUM. COUNT: 1  
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2002019968	A2	20020314	WO 2001-US28365	20010910
WO 2002019968	A3	20020516		
W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM			
RW:	GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG			
AU 2001092610	A5	20020322	AU 2001-92610	20010910
PRIORITY APPLN. INFO.:			US 2000-231070P	P 20000908
			US 2000-231376P	P 20000908
			US 2000-231403P	P 20000908
			US 2000-231449P	P 20000908
			WO 2001-US28365	W 20010910
TI	Genetically engineered co-expression DNA vaccines: construction and application			
IN	Hone, David; Lewis, George; Fouts, Timothy; Bagley, Ken; Boyson, Michael; Obriecht, Christine; Shata, M. T.; Agwale, Simon			

L4 ANSWER 14 OF 59 CAPLUS COPYRIGHT 2002 ACS  
ACCESSION NUMBER: 2002:157599 CAPLUS  
DOCUMENT NUMBER: 136:198922  
TITLE: Adjuvant activity of .alpha.2-macroglobulin,  
monophosphoryl lipid A, and GM-CSF  
INVENTOR(S): Haynes, Barton F.; Liao, Hua-Xin; Patel, Dhavalkumar  
D.  
PATENT ASSIGNEE(S): Duke University, USA  
SOURCE: PCT Int. Appl., 53 pp.  
CODEN: PIXXD2

DOCUMENT TYPE: Patent  
LANGUAGE: English  
FAMILY ACC. NUM. COUNT: 1  
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2002015930	A1	20020228	WO 2001-US26589	20010827
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
AU 2001086775	A5	20020304	AU 2001-86775	20010827
US 2002052318	A1	20020502	US 2001-938831	20010827
PRIORITY APPLN. INFO.:			US 2000-227624P P	20000825
			WO 2001-US26589 W	20010827
TI Adjuvant activity of .alpha.2-macroglobulin, monophosphoryl lipid A, and GM-CSF				
IN Haynes, Barton F.; Liao, Hua-Xin; Patel, Dhavalkumar D.				
REFERENCE COUNT: 4 THERE ARE 4 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE				

FORMAT

L4 ANSWER 15 OF 59 CAPLUS COPYRIGHT 2002 ACS  
ACCESSION NUMBER: 2002:54705 CAPLUS  
DOCUMENT NUMBER: 136:230952  
TITLE: MCP-1 causes leukocyte recruitment and subsequently endotoxemic ileus in rat  
AUTHOR(S): Turler, Andreas; Schwarz, Nicolas T.; Turler, Esther; Kalff, Jorg C.; Bauer, Anthony J.  
CORPORATE SOURCE: Department of Medicine, Division of Gastroenterology, University of Pittsburgh Medical Center, Pittsburgh, PA, 15261, USA  
SOURCE: American Journal of Physiology (2002), 282(1, Pt. 1), G145-G155  
CODEN: AJPHAP; ISSN: 0002-9513  
PUBLISHER: American Physiological Society  
DOCUMENT TYPE: Journal  
LANGUAGE: English  
TI MCP-1 causes leukocyte recruitment and subsequently endotoxemic ileus in rat  
AU Turler, Andreas; Schwarz, Nicolas T.; Turler, Esther; Kalff, Jorg C.; Bauer, Anthony J.  
REFERENCE COUNT: 57 THERE ARE 57 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE  
FORMAT

L4 ANSWER 16 OF 59 CAPLUS COPYRIGHT 2002 ACS  
ACCESSION NUMBER: 2001:846630 CAPLUS  
DOCUMENT NUMBER: 136:117262  
TITLE: Increased CCR4 expression in active systemic lupus erythematosus  
AUTHOR(S): Hase, Kayoko; Tani, Kenji; Shimizu, Teruki; Ohmoto, Yasukazu; Matsushima, Kouji; Sone, Saburo

CORPORATE SOURCE: Third Department of Internal Medicine, School of  
Medicine, Tokushima University, Tokushima City,  
770-8503, Japan

SOURCE: Journal of Leukocyte Biology (2001), 70(5), 749-755  
CODEN: JLBIE7; ISSN: 0741-5400

PUBLISHER: Federation of American Societies for Experimental  
Biology

DOCUMENT TYPE: Journal

LANGUAGE: English

TI Increased CCR4 expression in active systemic lupus erythematosus

AU Hase, Kayoko; Tani, Kenji; Shimizu, Teruki; Ohmoto, Yasukazu; Matsushima,  
Kouji; Sone, Saburo

REFERENCE COUNT: 41 THERE ARE 41 CITED REFERENCES AVAILABLE FOR  
THIS  
RECORD. ALL CITATIONS AVAILABLE IN THE RE  
FORMAT

L4 ANSWER 17 OF 59 CAPLUS COPYRIGHT 2002 ACS

ACCESSION NUMBER: 2001:781079 CAPLUS

DOCUMENT NUMBER: 135:348851

TITLE: Albumin fusion proteins with therapeutic proteins for  
improved shelf-life

INVENTOR(S): Rosen, Craig A.; Haseltine, William A.

PATENT ASSIGNEE(S): Human Genome Sciences, Inc, USA

SOURCE: PCT Int. Appl., 606 pp.  
CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 7

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2001079444	A2	20011025	WO 2001-US12013	20010412
WO 2001079444	A3	20020523		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
AU 2001074809	A5	20011020	AU 2001-74809	20010412
PRIORITY APPLN. INFO.:			US 2000-229358P	P 20000412
			US 2000-199384P	P 20000425
			US 2000-256931P	P 20001221
			WO 2001-US12013	W 20010412
TI Albumin fusion proteins with therapeutic proteins for improved shelf-life				
IN Rosen, Craig A.; Haseltine, William A.				

L4 ANSWER 18 OF 59 CAPLUS COPYRIGHT 2002 ACS

ACCESSION NUMBER: 2001:724619 CAPLUS

DOCUMENT NUMBER: 136:36134

TITLE: Enhancement of stromal cell-derived  
factor-1.alpha.-induced chemotaxis for CD4/8  
double-positive thymocytes by fibronectin and laminin  
in mice

AUTHOR(S): Yanagawa, Yoshiki; Iwabuchi, Kazuya; Onoe, Kazunori

CORPORATE SOURCE: Division of Immunobiology, Institute for Genetic  
Medicine, Hokkaido University, Sapporo, 060-0815,  
Japan  
SOURCE: Immunology (2001), 104(1), 43-49  
CODEN: IMMUAM; ISSN: 0019-2805  
PUBLISHER: Blackwell Science Ltd.  
DOCUMENT TYPE: Journal  
LANGUAGE: English  
TI Enhancement of stromal cell-derived factor-1.alpha.-induced chemotaxis  
for  
CD4/8 double-positive thymocytes by fibronectin and laminin in mice  
AU Yanagawa, Yoshiki; Iwabuchi, Kazuya; Onoe, Kazunori  
REFERENCE COUNT: 47 THERE ARE 47 CITED REFERENCES AVAILABLE FOR  
THIS  
RECORD. ALL CITATIONS AVAILABLE IN THE RE  
FORMAT

L4 ANSWER 19 OF 59 CAPLUS COPYRIGHT 2002 ACS  
ACCESSION NUMBER: 2001:642919 CAPLUS  
DOCUMENT NUMBER: 135:317236  
TITLE: Expression and function of chemokine receptors on  
human thymocytes: implications for infection by human  
immunodeficiency virus type 1  
AUTHOR(S): Taylor, James R., Jr.; Kimbrell, Katherine C.;  
Scoggins, Robert; Delaney, Marie; Wu, Lijun;  
Camerini,  
David  
CORPORATE SOURCE: Department of Microbiology and Myles H. Thaler Center  
for AIDS and Human Retrovirus Research, University of  
Virginia, Charlottesville, VA, 22908, USA  
SOURCE: Journal of Virology (2001), 75(18), 8752-8760  
CODEN: JOVIAM; ISSN: 0022-538X  
PUBLISHER: American Society for Microbiology  
DOCUMENT TYPE: Journal  
LANGUAGE: English  
TI Expression and function of chemokine receptors on human thymocytes:  
implications for infection by human immunodeficiency virus type 1  
AU Taylor, James R., Jr.; Kimbrell, Katherine C.; Scoggins, Robert; Delaney,  
Marie; Wu, Lijun; Camerini, David  
REFERENCE COUNT: 39 THERE ARE 39 CITED REFERENCES AVAILABLE FOR  
THIS  
RECORD. ALL CITATIONS AVAILABLE IN THE RE  
FORMAT

L4 ANSWER 20 OF 59 CAPLUS COPYRIGHT 2002 ACS  
ACCESSION NUMBER: 2001:489619 CAPLUS  
DOCUMENT NUMBER: 135:71268  
TITLE: Use of locked nucleic acid-modified oligonucleotides  
for treatment of cancer and inflammation  
INVENTOR(S): Orum, Henrik; Koch, Troel; Skouv, Jan; Jakobsen,  
Mogen  
Havsteen  
PATENT ASSIGNEE(S): Exiqon A/S, Den.  
SOURCE: PCT Int. Appl., 50 pp.  
CODEN: PIXXD2  
DOCUMENT TYPE: Patent  
LANGUAGE: English  
FAMILY ACC. NUM. COUNT: 1  
PATENT INFORMATION:



PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2001048190	A2	20010705	WO 2000-IB2043	20001222
WO 2001048190	A3	20020510		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
US 2002068709	A1	20020606	US 2000-747913	20001222
EP 1240322	A2	20020918	EP 2000-990866	20001222
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR				
PRIORITY APPLN. INFO.:			US 1999-171873P	P 19991223
			WO 2000-IB2043	W 20001222
TI	Use of locked nucleic acid-modified oligonucleotides for treatment of cancer and inflammation			
IN	Orum, Henrik; Koch, Troel; Skouv, Jan; Jakobsen, Mogen Havsteen			
L4	ANSWER 21 OF 59 CAPLUS COPYRIGHT 2002 ACS			
ACCESSION NUMBER:	2001:402803 CAPLUS			
DOCUMENT NUMBER:	136:84180			
TITLE:	Chemokines, chemokine receptors and allergy			
AUTHOR(S):	Kaplan, Allen P.			
CORPORATE SOURCE:	Division of Pulmonary Diseases and Central Case Medicine and Allergy and, Medical University of South Carolina, Charleston, SC, USA			
SOURCE:	International Archives of Allergy and Immunology (2001), 124(4), 423-431			
	CODEN: IAAIEG; ISSN: 1018-2438			
PUBLISHER:	S. Karger AG			
DOCUMENT TYPE:	Journal; General Review			
LANGUAGE:	English			
TI	Chemokines, chemokine receptors and allergy			
AU	Kaplan, Allen P.			
REFERENCE COUNT:	57	THERE ARE 57 CITED REFERENCES AVAILABLE FOR THIS		
RECORD. ALL CITATIONS AVAILABLE IN THE RE				
FORMAT				
L4	ANSWER 22 OF 59 CAPLUS COPYRIGHT 2002 ACS			
ACCESSION NUMBER:	2001:181821 CAPLUS			
DOCUMENT NUMBER:	134:339404			
TITLE:	The CC Chemokines MDC and TARC Induce Platelet Activation Via CCR4			
AUTHOR(S):	Abi-Younes, S.; Si-Tahar, M.; Luster, A. D.			
CORPORATE SOURCE:	Division of Rheumatology, Allergy and Immunology, Center for Immunology and Inflammatory Diseases, Massachusetts General Hospital and Harvard Medical School, Boston, MA, USA			
SOURCE:	Thrombosis Research (2001), 101(4), 279-289			
	CODEN: THBRAA; ISSN: 0049-3848			
PUBLISHER:	Elsevier Science Inc.			
DOCUMENT TYPE:	Journal			
LANGUAGE:	English			
TI	The CC Chemokines MDC and TARC Induce Platelet Activation Via CCR4			

AU Abi-Younes, S.; Si-Tahar, M.; Luster, A. D.  
REFERENCE COUNT: 55 THERE ARE 55 CITED REFERENCES AVAILABLE FOR  
THIS

RECORD. ALL CITATIONS AVAILABLE IN THE RE

FORMAT

L4 ANSWER 23 OF 59 CAPLUS COPYRIGHT 2002 ACS

ACCESSION NUMBER: 2001:151548 CAPLUS

DOCUMENT NUMBER: 135:271772

TITLE: Differential and sequential expression of multiple  
chemokines during elicitation of allergic contact  
hypersensitivity

AUTHOR(S): Goebeler, Matthias; Trautmann, Axel; Voss, Ariane;  
Brockner, Eva-Bettina; Toksoy, Atiye; Gillitzer,  
Reinhard

CORPORATE SOURCE: Department of Dermatology, University of Wurzburg  
Medical School, Wurzburg, 97080, Germany

SOURCE: American Journal of Pathology (2001), 158(2), 431-440  
CODEN: AJPA44; ISSN: 0002-9440

PUBLISHER: American Society for Investigative Pathology

DOCUMENT TYPE: Journal

LANGUAGE: English

TI Differential and sequential expression of multiple chemokines during  
elicitation of allergic contact hypersensitivity

AU Goebeler, Matthias; Trautmann, Axel; Voss, Ariane; Brockner, Eva-Bettina;  
Toksoy, Atiye; Gillitzer, Reinhard

REFERENCE COUNT: 34 THERE ARE 34 CITED REFERENCES AVAILABLE FOR  
THIS

RECORD. ALL CITATIONS AVAILABLE IN THE RE

FORMAT

L4 ANSWER 24 OF 59 CAPLUS COPYRIGHT 2002 ACS

ACCESSION NUMBER: 2000:911095 CAPLUS

DOCUMENT NUMBER: 134:70358

TITLE: Chimeric chemokine-antigen polypeptides and uses  
therefor

INVENTOR(S): Garzino-Demo, Alfredo; Gallo, Robert C.; Lim, Siew  
Pheng; Tan, Yin Hwee

PATENT ASSIGNEE(S): University of Maryland Biotechnology Institute, USA;  
Institute of Molecular and Cell Biology

SOURCE: PCT Int. Appl., 127 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2000078334	A1	20001228	WO 2000-US16598	20000616
W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM			
RW:	GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG			
PRIORITY APPLN. INFO.:			US 1999-335150	A 19990617

TI Chimeric chemokine-antigen polypeptides and uses therefor  
IN Garzino-Demo, Alfredo; Gallo, Robert C.; Lim, Siew Pheng; Tan, Yin Hwee  
REFERENCE COUNT: 3 THERE ARE 3 CITED REFERENCES AVAILABLE FOR THIS  
RECORD. ALL CITATIONS AVAILABLE IN THE RE

FORMAT

L4 ANSWER 25 OF 59 CAPLUS COPYRIGHT 2002 ACS  
ACCESSION NUMBER: 2000:879230 CAPLUS  
DOCUMENT NUMBER: 134:146195  
TITLE: Functional expression of CCR1, CCR3, CCR4, and CXCR4  
chemokine receptors on human platelets  
AUTHOR(S): Clemetson, Kenneth J.; Clemetson, Jeannine M.;  
Proudfoot, Amanda E. I.; Power, Christine A.;  
Baggiolini, Marco; Wells, Timothy N. C.  
CORPORATE SOURCE: Theodor Kocher Institute, University of Berne, Bern,  
CH-3012, Switz:  
SOURCE: Blood (2000), 96(13), 4046-4054  
CODEN: BLOOAW; ISSN: 0006-4971  
PUBLISHER: American Society of Hematology  
DOCUMENT TYPE: Journal  
LANGUAGE: English  
TI Functional expression of CCR1, CCR3, CCR4, and CXCR4 chemokine receptors  
on human platelets  
AU Clemetson, Kenneth J.; Clemetson, Jeannine M.; Proudfoot, Amanda E. I.;  
Power, Christine A.; Baggiolini, Marco; Wells, Timothy N. C.  
REFERENCE COUNT: 51 THERE ARE 51 CITED REFERENCES AVAILABLE FOR  
THIS

RECORD. ALL CITATIONS AVAILABLE IN THE RE

FORMAT

L4 ANSWER 26 OF 59 CAPLUS COPYRIGHT 2002 ACS  
ACCESSION NUMBER: 2000:790144 CAPLUS  
DOCUMENT NUMBER: 133:349154  
TITLE: CCR4 antagonists for treatment of septic shock  
INVENTOR(S): Power, Christina A.; Chivatchko, Yolande  
PATENT ASSIGNEE(S): Applied Research Systems ARS Holding N.V., Neth.  
Antilles  
SOURCE: Eur. Pat. Appl., 20 pp.  
CODEN: EPXXDW  
DOCUMENT TYPE: Patent  
LANGUAGE: English  
FAMILY ACC. NUM. COUNT: 1  
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
EP 1050307	A1	20001108	EP 1999-108954	19990506
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO				
WO 2000067791	A1	20001116	WO 2000-EP4018	20000504
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: GH, GM, KE, LS, MW, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
EP 1176980	A1	20020206	EP 2000-927140	20000504

R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT,  
IE, SI, LT, LV, FI, RO

PRIORITY APPLN. INFO.:

EP 1999-108954 A 19990506  
WO 2000-EP4018 W 20000504

TI CCR4 antagonists for treatment of septic shock

IN Power, Christina A.; Chivatchko, Yolande

REFERENCE COUNT: 9 THERE ARE 9 CITED REFERENCES AVAILABLE FOR THIS  
RECORD. ALL CITATIONS AVAILABLE IN THE RE

FORMAT

L4 ANSWER 27 OF 59 CAPLUS COPYRIGHT 2002 ACS

ACCESSION NUMBER: 2000:712650 CAPLUS

DOCUMENT NUMBER: 133:277217

TITLE: Serial analysis of gene expression in human  
monocyte-derived dendritic cells

INVENTOR(S): Hashimoto, Shinichi; Matsushima, Koji; Suzuki, Takuji

PATENT ASSIGNEE(S): Foundation for Scientific Technology Promotion, Japan

SOURCE: Jpn. Kokai Tokkyo Koho, 33 pp.

CODEN: JKXXAF

DOCUMENT TYPE: Patent

LANGUAGE: Japanese

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
JP 2000279181	A2	20001010	JP 1999-95481	19990401
CA 2333908	AA	20001012	CA 2000-2333908	20000330
WO 2000060074	A1	20001012	WO 2000-JP2019	20000330
W: CA, CN, KR, SG, US				
RW: AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE				
EP 1087012	A1	20010328	EP 2000-912973	20000330
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, FI				

PRIORITY APPLN. INFO.:

JP 1999-95481 A 19990401  
WO 2000-JP2019 W 20000330

TI Serial analysis of gene expression in human monocyte-derived dendritic  
cells

IN Hashimoto, Shinichi; Matsushima, Koji; Suzuki, Takuji

L4 ANSWER 28 OF 59 CAPLUS COPYRIGHT 2002 ACS

ACCESSION NUMBER: 2000:493576 CAPLUS

DOCUMENT NUMBER: 133:118955

TITLE: **Antibodies** to CC chemokine receptor 4

INVENTOR(S): Wu, Lijun; Ruffing, Nancy; Andrew, David

PATENT ASSIGNEE(S): Millennium Pharmaceuticals, Inc., USA

SOURCE: PCT Int. Appl., 82 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2000042074	A1	20000720	WO 2000-US917	20000114
W: AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CU, CZ, DE, DK, DM, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA,				

MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI,  
 SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM,  
 AZ, BY, KG, KZ, MD, RU, TJ, TM  
 RW: GH, GM, KE, LS, MW, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE,  
 DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF,  
 CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG  
 EP 1144453 A1 20011017 EP 2000-905613 20000114  
 R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT,  
 IE, SI, LT, LV, FI, RO  
 JP 2002539079 T2 20021119 JP 2000-593640 20000114  
 PRIORITY APPLN. INFO.: US 1999-231759 A2 19990115  
 WO 2000-US917 W 20000114  
 TI **Antibodies** to CC chemokine receptor 4  
 IN Wu, Lijun; Ruffing, Nancy; Andrew, David  
 REFERENCE COUNT: 9 THERE ARE 9 CITED REFERENCES AVAILABLE FOR THIS  
 RECORD. ALL CITATIONS AVAILABLE IN THE RE

FORMAT

L4 ANSWER 29 OF 59 CAPLUS COPYRIGHT 2002 ACS  
 ACCESSION NUMBER: 2000:421887 CAPLUS  
 DOCUMENT NUMBER: 133:162913  
 TITLE: CD4+ T cell subsets during virus infection:  
 protective capacity depends on effector cytokine secretion and  
 on migratory capability  
 AUTHOR(S): Maloy, Kevin J.; Burkhart, Christoph; Junt, Tobias  
 M.; Odermatt, Bernhard; Oxenius, Annette; Piali, Luca;  
 Zinkernagel, Rolf M.; Hengartner, Hans  
 CORPORATE SOURCE: Department of Pathology, Institute of Experimental  
 Immunology, Zurich, CH-8091, Switz.  
 SOURCE: Journal of Experimental Medicine (2000), 191(12),  
 2159-2170  
 CODEN: JEMEAU; ISSN: 0022-1007  
 PUBLISHER: Rockefeller University Press  
 DOCUMENT TYPE: Journal  
 LANGUAGE: English  
 TI CD4+ T cell subsets during virus infection: protective capacity depends  
 on effector cytokine secretion and on migratory capability  
 AU Maloy, Kevin J.; Burkhart, Christoph; Junt, Tobias M.; Odermatt,  
 Bernhard; Oxenius, Annette; Piali, Luca; Zinkernagel, Rolf M.; Hengartner, Hans  
 REFERENCE COUNT: 72 THERE ARE 72 CITED REFERENCES AVAILABLE FOR  
 THIS

RECORD. ALL CITATIONS AVAILABLE IN THE RE

FORMAT

L4 ANSWER 30 OF 59 CAPLUS COPYRIGHT 2002 ACS  
 ACCESSION NUMBER: 2000:251557 CAPLUS  
 DOCUMENT NUMBER: 133:236442  
 TITLE: The role of lymphocytes in allergic disease  
 AUTHOR(S): Romagnani, Sergio  
 CORPORATE SOURCE: Section of Clinical Immunology, Allergy and  
 Respiratory Disorders, Department of Internal  
 Medicine, University of Florence, Florence, 50134,  
 Italy  
 SOURCE: Journal of Allergy and Clinical Immunology (2000),  
 105(3), 399-408

CODEN: JACIBY; ISSN: 0091-6749  
PUBLISHER: Mosby, Inc.  
DOCUMENT TYPE: Journal; General Review  
LANGUAGE: English  
TI The role of lymphocytes in allergic disease  
AU Romagnani, Sergio  
REFERENCE COUNT: 115 THERE ARE 115 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 31 OF 59 CAPLUS COPYRIGHT 2002 ACS  
ACCESSION NUMBER: 2000:68155 CAPLUS  
DOCUMENT NUMBER: 132:106969  
TITLE: Chemokines as adjuvants of immune response  
INVENTOR(S): Caux, Christophe; Vanbervliet, Beatrice; Lebecque, Serge; Vicari, Alain; Dieu, Marie-Caroline  
PATENT ASSIGNEE(S): Schering-Plough, Fr.  
SOURCE: Eur. Pat. Appl., 16 pp.  
CODEN: EPXXDW  
DOCUMENT TYPE: Patent  
LANGUAGE: English  
FAMILY ACC. NUM. COUNT: 1  
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
EP 974357	A1	20000126	EP 1998-401799	19980716
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO				
WO 2000003728	A1	20000127	WO 1999-US14148	19990715
W: AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CZ, DE, DK, EE, ES, FI, GB, GD, GE, HR, HU, ID, IL, IN, IS, JP, KG, KR, KZ, LC, LK, LR, LT, LU, LV, MD, MG, MK, MN, MX, NO, NZ, PL, PT, RO, RU, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, US, UZ, VN, YU, ZA, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: GH, GM, KE, LS, MW, SD, SL, SZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
AU 9949591	A1	20000207	AU 1999-49591	19990715
US 2002034494	A1	20020321	US 2001-768917	20010124
WO 2002058723	A2	20020801	WO 2002-US1849	20020122
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, HR, HU, ID, IL, IN, IS, JP, KG, KR, KZ, LC, LK, LR, LT, LU, LV, MA, MD, MG, MK, MN, MX, MZ, NO, NZ, PH, PL, PT, RO, RU, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UZ, VN, YU, ZA, ZM, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
PRIORITY APPLN. INFO.:			EP 1998-401799	A 19980716
			WO 1999-US14148	W 19990715
			US 2001-768917	A 20010124
TI Chemokines as adjuvants of immune response				
IN Caux, Christophe; Vanbervliet, Beatrice; Lebecque, Serge; Vicari, Alain; Dieu, Marie-Caroline				
REFERENCE COUNT:	4	THERE ARE 4 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE		
FORMAT				

L4 ANSWER 32 OF 59 CAPLUS COPYRIGHT 2002 ACS

ACCESSION NUMBER: 1999:811259 CAPLUS  
DOCUMENT NUMBER: 132:63143  
TITLE: Preparation and use of superior vaccines  
INVENTOR(S): Roberts, Bruce L.; Shankara, Srinivas  
PATENT ASSIGNEE(S): Genzyme Corporation, USA  
SOURCE: PCT Int. Appl., 130 pp.  
CODEN: PIXXD2  
DOCUMENT TYPE: Patent  
LANGUAGE: English  
FAMILY ACC. NUM. COUNT: 1  
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9965924	A2	19991223	WO 1999-US13800	19990618
WO 9965924	A3	20000413		
W:	AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM			
RW:	GH, GM, KE, LS, MW, SD, SL, SZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG			
WO 9966303	A2	19991223	WO 1999-US13820	19990617
WO 9966303	A3	20000323		
W:	AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM			
RW:	GH, GM, KE, LS, MW, SD, SL, SZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG			
CA 2335452	AA	19991223	CA 1999-2335452	19990618
WO 9965928	A2	19991223	WO 1999-US13647	19990618
W:	AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA			
RW:	GH, GM, KE, LS, MW, SD, SL, SZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG			
AU 9948241	A1	20000105	AU 1999-48241	19990618
EP 1086215	A2	20010328	EP 1999-937160	19990618
R:	AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, FI			
JP 2002534056	T2	20021015	JP 2000-554749	19990618
US 2002151515	A1	20021017	US 2001-33145	20011105
PRIORITY APPLN. INFO.:			US 1998-89844P	P 19980619
			US 1998-89853P	P 19980619
			US 1998-89878P	P 19980619
			US 1998-89991P	P 19980619
			US 1998-89992P	P 19980619
			US 1998-89993P	P 19980619
			US 1998-89997P	P 19980619

US 1998-89999P P 19980619  
 US 1998-90000P P 19980619  
 US 1998-90035P P 19980619  
 US 1998-90036P P 19980619  
 US 1998-90039P P 19980619  
 US 1998-90040P P 19980619  
 US 1998-90041P P 19980619  
 US 1998-90042P P 19980619  
 US 1998-90043P P 19980619  
 US 1998-90044P P 19980619  
 US 1998-90048P P 19980619  
 US 1998-90072P P 19980619  
 US 1998-90079P P 19980619  
 US 1998-89833P P 19980619  
 US 1998-89994P P 19980619  
 US 1998-90045P P 19980619  
 US 1998-90047P P 19980619  
 US 1998-90076P P 19980619  
 US 1998-90077P P 19980619  
 US 1998-90078P P 19980619  
 US 1998-90080P P 19980619  
 US 1998-111715P P 19981208  
 WO 1999-US13647 W 19990618  
 WO 1999-US13800 W 19990618

TI Preparation and use of superior vaccines  
 IN Roberts, Bruce L.; Shankara, Srinivas

L4 ANSWER 33 OF 59 CAPLUS COPYRIGHT 2002 ACS

ACCESSION NUMBER: 1999:595395 CAPLUS

DOCUMENT NUMBER: 131:237964

TITLE: Methods and compositions of chemokine-tumor antigen fusion proteins as cancer vaccines

INVENTOR(S): Kwak, Larry W.; Biragyn, Arya

PATENT ASSIGNEE(S): United States Dept. of Health and Human Services, USA

SOURCE: PCT Int. Appl., 142 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9946392	A1	19990916	WO 1999-US5345	19990312
W: AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: GH, GM, KE, LS, MW, SD, SL, SZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
AU 9929039	A1	19990927	AU 1999-29039	19990312
PRIORITY APPLN. INFO.:			US 1998-77745P	P 19980312
			WO 1999-US5345	W 19990312

TI Methods and compositions of chemokine-tumor antigen fusion proteins as cancer vaccines

IN Kwak, Larry W.; Biragyn, Arya

REFERENCE COUNT: 7 THERE ARE 7 CITED REFERENCES AVAILABLE FOR THIS



RECORD. ALL CITATIONS AVAILABLE IN THE RE

FORMAT

L4 ANSWER 34 OF 59 CAPLUS COPYRIGHT 2002 ACS  
 ACCESSION NUMBER: 1999:538432 CAPLUS  
 DOCUMENT NUMBER: 131:298474  
 TITLE: Differential Utilization of Cyclic ADP-Ribose Pathway  
 by Chemokines to Induce the Mobilization of  
 Intracellular Calcium in NK Cells  
 AUTHOR(S): Inngjerdengen, Marit; Al-Aoukaty, Ala; Damaj, Bassam;  
 Maghazachi, Azzam A.  
 CORPORATE SOURCE: Department of Anatomy, Institute of Basic Medical  
 Sciences, University of Oslo, Oslo, N-0317, Norway  
 SOURCE: Biochemical and Biophysical Research Communications  
 (1999), 262(2), 467-472  
 CODEN: BBRCA9; ISSN: 0006-291X  
 PUBLISHER: Academic Press  
 DOCUMENT TYPE: Journal  
 LANGUAGE: English  
 TI Differential Utilization of Cyclic ADP-Ribose Pathway by Chemokines to  
 Induce the Mobilization of Intracellular Calcium in NK Cells  
 AU Inngjerdengen, Marit; Al-Aoukaty, Ala; Damaj, Bassam; Maghazachi, Azzam  
 A.  
 REFERENCE COUNT: 23 THERE ARE 23 CITED REFERENCES AVAILABLE FOR  
 THIS

RECORD. ALL CITATIONS AVAILABLE IN THE RE

FORMAT

L4 ANSWER 35 OF 59 CAPLUS COPYRIGHT 2002 ACS  
 ACCESSION NUMBER: 1999:487126 CAPLUS  
 DOCUMENT NUMBER: 131:129056  
 TITLE: A C-C chemokine of human macrophage and a cDNA  
 encoding it and their uses  
 INVENTOR(S): Godiska, Ronald; Gray, Patrick W.  
 PATENT ASSIGNEE(S): ICOS Corp., USA  
 SOURCE: U.S., 43 pp.  
 CODEN: USXXAM  
 DOCUMENT TYPE: Patent  
 LANGUAGE: English  
 FAMILY ACC. NUM. COUNT: 3  
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 5932703	A	19990803	US 1996-660542	19960607
CA 2196691	AA	19961219	CA 1996-2196691	19960607
CN 1163635	A	19971029	CN 1996-190875	19960607
WO 9915666	A2	19990401	WO 1998-US20270	19980928
WO 9915666	A3	19990916		

W: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE,  
 DK, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IS, JP, KE,  
 KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW,  
 MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR,  
 TT, UA, UG, US, US, US, US, US, UZ, VN, YU, ZW, AM, AZ, BY, KG,  
 KZ, MD, RU, TJ, TM  
 RW: GH, GM, KE, LS, MW, SD, SZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES,  
 FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI,  
 CM, GA, GN, GW, ML, MR, NE, SN, TD, TG

TY APPLN. INFO.: US 1995-479620 A2 19950607  
 US 1995-558658 A2 19951116

US 1996-660542 A2 19960607  
US 1997-939107 A2 19970926  
US 1998-67447 A2 19980428

TI A C-C chemokine of human macrophage and a cDNA encoding it and their uses  
IN Godiska, Ronald; Gray, Patrick W.  
REFERENCE COUNT: 26 THERE ARE 26 CITED REFERENCES AVAILABLE FOR  
THIS

RECORD. ALL CITATIONS AVAILABLE IN THE RE

FORMAT

L4 ANSWER 36 OF 59 CAPLUS COPYRIGHT 2002 ACS

ACCESSION NUMBER: 1999:376777 CAPLUS

DOCUMENT NUMBER: 131:128890

TITLE: Switch in chemokine receptor expression upon TCR  
stimulation reveals novel homing potential for  
recently activated T cells

AUTHOR(S): Sallusto, Federica; Kremmer, Elisabeth; Palermo,  
Belinda; Hoy, Andre; Ponath, Paul; Qin, Shixin;  
Forster, Reinhold; Lipp, Martin; Lanzavecchia,

Antonio

CORPORATE SOURCE: Basel Institute Immunology, Basel, CH-4005, Switz.

SOURCE: European Journal of Immunology (1999), 29(6),  
2037-2045

CODEN: EJIMAF; ISSN: 0014-2980

PUBLISHER: Wiley-VCH Verlag GmbH

DOCUMENT TYPE: Journal

LANGUAGE: English

TI Switch in chemokine receptor expression upon TCR stimulation reveals  
novel

homing potential for recently activated T cells

AU Sallusto, Federica; Kremmer, Elisabeth; Palermo, Belinda; Hoy, Andre;  
Ponath, Paul; Qin, Shixin; Forster, Reinhold; Lipp, Martin; Lanzavecchia,  
Antonio

REFERENCE COUNT: 35 THERE ARE 35 CITED REFERENCES AVAILABLE FOR  
THIS

RECORD. ALL CITATIONS AVAILABLE IN THE RE

FORMAT

L4 ANSWER 37 OF 59 CAPLUS COPYRIGHT 2002 ACS

ACCESSION NUMBER: 1999:223049 CAPLUS

DOCUMENT NUMBER: 130:251233

TITLE: **Macrophage-derived**

**chemokine** (MDC), MDC analogs, MDC inhibitor  
substances, and their therapeutic applications

INVENTOR(S): Gray, Patrick W.; Chantry, David H.; Deeley, Michael  
C.; Raport, Carol J.; Godiska, Ronald

PATENT ASSIGNEE(S): Icos Corporation, USA

SOURCE: PCT Int. Appl., 159 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 3

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
9915666	A2	19990401	WO 1998-US20270	19980928
9915666	A3	19990916		

W: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE,  
DK, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IS, JP, KE,

KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW,  
 MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR,  
 TT, UA, UG, US, US, US, US, US, UZ, VN, YU, ZW, AM, AZ, BY, KG,  
 KZ, MD, RU, TJ, TM  
 RW: GH, GM, KE, LS, MW, SD, SZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES,  
 FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI,  
 CM, GA, GN, GW, ML, MR, NE, SN, TD, TG  
 CN 1163635 A 19971029 CN 1996-190875 19960607  
 US 5932703 A 19990803 US 1996-660542 19960607  
 CA 2302806 AA 19990401 CA 1998-2302806 19980928  
 AU 9897778 A1 19990412 AU 1998-97778 19980928  
 EP 1017818 A2 20000712 EP 1998-951961 19980928  
 R: AT, BE, CH, DE, ES, FR, GB, IT, LI, SE, IE  
 PRIORITY APPLN. INFO.: US 1995-479620 A2 19950607  
 US 1995-558658 A2 19951116  
 US 1996-660542 A2 19960607  
 US 1997-939107 A2 19970926  
 US 1998-67447 A2 19980428  
 WO 1998-US20270 W 19980928  
 TI **Macrophage-derived chemokine** (MDC), MDC  
 analogs, MDC inhibitor substances, and their therapeutic applications  
 IN Gray, Patrick W.; Chantry, David H.; Deeley, Michael C.; Raport, Carol  
 J.;  
 Godiska, Ronald  
 L4 ANSWER 38 OF 59 CAPLUS COPYRIGHT 2002 ACS  
 ACCESSION NUMBER: 1999:214274 CAPLUS  
 DOCUMENT NUMBER: 131:57588  
 TITLE: **Macrophage-derived**  
**chemokine** induces human eosinophil chemotaxis  
 in a CC chemokine receptor 3- and CC chemokine  
 receptor 4-independent manner  
 AUTHOR(S): Bochner, Bruce S.; Bickel, Carol A.; Taylor, Marcia  
 L.; MacGlashan, Donald W., Jr.; Gray, Patrick W.;  
 Raport, Carol J.; Godiska, Ronald  
 CORPORATE SOURCE: Division of Clinical Immunology, Department of  
 Medicine, Johns Hopkins Asthma and Allergy Center,  
 The  
 Johns Hopkins University School of Medicine,  
 Baltimore, MD, 21224, USA  
 SOURCE: Journal of Allergy and Clinical Immunology (1999),  
 103(3, Pt. 1), 527-532  
 CODEN: JACIBY; ISSN: 0091-6749  
 PUBLISHER: Mosby, Inc.  
 DOCUMENT TYPE: Journal  
 LANGUAGE: English  
 TI **Macrophage-derived chemokine** induces human  
 eosinophil chemotaxis in a CC chemokine receptor 3- and CC chemokine  
 receptor 4-independent manner  
 AU Bochner, Bruce S.; Bickel, Carol A.; Taylor, Marcia L.; MacGlashan,  
 Donald  
 W., Jr.; Gray, Patrick W.; Raport, Carol J.; Godiska, Ronald  
 REFERENCE COUNT: 33 THERE ARE 33 CITED REFERENCES AVAILABLE FOR  
 THIS  
 RECORD. ALL CITATIONS AVAILABLE IN THE RE  
 FORMAT  
 L4 ANSWER 39 OF 59 CAPLUS COPYRIGHT 2002 ACS  
 ACCESSION NUMBER: 1998:398418 CAPLUS  
 DOCUMENT NUMBER: 129:53370

TITLE: Human chemokine .beta.-13, recombinant production, **antibody** and nucleic acid probes, and gene therapy

INVENTOR(S): Li, Haodong; Seibel, George

PATENT ASSIGNEE(S): Human Genome Sciences, Inc., USA; Li, Haodong; Seibel, George

SOURCE: PCT Int. Appl., 86 pp.  
CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 2

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9824908	A1	19980611	WO 1997-US23144	19971205
W: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, GH, HU, ID, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: GH, KE, LS, MW, SD, SZ, UG, ZW, AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG				
AU 9853834	A1	19980629	AU 1998-53834	19971205
EP 958366	A1	19991124	EP 1997-950969	19971205
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, FI				
JP 2001506492	T2	20010522	JP 1998-525919	19971205
US 2002055147	A1	20020509	US 2001-908599	20010720
US 2002098545	A1	20020725	US 2001-908600	20010720

PRIORITY APPLN. INFO.:

US 1996-32432P	P	19961205
US 1995-464594	A2	19950605
US 1997-986188	B2	19971205
WO 1997-US23144	W	19971205
US 1999-432768	B1	19991103
US 2000-484221	B1	20000118

TI Human chemokine .beta.-13, recombinant production, **antibody** and nucleic acid probes, and gene therapy

IN Li, Haodong; Seibel, George

REFERENCE COUNT: 9 THERE ARE 9 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE

FORMAT

L4 ANSWER 40 OF 59 CAPLUS COPYRIGHT 2002 ACS

ACCESSION NUMBER: 1997:752774 CAPLUS

DOCUMENT NUMBER: 128:21878

TITLE: **Macrophage-derived chemokine**

INVENTOR(S): Godiska, Ronald; Gray, Patrick W.

PATENT ASSIGNEE(S): ICOS Corp., USA

SOURCE: U.S., 22 pp.  
CODEN: USXXAM

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
------------	------	------	-----------------	------

-----  
US 5688927            A     19971118            US 1995-480449     19950607  
TI   **Macrophage-derived chemokine**  
IN   Godiska, Ronald; Gray, Patrick W.

L4   ANSWER 41 OF 59   CAPLUS   COPYRIGHT 2002 ACS

ACCESSION NUMBER:     1997:130062   CAPLUS

DOCUMENT NUMBER:     126:130601

TITLE:                **Macrophage-derived**  
                         **chemokine** and chemokine analogs

INVENTOR(S):           Godiska, Ronald; Gray, Patrick W.

PATENT ASSIGNEE(S):    Icos Corporation, USA

SOURCE:               PCT Int. Appl., 104 pp.

CODEN: PIXXD2

DOCUMENT TYPE:        Patent

LANGUAGE:             English

FAMILY ACC. NUM. COUNT: 3

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9640923	A1	19961219	WO 1996-US10114	19960607
, W: AU, BR, CA, CN, CZ, FI, HU, IL, JP, MX, NO, PL, RU, SK				
RW: AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT,				
SE				
CA 2196691	AA	19961219	CA 1996-2196691	19960607
AU 9661724	A1	19961230	AU 1996-61724	19960607
AU 708743	B2	19990812		
EP 778892	A1	19970618	EP 1996-919371	19960607
R: AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LI, LU, MC, NL,				
PT, SE				
BR 9606437	A	19970930	BR 1996-6437	19960607
CN 1163635	A	19971029	CN 1996-190875	19960607
JP 10507646	T2	19980728	JP 1996-502209	19960607
FI 9700502	A	19970404	FI 1997-502	19970206
NO 9700545	A	19970407	NO 1997-545	19970206
PRIORITY APPLN. INFO.:			US 1995-479620	A 19950607
			US 1995-558658	A 19951116
			WO 1996-US10114	W 19960607

TI   **Macrophage-derived chemokine** and chemokine  
      analogs

IN   Godiska, Ronald; Gray, Patrick W.

L4   ANSWER 42 OF 59   BIOSIS   COPYRIGHT 2002 BIOLOGICAL ABSTRACTS INC.

ACCESSION NUMBER:     2002:550625   BIOSIS

DOCUMENT NUMBER:     PREV200200550625

TITLE:                Expression of T lymphocyte chemoattractants and activation  
                         markers in vernal keratoconjunctivitis.

AUTHOR(S):            El-Asrar, A. M. Abu (1); Struyf, S.; Al-Kharashi, S. A.;  
                         Missotten, L.; Van Domme, J.; Geboes, K.

CORPORATE SOURCE:    (1) Department of Ophthalmology, King Abdulaziz University  
                         Hospital, Airport Road, PO Box 245, Riyadh, 11411:  
                         abuasrar@KSU.edu.sa Saudi Arabia

SOURCE:               British Journal of Ophthalmology, (October, 2002) Vol. 86,  
                         No. 10, pp. 1175-1180. <http://bjo.bmjournals.com/>.

print.

ISSN: 0007-1161.

DOCUMENT TYPE:        Article

LANGUAGE:             English

TI   Expression of T lymphocyte chemoattractants and activation markers in

vernal keratoconjunctivitis.

AU El-Asrar, A. M. Abu (1); Struyf, S.; Al-Kharashi, S. A.; Missotten, L.;  
Van Domme, J.; Geboes, K.

L4 ANSWER 43 OF 59 BIOSIS COPYRIGHT 2002 BIOLOGICAL ABSTRACTS INC.

ACCESSION NUMBER: 2002:530584 BIOSIS

DOCUMENT NUMBER: PREV200200530584

TITLE: Exacerbation of autoimmune-like pancreatitis in MAIDS mice  
by a monoclonal **antibody** against  
macrophage-derived chemokine (MDC.

AUTHOR(S): Suzuki, Kenji (1); Watanabe, Shiro (1); Suriki, Hidehisa  
(1); Yoneyama, Hiroyuki (1); Sasaki, Shunya (1); Kawauchi,  
Yusuke (1); Kawachi, Hiroshi (1); Shimizu, Fujio (1);  
Asakura, Hitoshi (1)

CORPORATE SOURCE: (1) Niigata Japan

SOURCE: Gastroenterology, (April, 2002) Vol. 122, No. 4 Suppl. 1,  
pp. A-414. <http://www.gastrojournal.org/>. print.  
Meeting Info.: Digestive Disease Week and the 103rd Annual  
Meeting of the American Gastroenterological Association

San

Francisco, CA, USA May 19-22, 2002

ISSN: 0016-5085.

DOCUMENT TYPE: Conference

LANGUAGE: English

TI Exacerbation of autoimmune-like pancreatitis in MAIDS mice by a  
monoclonal

**antibody** against macrophage-derived chemokine (MDC.

AU Suzuki, Kenji (1); Watanabe, Shiro (1); Suriki, Hidehisa (1); Yoneyama,  
Hiroyuki (1); Sasaki, Shunya (1); Kawauchi, Yusuke (1); Kawachi, Hiroshi  
(1); Shimizu, Fujio (1); Asakura, Hitoshi (1)

L4 ANSWER 44 OF 59 BIOSIS COPYRIGHT 2002 BIOLOGICAL ABSTRACTS INC.

ACCESSION NUMBER: 2002:530470 BIOSIS

DOCUMENT NUMBER: PREV200200530470

TITLE: Prevention of chronic experimental colitis by a monoclonal  
**antibody** against Interferon inducible Protein 10.

AUTHOR(S): Kawauchi, Yusuke (1); Suzuki, Kenji; Suriki, Hidehisa;  
Yoneyama, Hiroyuki; Baba, Yasuyuki; Sasaki, Shunya; Aiba,  
Tuneo; Watanabe, Shiro; Kawachi, Hiroshi; Shimizu, Fujio;  
Asakura, Hitoshi

CORPORATE SOURCE: (1) Niigata Japan

SOURCE: Gastroenterology, (April, 2002) Vol. 122, No. 4 Suppl. 1,  
pp. A-393. <http://www.gastrojournal.org/>. print.  
Meeting Info.: Digestive Disease Week and the 103rd Annual  
Meeting of the American Gastroenterological Association

San

Francisco, CA, USA May 19-22, 2002

ISSN: 0016-5085.

DOCUMENT TYPE: Conference

LANGUAGE: English

TI Prevention of chronic experimental colitis by a monoclonal  
**antibody** against Interferon inducible Protein 10.

AU Kawauchi, Yusuke (1); Suzuki, Kenji; Suriki, Hidehisa; Yoneyama,  
Hiroyuki;  
Baba, Yasuyuki; Sasaki, Shunya; Aiba, Tuneo; Watanabe, Shiro; Kawachi,  
Hiroshi; Shimizu, Fujio; Asakura, Hitoshi

L4 ANSWER 45 OF 59 BIOSIS COPYRIGHT 2002 BIOLOGICAL ABSTRACTS INC.

ACCESSION NUMBER: 2002:454068 BIOSIS

DOCUMENT NUMBER: PREV200200454068

TITLE: DNA vaccines encoding human immunodeficiency virus-1 glycoprotein 120 fusions with proinflammatory chemoattractants induce systemic and mucosal immune responses.

AUTHOR(S): Biragyn, Arya (1); Belyakov, Igor M.; Chow, Yen-Hung; Dimitrov, Dimitre S.; Berzofsky, Jay A.; Kwak, Larry W.

CORPORATE SOURCE: (1) National Cancer Institute, Building 567, Room 207, Frederick, MD, 21702: [arya@mail.ncifcrf.gov](mailto:arya@mail.ncifcrf.gov) USA

SOURCE: Blood, (August 15, 2002) Vol. 100, No. 4, pp. 1153-1159. <http://www.bloodjournal.org/>. print. ISSN: 0006-4971.

DOCUMENT TYPE: Article

LANGUAGE: English

TI DNA vaccines encoding human immunodeficiency virus-1 glycoprotein 120 fusions with proinflammatory chemoattractants induce systemic and mucosal immune responses.

AU Biragyn, Arya (1); Belyakov, Igor M.; Chow, Yen-Hung; Dimitrov, Dimitre S.; Berzofsky, Jay A.; Kwak, Larry W.

L4 ANSWER 46 OF 59 BIOSIS COPYRIGHT 2002 BIOLOGICAL ABSTRACTS INC.

ACCESSION NUMBER: 2002:329299 BIOSIS

DOCUMENT NUMBER: PREV200200329299

TITLE: CD26 is expressed on a restricted subpopulation of dendritic cells in vivo.

AUTHOR(S): Gliddon, Daniel R. (1); Howard, Chris J.

CORPORATE SOURCE: (1) Institute for Animal Health, Compton, Newbury, Berks, RG20 7NN: [daniel.gliddon@bbsrc.ac.uk](mailto:daniel.gliddon@bbsrc.ac.uk) UK

SOURCE: European Journal of Immunology, (May, 2002) Vol. 32, No. 5, pp. 1472-1481. [http://www.wiley-](http://www.wiley-vch.de/publish/en/journals/alphabeticalIndex/2040/?sID=87ce709e9d93384f19ebcbf2d13f6116)

[vch.de/publish/en/journals/alphabeticalIndex/2040/?sID=87ce709e9d93384f19ebcbf2d13f6116](http://www.wiley-vch.de/publish/en/journals/alphabeticalIndex/2040/?sID=87ce709e9d93384f19ebcbf2d13f6116). print. ISSN: 0014-2980.

DOCUMENT TYPE: Article

LANGUAGE: English

TI CD26 is expressed on a restricted subpopulation of dendritic cells in vivo.

AU Gliddon, Daniel R. (1); Howard, Chris J.

L4 ANSWER 47 OF 59 BIOSIS COPYRIGHT 2002 BIOLOGICAL ABSTRACTS INC.

ACCESSION NUMBER: 2002:251181 BIOSIS

DOCUMENT NUMBER: PREV200200251181

TITLE: Multiplexed protein profiling on microarrays by rolling-circle amplification.

AUTHOR(S): Schweitzer, Barry; Roberts, Scott; Grimwade, Brian; Shao, Weiping; Wang, Minjuan; Fu, Qin; Shu, Quiping; Laroche, Isabelle; Zhou, Zhimin; Tchernev, Velizar T.; Christiansen, Jason; Velleca, Mark; Kingsmore, Stephen F. (1)

CORPORATE SOURCE: (1) Molecular Staging, Inc., 300 George Street, Suite 701, New Haven, CT, 06511: [stephenk@molecularstaging.com](mailto:stephenk@molecularstaging.com) USA

SOURCE: Nature Biotechnology, (April, 2002) Vol. 20, No. 4, pp. 359-365. <http://www.nature.com/nbt/>. print. ISSN: 1087-0156.

DOCUMENT TYPE: Article

LANGUAGE: English

TI Multiplexed protein profiling on microarrays by rolling-circle amplification.

AU Schweitzer, Barry; Roberts, Scott; Grimwade, Brian; Shao, Weiping; Wang,

Minjuan; Fu, Qin; Shu, Quiping; Laroche, Isabelle; Zhou, Zhimin;  
Tchernev,  
Velizar T.; Christiansen, Jason; Velleca, Mark; Kingsmore, Stephen F. (1)

L4 ANSWER 48 OF 59 BIOSIS COPYRIGHT 2002 BIOLOGICAL ABSTRACTS INC.  
ACCESSION NUMBER: 2002:217603 BIOSIS  
DOCUMENT NUMBER: PREV200200217603  
TITLE: The identification, characterization, and distribution of  
guinea pig CCR4 and epitope mapping of a blocking  
**antibody**.  
AUTHOR(S): Jopling, Louise A.; Sabroe, Ian; Andrew, David P.;  
Mitchell, Tracey J.; Li, You; Hodge, Martin R.; Williams,  
Timothy J.; Pease, James E. (1)  
CORPORATE SOURCE: (1) Leukocyte Biology Section, Biomedical Sciences  
Division, Imperial College of Science, Technology and  
Medicine, Exhibition Rd., Sir Alexander Fleming Bldg.,  
Faculty of Medicine, London, SW7 2AZ: j.pease@ic.ac.uk UK  
SOURCE: Journal of Biological Chemistry, (March 1, 2002) Vol. 277,  
No. 9, pp. 6864-6873. <http://www.jbc.org/>. print.  
ISSN: 0021-9258.  
DOCUMENT TYPE: Article  
LANGUAGE: English  
TI The identification, characterization, and distribution of guinea pig CCR4  
and epitope mapping of a blocking **antibody**.  
AU Jopling, Louise A.; Sabroe, Ian; Andrew, David P.; Mitchell, Tracey J.;  
Li, You; Hodge, Martin R.; Williams, Timothy J.; Pease, James E. (1)

L4 ANSWER 49 OF 59 BIOSIS COPYRIGHT 2002 BIOLOGICAL ABSTRACTS INC.  
ACCESSION NUMBER: 2001:493372 BIOSIS  
DOCUMENT NUMBER: PREV200100493372  
TITLE: Antigen-pulsed dendritic cells expressing  
**macrophage-derived chemokine**  
elicit Th2 responses and promote specific humoral  
immunity.  
AUTHOR(S): Kikuchi, Toshiaki; Crystal, Ronald G. (1)  
CORPORATE SOURCE: (1) Institute of Genetic Medicine, Weill Medical College  
of  
Cornell University, 520 East 70th Street, ST 505, New  
York,  
NY, 10021: [geneticmedicine@med.cornell.edu](mailto:geneticmedicine@med.cornell.edu) USA  
SOURCE: Journal of Clinical Investigation, (September, 2001) Vol.  
108, No. 6, pp. 917-927. print.  
ISSN: 0021-9738.  
DOCUMENT TYPE: Article  
LANGUAGE: English  
SUMMARY LANGUAGE: English  
TI Antigen-pulsed dendritic cells expressing **macrophage-**  
**derived chemokine** elicit Th2 responses and promote  
specific humoral immunity.  
AU Kikuchi, Toshiaki; Crystal, Ronald G. (1)

L4 ANSWER 50 OF 59 BIOSIS COPYRIGHT 2002 BIOLOGICAL ABSTRACTS INC.  
ACCESSION NUMBER: 2001:493349 BIOSIS  
DOCUMENT NUMBER: PREV200100493349  
TITLE: Enhancement of stromal cell-derived factor-1alpha-induced  
chemotaxis for CD4/8 double-positive thymocytes by  
fibronectin and laminin in mice.  
AUTHOR(S): Yanagawa, Yoshiki; Iwabuchi, Kazuya; Onoe, Kazunori (1)  
CORPORATE SOURCE: (1) Division of Immunobiology, Institute for Genetic  
Medicine, Hokkaido University, Kita-15, Nishi-7, Kita-ku,



SOURCE: Sapporo, 060-0815: kazunori@imm.hokudai.ac.jp Japan  
Immunology, (September, 2001) Vol. 104, No. 1, pp. 43-49.  
print.  
ISSN: 0019-2805.

DOCUMENT TYPE: Article

LANGUAGE: English

SUMMARY LANGUAGE: English

TI Enhancement of stromal cell-derived factor-1alpha-induced chemotaxis for  
CD4/8 double-positive thymocytes by fibronectin and laminin in mice.

AU Yanagawa, Yoshiki; Iwabuchi, Kazuya; Onoe, Kazunori (1)

L4 ANSWER 51 OF 59 BIOSIS COPYRIGHT 2002 BIOLOGICAL ABSTRACTS INC.

ACCESSION NUMBER: 2001:266047 BIOSIS

DOCUMENT NUMBER: PREV200100266047

TITLE: Chemokines, chemokine receptors and allergy.

AUTHOR(S): Kaplan, Allen P. (1)

CORPORATE SOURCE: (1) Department of Medicine Division of Pulmonary, Allergy  
and Critical Care, Medical University of South Carolina,  
171 Ashley Avenue, Charleston, SC, 29425-2220:  
kaplana@musc.edu USA

SOURCE: International Archives of Allergy and Immunology, (April,  
2001) Vol. 124, No. 4, pp. 423-431. print.

ISSN: 1018-2438.

DOCUMENT TYPE: General Review

LANGUAGE: English

SUMMARY LANGUAGE: English

TI Chemokines, chemokine receptors and allergy.

AU Kaplan, Allen P. (1)

L4 ANSWER 52 OF 59 BIOSIS COPYRIGHT 2002 BIOLOGICAL ABSTRACTS INC.

ACCESSION NUMBER: 2001:185996 BIOSIS

DOCUMENT NUMBER: PREV200100185996

TITLE: The CC chemokines MDC and TARC induce platelet activation  
via CCR4.

AUTHOR(S): Abi-Younes, Sylvie; Si-Tahar, Mustapha; Luster, Andrew D.  
(1)

CORPORATE SOURCE: (1) Massachusetts General Hospital-East, 13th Street,  
Building 149, Charlestown, MA, 02129:  
luster@helix.mgh.harvard.edu USA

SOURCE: Thrombosis Research, (February 15, 2001) Vol. 101, No. 4,  
pp. 279-289. print.

ISSN: 0049-3848.

DOCUMENT TYPE: Article

LANGUAGE: English

SUMMARY LANGUAGE: English

TI The CC chemokines MDC and TARC induce platelet activation via CCR4.

AU Abi-Younes, Sylvie; Si-Tahar, Mustapha; Luster, Andrew D. (1)

L4 ANSWER 53 OF 59 BIOSIS COPYRIGHT 2002 BIOLOGICAL ABSTRACTS INC.

ACCESSION NUMBER: 2001:115423 BIOSIS

DOCUMENT NUMBER: PREV200100115423

TITLE: Adenosine diphosphate strongly potentiates the ability of  
the chemokines MDC, TARC, and SDF-1 to stimulate platelet  
function.

AUTHOR(S): Gear, Adrian R. L. (1); Suttitanamongkol, Sudawadee;  
Viisoreanu, Delia; Polanowska-Grabowska, Renata K.; Raha,  
Sanghamitra; Camerini, David

CORPORATE SOURCE: (1) Department of Biochemistry and Molecular Genetics,  
University of Virginia Health Sciences Center, 1300  
Jefferson Park Ave, Charlottesville, VA, 22908:

alg4p@virginia.edu USA

SOURCE: Blood, (February 15, 2001) Vol. 97, No. 4, pp. 937-945.  
print.  
ISSN: 0006-4971.

DOCUMENT TYPE: Article

LANGUAGE: English

SUMMARY LANGUAGE: English

TI Adenosine diphosphate strongly potentiates the ability of the chemokines MDC, TARC, and SDF-1 to stimulate platelet function.

AU Gear, Adrian R. L. (1); Suttitanamongkol, Sudawadee; Viisoreanu, Delia; Polanowska-Grabowska, Renata K.; Raha, Sanghamitra; Camerini, David

L4 ANSWER 54 OF 59 BIOSIS COPYRIGHT 2002 BIOLOGICAL ABSTRACTS INC.

ACCESSION NUMBER: 2001:58554 BIOSIS

DOCUMENT NUMBER: PREV200100058554

TITLE: Functional expression of CCR1, CCR3, CCR4, and CXCR4 chemokine receptors on human platelets.

AUTHOR(S): Clemetson, Kenneth J. (1); Clemetson, Jeannine M.; Proudfoot, Amanda E. I.; Power, Christine A.; Baggiolini, Marco; Wells, Timothy N. C.

CORPORATE SOURCE: (1) Theodor Kocher Institute, University of Berne, Freiestrasse 1, CH-3012, Berne: clemetson@tki.unibe.ch Switzerland

SOURCE: Blood, (December 15, 2000) Vol. 96, No. 13, pp. 4046-4054.  
print.  
ISSN: 0006-4971.

DOCUMENT TYPE: Article

LANGUAGE: English

SUMMARY LANGUAGE: English

TI Functional expression of CCR1, CCR3, CCR4, and CXCR4 chemokine receptors on human platelets.

AU Clemetson, Kenneth J. (1); Clemetson, Jeannine M.; Proudfoot, Amanda E. I.; Power, Christine A.; Baggiolini, Marco; Wells, Timothy N. C.

L4 ANSWER 55 OF 59 BIOSIS COPYRIGHT 2002 BIOLOGICAL ABSTRACTS INC.

ACCESSION NUMBER: 2001:42973 BIOSIS

DOCUMENT NUMBER: PREV200100042973

TITLE: Mitomycin-C and vernal conjunctivitis: Author's reply.

AUTHOR(S): Akpek, Esen K. (1); Kalayci, Defne

CORPORATE SOURCE: (1) Baltimore, MD USA

SOURCE: Ophthalmology, (December, 2000) Vol. 107, No. 12, pp. 2126-2127. print.  
ISSN: 0161-6420.

DOCUMENT TYPE: Letter

LANGUAGE: English

SUMMARY LANGUAGE: English

TI Mitomycin-C and vernal conjunctivitis: Author's reply.

AU Akpek, Esen K. (1); Kalayci, Defne

L4 ANSWER 56 OF 59 BIOSIS COPYRIGHT 2002 BIOLOGICAL ABSTRACTS INC.

ACCESSION NUMBER: 2000:242075 BIOSIS

DOCUMENT NUMBER: PREV200000242075

TITLE: The role of lymphocytes in allergic disease.

AUTHOR(S): Romagnani, Sergio (1)

CORPORATE SOURCE: (1) Department of Internal Medicine, Section of Clinical Immunology, Allergy, and Respiratory Disorders, University of Florence, Viale Morgagni 85, Florence, 50134 Italy

SOURCE: Journal of Allergy and Clinical Immunology, (March, 2000) Vol. 105, No. 3, pp. 399-408.  
ISSN: 0091-6749.

DOCUMENT TYPE: Article  
LANGUAGE: English  
SUMMARY LANGUAGE: English  
TI The role of lymphocytes in allergic disease.  
AU Romagnani, Sergio (1)

L4 ANSWER 57 OF 59 BIOSIS COPYRIGHT 2002 BIOLOGICAL ABSTRACTS INC.  
ACCESSION NUMBER: 1999:430861 BIOSIS  
DOCUMENT NUMBER: PREV199900430861  
TITLE: Differential utilization of cyclic ADP-ribose pathway by chemokines to induce the mobilization of intracellular calcium in NK cells.  
AUTHOR(S): Inngjerdengen, Marit; Al-Aoukaty, Ala; Damaj, Bassam; Maghazachi, Azzam A. (1)  
CORPORATE SOURCE: (1) Department of Anatomy, Institute of Basic Medical Sciences, University of Oslo, Blindern, N-0317, Oslo Norway  
SOURCE: Biochemical and Biophysical Research Communications, (Aug. 27, 1999) Vol. 262, No. 2, pp. 467-472.  
ISSN: 0006-291X.  
DOCUMENT TYPE: Article  
LANGUAGE: English  
SUMMARY LANGUAGE: English  
TI Differential utilization of cyclic ADP-ribose pathway by chemokines to induce the mobilization of intracellular calcium in NK cells.  
AU Inngjerdengen, Marit; Al-Aoukaty, Ala; Damaj, Bassam; Maghazachi, Azzam A.  
(1)

L4 ANSWER 58 OF 59 BIOSIS COPYRIGHT 2002 BIOLOGICAL ABSTRACTS INC.  
ACCESSION NUMBER: 1999:311711 BIOSIS  
DOCUMENT NUMBER: PREV199900311711  
TITLE: Switch in chemokine receptor expression upon TCR stimulation reveals novel homing potential for recently activated T cells.  
AUTHOR(S): Sallusto, Federica (1); Kremmer, Elisabeth; Palermo, Belinda; Hoy, Andre; Ponath, Paul; Qin, Shixin; Foerster, Reinhold; Lipp, Martin; Lanzavecchia, Antonio  
CORPORATE SOURCE: (1) Basel Institute for Immunology, Grenzacherstrasse 487, CH-4005, Basel Switzerland  
SOURCE: European Journal of Immunology, (June, 1999) Vol. 29, No. 6, pp. 2037-2045.  
ISSN: 0014-2980.  
DOCUMENT TYPE: Article  
LANGUAGE: English  
SUMMARY LANGUAGE: English  
TI Switch in chemokine receptor expression upon TCR stimulation reveals novel homing potential for recently activated T cells.  
AU Sallusto, Federica (1); Kremmer, Elisabeth; Palermo, Belinda; Hoy, Andre; Ponath, Paul; Qin, Shixin; Foerster, Reinhold; Lipp, Martin; Lanzavecchia, Antonio

L4 ANSWER 59 OF 59 BIOSIS COPYRIGHT 2002 BIOLOGICAL ABSTRACTS INC.  
ACCESSION NUMBER: 1999:204727 BIOSIS  
DOCUMENT NUMBER: PREV199900204727  
TITLE: **Macrophage-derived chemokine** induces human eosinophil chemotaxis in a CC chemokine receptor 3- and CC chemokine receptor 4-independent manner.

AUTHOR(S): Bochner, Bruce S. (1); Bickel, Carol A.; Taylor, Marcia L.;  
 MacGlashan, Donald W., Jr. ; Gray, Patrick W.; Raport, Carol J.; Godiska, Ronald  
 CORPORATE SOURCE: (1) John Hopkins Asthma and Allergy Center, 5501 Hopkins Bayview Circle, Baltimore, MD, 21224 USA  
 SOURCE: Journal of Allergy and Clinical Immunology, (March, 1999) Vol. 103, No. 3 PART 1, pp. 527-532.  
 ISSN: 0091-6749.  
 DOCUMENT TYPE: Article  
 LANGUAGE: English  
 SUMMARY LANGUAGE: English  
 TI **Macrophage-derived chemokine** induces human eosinophil chemotaxis in a CC chemokine receptor 3- and CC chemokine receptor 4-independent manner.  
 AU Bochner, Bruce S. (1); Bickel, Carol A.; Taylor, Marcia L.; MacGlashan, Donald W., Jr. ; Gray, Patrick W.; Raport, Carol J.; Godiska, Ronald

=> D L13, IBIB TI AU 1-62

L13 ANSWER 1 OF 62 CAPLUS COPYRIGHT 2002 ACS  
 ACCESSION NUMBER: 2002:832576 CAPLUS  
 TITLE: **Treatment** of respiratory and lung diseases with antisense oligonucleotides and a bronchodilating agent  
 INVENTOR(S): Nyce, Jonathan W.; Li, Yukui; Sandrasagra, Anthony; Katz, Evan; Pabalan, Jonathan; Aguilar, Douglas; Miller, Shoreh; Tang, Lei; Shahabuddin, Syed  
 PATENT ASSIGNEE(S): Epigenesis Pharmaceuticals, Inc., USA  
 SOURCE: PCT Int. Appl., 764 pp.  
 CODEN: PIXXD2  
 DOCUMENT TYPE: Patent  
 LANGUAGE: English  
 FAMILY ACC. NUM. COUNT: 1  
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2002085309	A2	20021031	WO 2002-US13143	20020423
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				

PRIORITY APPLN. INFO.: US 2001-286036P P 20010424  
 TI **Treatment** of respiratory and lung diseases with antisense oligonucleotides and a bronchodilating agent  
 IN Nyce, Jonathan W.; Li, Yukui; Sandrasagra, Anthony; Katz, Evan; Pabalan, Jonathan; Aguilar, Douglas; Miller, Shoreh; Tang, Lei; Shahabuddin, Syed

L13 ANSWER 2 OF 62 CAPLUS COPYRIGHT 2002 ACS  
 ACCESSION NUMBER: 2002:832575 CAPLUS  
 TITLE: **Treatment** of respiratory and lung diseases with antisense oligonucleotides and a bronchodilating agent

INVENTOR(S): agent  
 Nyce, Jonathan W.; Li, Yukui; Sandrasagra, Anthony;  
 Katz, Evan; Pabalan, Jonathan; Aguilar, Douglas;  
 Miller, Shoreh; Tang, Lei; Shahabuddin, Syed  
 PATENT ASSIGNEE(S): Epigenesis Pharmaceuticals, Inc., USA  
 SOURCE: PCT Int. Appl., 872 pp.  
 CODEN: PIXXD2  
 DOCUMENT TYPE: Patent  
 LANGUAGE: English  
 FAMILY ACC. NUM. COUNT: 4  
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2002085308	A2	20021031	WO 2002-US13135	20020423
W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM			
RW:	GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG			
WO 2002085308	A2	20021031	WO 2002-XA13135	20020423
W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM			
RW:	GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG			
WO 2002085308	A2	20021031	WO 2002-XB13135	20020423
W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM			
RW:	GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG			
WO 2002085308	A2	20021031	WO 2002-XC13135	20020423
W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM			
RW:	GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG			

PRIORITY APPLN. INFO.:  
 US 2001-286137P P 20010424  
 WO 2002-US13135 A 20020423

TI **Treatment** of respiratory and lung diseases with antisense  
oligonucleotides and a bronchodilating agent  
IN Nyce, Jonathan W.; Li, Yukui; Sandrasagra, Anthony; Katz, Evan; Pabalan,  
Jonathan; Aguilar, Douglas; Miller, Shoreh; Tang, Lei; Shahabuddin, Syed

L13 ANSWER 3 OF 62 CAPLUS COPYRIGHT 2002 ACS

ACCESSION NUMBER: 2002:709704 CAPLUS  
DOCUMENT NUMBER: 137:212010  
TITLE: Protein and cDNA sequences of a novel human  
nucleotide excision repair protein 9.24 and therapeutic use  
thereof  
INVENTOR(S): Mao, Yumin; Xie, Yi  
PATENT ASSIGNEE(S): Shanghai Bode Gene Development Co. Ltd., Peop. Rep.  
China  
SOURCE: Faming Zhuanli Shenqing Gongkai Shuomingshu, 35 pp.  
CODEN: CNXXEV  
DOCUMENT TYPE: Patent  
LANGUAGE: Chinese  
FAMILY ACC. NUM. COUNT: 1  
PATENT INFORMATION:

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
	CN 1329052	A	20020102	CN 2000-116587	20000619
TI	Protein and cDNA sequences of a novel human nucleotide excision repair protein 9.24 and therapeutic use thereof				
IN	Mao, Yumin; Xie, Yi				

L13 ANSWER 4 OF 62 CAPLUS COPYRIGHT 2002 ACS

ACCESSION NUMBER: 2002:709703 CAPLUS  
DOCUMENT NUMBER: 137:212009  
TITLE: Protein and cDNA sequences of a novel human  
CCR4 related protein 9 and therapeutic use  
thereof  
INVENTOR(S): Mao, Yumin; Xie, Yi  
PATENT ASSIGNEE(S): Shanghai Bode Gene Development Co. Ltd., Peop. Rep.  
China  
SOURCE: Faming Zhuanli Shenqing Gongkai Shuomingshu, 33 pp.  
CODEN: CNXXEV  
DOCUMENT TYPE: Patent  
LANGUAGE: Chinese  
FAMILY ACC. NUM. COUNT: 1  
PATENT INFORMATION:

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
	CN 1329051	A	20020102	CN 2000-116586	20000619
TI	Protein and cDNA sequences of a novel human CCR4 related protein 9 and therapeutic use thereof				
IN	Mao, Yumin; Xie, Yi				

L13 ANSWER 5 OF 62 CAPLUS COPYRIGHT 2002 ACS

ACCESSION NUMBER: 2002:709694 CAPLUS  
DOCUMENT NUMBER: 137:212000  
TITLE: Protein and cDNA sequences of a novel human Mch2 (a  
member of cysteine protease family) protein 10.45 and  
therapeutic use thereof  
INVENTOR(S): Mao, Yumin; Xie, Yi  
PATENT ASSIGNEE(S): Shanghai Bode Gene Development Co. Ltd., Peop. Rep.

SOURCE: China  
 Faming Zhuanli Shenqing Gongkai Shuomingshu, 33 pp.  
 CODEN: CNXXEV  
 DOCUMENT TYPE: Patent  
 LANGUAGE: Chinese  
 FAMILY ACC. NUM. COUNT: 1  
 PATENT INFORMATION:

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
	CN 1329039	A	20020102	CN 2000-116570	20000619
TI	Protein and cDNA sequences of a novel human Mch2 (a member of cysteine protease family) protein 10.45 and therapeutic use thereof				
IN	Mao, Yumin; Xie, Yi				

L13 ANSWER 6 OF 62 CAPLUS COPYRIGHT 2002 ACS  
 ACCESSION NUMBER: 2002:662210 CAPLUS  
 TITLE: Chemokine responses in schistosomal antigen-elicited granuloma formation  
 AUTHOR(S): Chiu, Bo-Chin; Chensue, Stephen W.  
 CORPORATE SOURCE: Department of Pathology, University of Michigan Medical School, Ann Arbor, MI, USA  
 SOURCE: Parasite Immunology (2002), 24(6), 285-294  
 CODEN: PAIMD8; ISSN: 0141-9838  
 PUBLISHER: Blackwell Science Ltd.  
 DOCUMENT TYPE: Journal  
 LANGUAGE: English  
 TI Chemokine responses in schistosomal antigen-elicited granuloma formation  
 AU Chiu, Bo-Chin; Chensue, Stephen W.  
 REFERENCE COUNT: 47 THERE ARE 47 CITED REFERENCES AVAILABLE FOR THIS

RECORD. ALL CITATIONS AVAILABLE IN THE RE

FORMAT

L13 ANSWER 7 OF 62 CAPLUS COPYRIGHT 2002 ACS  
 ACCESSION NUMBER: 2002:554394 CAPLUS  
 DOCUMENT NUMBER: 137:139240  
 TITLE: IFN-.gamma.-inducible expression of thymus and activation-regulated chemokine/CCL17 and macrophage-derived chemokine/CCL22 in epidermal keratinocytes and their roles in atopic dermatitis  
 AUTHOR(S): Horikawa, Tatsuya; Nakayama, Takashi; Hikata, Ichiro; Yamada, Hidekazu; Fujisawa, Ryuichi; Bito, Toshinori; Harada, Susumu; Fukunaga, Atsushi; Chantry, David; Gray, Patrick W.; Morita, Atsushi; Suzuki, Ryuji; Tezuka, Tadashi; Ichihashi, Masamitsu; Yoshie, Osamu  
 CORPORATE SOURCE: Division of Dermatology, Department of Clinical Molecular Medicine, Kobe University Graduate School of Medicine, Kobe, 650-0017, Japan  
 SOURCE: International Immunology (2002), 14(7), 767-773  
 CODEN: INIMEN; ISSN: 0953-8178  
 PUBLISHER: Oxford University Press  
 DOCUMENT TYPE: Journal  
 LANGUAGE: English  
 TI IFN-.gamma.-inducible expression of thymus and activation-regulated chemokine/CCL17 and macrophage-derived chemokine/CCL22 in epidermal keratinocytes and their roles in atopic dermatitis  
 AU Horikawa, Tatsuya; Nakayama, Takashi; Hikata, Ichiro; Yamada, Hidekazu; Fujisawa, Ryuichi; Bito, Toshinori; Harada, Susumu; Fukunaga, Atsushi;

Chantry, David; Gray, Patrick W.; Morita, Atsushi; Suzuki, Ryuji; Tezuka, Tadashi; Ichihashi, Masamitsu; Yoshie, Osamu  
REFERENCE COUNT: 24 THERE ARE 24 CITED REFERENCES AVAILABLE FOR THIS

RECORD. ALL CITATIONS AVAILABLE IN THE RE  
FORMAT

L13 ANSWER 8 OF 62 CAPLUS COPYRIGHT 2002 ACS

ACCESSION NUMBER: 2002:461226 CAPLUS  
DOCUMENT NUMBER: 137:30221  
TITLE: Method for identification of interventions which mimic effects of calorie restriction on aging  
INVENTOR(S): Spindler, Stephen R.  
PATENT ASSIGNEE(S): The Regents of the University of California, USA  
SOURCE: U.S., 150 pp., Cont.-in-part of U.S. Ser. No. 471,225.

CODEN: USXXAM  
DOCUMENT TYPE: Patent  
LANGUAGE: English  
FAMILY ACC. NUM. COUNT: 3  
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 6406853	B1	20020618	US 2000-648642	20000825
US 6391270	B1	20020521	US 1999-471225	19991223
WO 2001045752	A1	20010628	WO 2000-US35437	20001222
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
EP 1239885	A1	20020918	EP 2000-988400	20001222
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR				
PRIORITY APPLN. INFO.:			US 1999-471225	A2 19991223
			US 1999-471224	A 19991223
			US 2000-648642	A 20000825
			WO 2000-US35437	W 20001222
TI Method for identification of interventions which mimic effects of calorie restriction on aging				
IN Spindler, Stephen R.				
REFERENCE COUNT: 4			THERE ARE 4 CITED REFERENCES AVAILABLE FOR THIS	
			RECORD. ALL CITATIONS AVAILABLE IN THE RE	
FORMAT				

L13 ANSWER 9 OF 62 CAPLUS COPYRIGHT 2002 ACS

ACCESSION NUMBER: 2002:449493 CAPLUS  
DOCUMENT NUMBER: 137:15782  
TITLE: Therapeutics for chemokine-mediated diseases  
INVENTOR(S): Saxena, Geeta; Tudan, Christopher R.; Salari, Hassan  
PATENT ASSIGNEE(S): Chemokine Therapeutics Corporation, Can.  
SOURCE: PCT Int. Appl., 52 pp.  
CODEN: PIXXD2  
DOCUMENT TYPE: Patent



LANGUAGE: English  
FAMILY ACC. NUM. COUNT: 1  
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2002045702	A2	20020613	WO 2001-CA1748	20011205
W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM			
RW:	GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG			
AU 2002015737	A5	20020618	AU 2002-15737	20011205
PRIORITY APPLN. INFO.:	CA 2000-2330350 A 20001205 US 2001-767378 A 20010122 WO 2001-CA1748 W 20011205			

OTHER SOURCE(S): MARPAT 137:15782  
TI Therapeutics for chemokine-mediated diseases  
IN Saxena, Geeta; Tudan, Christopher R.; Salari, Hassan

L13 ANSWER 10 OF 62 CAPLUS COPYRIGHT 2002 ACS  
ACCESSION NUMBER: 2002:424142 CAPLUS  
DOCUMENT NUMBER: 136:381371  
TITLE: Protein and cDNA sequences of a novel human protein CCR4-like protein 16 and therapeutical uses  
INVENTOR(S): Mao, Yumin; Xie, Yi  
PATENT ASSIGNEE(S): Bode Gene Development Co., Ltd., Shanghai, Peop. Rep. China  
SOURCE: Faming Zhuanli Shenqing Gongkai Shuomingshu, 33 pp.  
CODEN: CNXXEV  
DOCUMENT TYPE: Patent  
LANGUAGE: Chinese  
FAMILY ACC. NUM. COUNT: 1  
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
CN 1315438	A	20011003	CN 2000-115260	20000329
WO 2001079280	A1	20011025	WO 2001-CN531	20010326
W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CO, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM			
RW:	GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG			
PRIORITY APPLN. INFO.:	CN 2000-115260 A 20000329			
TI	Protein and cDNA sequences of a novel human protein CCR4-like protein 16 and therapeutical uses			
IN	Mao, Yumin; Xie, Yi			

L13 ANSWER 11 OF 62 CAPLUS COPYRIGHT 2002 ACS  
ACCESSION NUMBER: 2002:355048 CAPLUS

TITLE: AMD3100, a CXCR4 antagonist, attenuates allergic lung inflammation and airway hyperreactivity

AUTHOR(S): Lukacs, Nicholas W.; Berlin, Aaron; Schols, Dominique;

CORPORATE SOURCE: Skerlj, Renato T.; Bridger, Gary J.  
Department of Pathology, University of Michigan Medical School, Ann Arbor, MI, 48109-0602, USA

SOURCE: American Journal of Pathology (2002), 160(4), 1353-1360  
CODEN: AJPA44; ISSN: 0002-9440

PUBLISHER: American Society for Investigative Pathology

DOCUMENT TYPE: Journal

LANGUAGE: English

TI AMD3100, a CXCR4 antagonist, attenuates allergic lung inflammation and airway hyperreactivity

AU Lukacs, Nicholas W.; Berlin, Aaron; Schols, Dominique; Skerlj, Renato T.; Bridger, Gary J.

REFERENCE COUNT: 56 THERE ARE 56 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE

FORMAT

L13 ANSWER 12 OF 62 CAPLUS COPYRIGHT 2002 ACS

ACCESSION NUMBER: 2002:332188 CAPLUS

DOCUMENT NUMBER: 136:355235

TITLE: Preparation of tertiary N-(5,6,7,8-tetrahydro-8-quinolinyl)-N-(1H-benzimidazol-2-ylmethyl)amines and analogs as chemokine receptor modulators for **treatment** of HIV or FIV

INVENTOR(S): Bridger, Gary; Skerlj, Renato; Kaller, Al; Harwig, Curtis; Bogucki, David; Wilson, Trevor R.; Crawford, Jason; Mceachern, Ernest J.; Atsman, Berm; Nan, Siqiao; Zhou, Yuanxi; Schols, Dominique; Smith, Christopher Dennis; Di Fluri, Rosaria Maria

PATENT ASSIGNEE(S): Anormed Inc., Can.

SOURCE: PCT Int. Appl., 187 pp.  
CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 3

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2002034745	A1	20020502	WO 2001-US29590	20010919
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
AU 2001094628	A5	20020506	AU 2001-94628	20010919
PRIORITY APPLN. INFO.:			US 2000-234510P	P 20000922
			US 2000-234816P	P 20000922
			WO 2001-US29590	W 20010919
OTHER SOURCE(S): MARPAT 136:355235				
TI Preparation of tertiary N-(5,6,7,8-tetrahydro-8-quinolinyl)-N-(1H-				

benzimidazol-2-ylmethyl)amines and analogs as chemokine receptor modulators for **treatment** of HIV or FIV

IN Bridger, Gary; Skerlj, Renato; Kaller, Al; Harwig, Curtis; Bogucki, David;

Wilson, Trevor R.; Crawford, Jason; Mceachern, Ernest J.; Atsman, Berm; Nan, Sigiao; Zhou, Yuanxi; Schols, Dominique; Smith, Christopher Dennis; Di Fluri, Rosaria Maria

REFERENCE COUNT: 6 THERE ARE 6 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE

FORMAT

L13 ANSWER 13 OF 62 CAPLUS COPYRIGHT 2002 ACS

ACCESSION NUMBER: 2002:293390 CAPLUS

DOCUMENT NUMBER: 136:304071

TITLE: Modulation of **CCR4** function for disease therapy

INVENTOR(S): Collins, Tassie; Dairaghi, Daniel J.; Mahmud, Hoosen; McMaster, Brian E.; Medina, Julio C.; Schall, Thomas J.; Xu, Feng; Wang, Xuemei

PATENT ASSIGNEE(S): Tularik Inc., USA; Chemocentryx, Inc.

SOURCE: PCT Int. Appl., 78 pp.  
CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 2

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2002030358	A2	20020418	WO 2001-US42625	20011011
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
AU 2002013467	A5	20020422	AU 2002-13467	20011011
PRIORITY APPLN. INFO.:				
			US 2000-240022P	P 20001011
			US 2001-293781P	P 20010523
			WO 2001-US42625	W 20011011
OTHER SOURCE(S): MARPAT 136:304071				
TI Modulation of <b>CCR4</b> function for disease therapy				
IN Collins, Tassie; Dairaghi, Daniel J.; Mahmud, Hoosen; McMaster, Brian E.; Medina, Julio C.; Schall, Thomas J.; Xu, Feng; Wang, Xuemei				

L13 ANSWER 14 OF 62 CAPLUS COPYRIGHT 2002 ACS

ACCESSION NUMBER: 2002:293389 CAPLUS

DOCUMENT NUMBER: 136:304070

TITLE: Compounds and methods for modulating **CCR4** function for prevention and **treatment** of inflammatory and immunoregulatory disorders and diseases

INVENTOR(S): Dairaghi, Daniel J.; McMaster, Brian E.; Schall, Thomas J.

PATENT ASSIGNEE(S): Chemocentryx, Inc., USA

SOURCE: PCT Int. Appl., 44 pp.  
CODEN: PIXXD2

DOCUMENT TYPE: Patent  
LANGUAGE: English  
FAMILY ACC. NUM. COUNT: 2  
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2002030357	A2	20020418	WO 2001-US42624	20011011
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
AU 2002013466	A5	20020422	AU 2002-13466	20011011
US 2002132836	A1	20020919	US 2001-975567	20011011
PRIORITY APPLN. INFO.:			US 2000-240022P P	20001011
			WO 2001-US42624 W	20011011

OTHER SOURCE(S): MARPAT 136:304070

TI Compounds and methods for modulating **CCR4** function for prevention and **treatment** of inflammatory and immunoregulatory disorders and diseases

IN Dairaghi, Daniel J.; McMaster, Brian E.; Schall, Thomas J.

L13 ANSWER 15 OF 62 CAPLUS COPYRIGHT 2002 ACS

ACCESSION NUMBER: 2002:277417 CAPLUS

DOCUMENT NUMBER: 137:168130

TITLE: Serum macrophage-derived chemokine (MDC) levels are closely related with the disease activity of atopic dermatitis

AUTHOR(S): Kakinuma, T.; Nakamura, K.; Wakugawa, M.; Mitsui, H.; Tada, Y.; Saeki, H.; Torii, H.; Komine, M.; Asahina, A.; Tamaki, K.

CORPORATE SOURCE: Department of Dermatology, Faculty of Medicine, University of Tokyo, Tokyo, 113-8655, Japan

SOURCE: Clinical and Experimental Immunology (2002), 127(2), 270-273

CODEN: CEXIAL; ISSN: 0009-9104

PUBLISHER: Blackwell Science Ltd.

DOCUMENT TYPE: Journal

LANGUAGE: English

TI Serum macrophage-derived chemokine (MDC) levels are closely related with the disease activity of atopic dermatitis

AU Kakinuma, T.; Nakamura, K.; Wakugawa, M.; Mitsui, H.; Tada, Y.; Saeki, H.;

Torii, H.; Komine, M.; Asahina, A.; Tamaki, K.

REFERENCE COUNT: 22 THERE ARE 22 CITED REFERENCES AVAILABLE FOR THIS

RECORD. ALL CITATIONS AVAILABLE IN THE RE

FORMAT

L13 ANSWER 16 OF 62 CAPLUS COPYRIGHT 2002 ACS

ACCESSION NUMBER: 2002:196428 CAPLUS

DOCUMENT NUMBER: 137:41160

TITLE: Cytokine modulators as novel therapies for asthma

AUTHOR(S): Barnes, Peter J.

CORPORATE SOURCE: Department of Thoracic Medicine, Imperial College,

UK  
 SOURCE: National Heart and Lung Institute, London, SW3 6LY,  
 Annual Review of Pharmacology and Toxicology (2002),  
 42, 81-98  
 CODEN: ARPTDI; ISSN: 0362-1642  
 PUBLISHER: Annual Reviews Inc.  
 DOCUMENT TYPE: Journal; General Review  
 LANGUAGE: English  
 TI Cytokine modulators as novel therapies for asthma  
 AU Barnes, Peter J.  
 REFERENCE COUNT: 84 THERE ARE 84 CITED REFERENCES AVAILABLE FOR  
 THIS  
 RECORD. ALL CITATIONS AVAILABLE IN THE RE  
 FORMAT

L13 ANSWER 17 OF 62 CAPLUS COPYRIGHT 2002 ACS  
 ACCESSION NUMBER: 2002:124627 CAPLUS  
 DOCUMENT NUMBER: 137:27901  
 TITLE: Complementary whole-genome technologies reveal the  
 cellular response to proteasome inhibition by PS-341  
 AUTHOR(S): Fleming, James A.; Lightcap, Eric S.; Sadis, Seth;  
 Thoroddsen, Vala; Bulawa, Christine E.; Blackman,  
 Ronald K.  
 CORPORATE SOURCE: Millennium Pharmaceuticals, Incorporated, Cambridge,  
 MA, 02139, USA  
 SOURCE: Proceedings of the National Academy of Sciences of  
 the  
 United States of America (2002), 99(3), 1461-1466  
 CODEN: PNASA6; ISSN: 0027-8424  
 PUBLISHER: National Academy of Sciences  
 DOCUMENT TYPE: Journal  
 LANGUAGE: English  
 TI Complementary whole-genome technologies reveal the cellular response to  
 proteasome inhibition by PS-341  
 AU Fleming, James A.; Lightcap, Eric S.; Sadis, Seth; Thoroddsen, Vala;  
 Bulawa, Christine E.; Blackman, Ronald K.  
 REFERENCE COUNT: 43 THERE ARE 43 CITED REFERENCES AVAILABLE FOR  
 THIS  
 RECORD. ALL CITATIONS AVAILABLE IN THE RE  
 FORMAT

L13 ANSWER 18 OF 62 CAPLUS COPYRIGHT 2002 ACS  
 ACCESSION NUMBER: 2002:107319 CAPLUS  
 DOCUMENT NUMBER: 136:149844  
 TITLE: Chemokine and chemokine receptor gene expression as a  
 diagnostic indicator for inflammatory disease of the  
 gastrointestinal tract  
 INVENTOR(S): Smith, Kathleen M.; Zlotnik, Albert  
 PATENT ASSIGNEE(S): Schering Corporation, USA  
 SOURCE: PCT Int. Appl., 22 pp.  
 CODEN: PIXXD2  
 DOCUMENT TYPE: Patent  
 LANGUAGE: English  
 FAMILY ACC. NUM. COUNT: 1  
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2002010138	A2	20020207	WO 2001-US23891	20010730
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN,				

CO, CR, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, HR, HU,  
 ID, IL, IN, IS, JP, KG, KR, KZ, LC, LK, LR, LT, LU, LV, MA, MD,  
 MG, MK, MN, MX, MZ, NO, NZ, PL, PT, RO, RU, SE, SG, SI, SK, SL,  
 TJ, TM, TR, TT, TZ, UA, UZ, VN, YU, ZA, AM, AZ, BY, KG, KZ, MD,  
 RU, TJ, TM  
 RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY,  
 DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF,  
 BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG

US 2002115115 A1 20020822 US 2001-920318 20010731  
 PRIORITY APPLN. INFO.: US 2000-222258P P 20000801  
 TI Chemokine and chemokine receptor gene expression as a diagnostic  
 indicator  
 for inflammatory disease of the gastrointestinal tract  
 IN Smith, Kathleen M.; Zlotnik, Albert

L13 ANSWER 19 OF 62 CAPLUS COPYRIGHT 2002 ACS  
 ACCESSION NUMBER: 2001:886505 CAPLUS  
 DOCUMENT NUMBER: 136:32804  
 TITLE: cDNA and protein sequence of a novel human protein  
 9.5  
 and their uses in drug screening, diagnosis and  
 therapeutics  
 INVENTOR(S): Mao, Yumin; Xie, Yi  
 PATENT ASSIGNEE(S): Shanghai Biowindow Gene Development Inc., Peop. Rep.  
 China  
 SOURCE: PCT Int. Appl., 36 pp.  
 CODEN: PIXXD2  
 DOCUMENT TYPE: Patent  
 LANGUAGE: Chinese  
 FAMILY ACC. NUM. COUNT: 1  
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2001092518	A1	20011206	WO 2001-CN842	20010521
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CO, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
CN 1324862	A	20011205	CN 2000-115846	20000524
PRIORITY APPLN. INFO.: CN 2000-115846 A 20000524 TI cDNA and protein sequence of a novel human protein 9.5 and their uses in drug screening, diagnosis and therapeutics IN Mao, Yumin; Xie, Yi				

L13 ANSWER 20 OF 62 CAPLUS COPYRIGHT 2002 ACS  
 ACCESSION NUMBER: 2001:877804 CAPLUS  
 DOCUMENT NUMBER: 136:1636  
 TITLE: Protein and cDNA sequences of 31 kDa human  
 CCR4 related protein CAF1 sequence homolog  
 (HCAF31) and therapeutic use thereof  
 INVENTOR(S): Mao, Yumin; Xie, Yi  
 PATENT ASSIGNEE(S): Borong Gene Development Co., Ltd., Shanghai, Peop.  
 Rep. China  
 SOURCE: Faming Zhuanli Shenqing Gongkai Shuomingshu, 34 pp.

CODEN: CNXXEV  
DOCUMENT TYPE: Patent  
LANGUAGE: Chinese  
FAMILY ACC. NUM. COUNT: 1  
PATENT INFORMATION:

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
	CN 1296960	A	20010530	CN 1999-124049	19991122
TI	Protein and cDNA sequences of 31 kDa human <b>CCR4</b> related protein CAF1 sequence homolog (HCAF31) and therapeutic use thereof				
IN	Mao, Yumin; Xie, Yi				

L13 ANSWER 21 OF 62 CAPLUS COPYRIGHT 2002 ACS  
ACCESSION NUMBER: 2001:851215 CAPLUS  
DOCUMENT NUMBER: 136:1681  
TITLE: Protein and cDNA sequences of 10 kDa human **CCR4** associated protein-like protein and therapeutic use thereof  
INVENTOR(S): Mao, Yumin; Xie, Yi  
PATENT ASSIGNEE(S): Shanghai Biowindow Gene Development Inc., Peop. Rep. China  
SOURCE: PCT Int. Appl., 37 pp.  
CODEN: PIXXD2  
DOCUMENT TYPE: Patent  
LANGUAGE: Chinese  
FAMILY ACC. NUM. COUNT: 1  
PATENT INFORMATION:

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
	WO 2001087947	A1	20011122	WO 2001-CN700	20010508
W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CO, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW:	GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
	CN 1322744	A	20011121	CN 2000-115620	20000509
PRIORITY APPLN. INFO.:				CN 2000-115620	A 20000509
TI	Protein and cDNA sequences of 10 kDa human <b>CCR4</b> associated protein-like protein and therapeutic use thereof				
IN	Mao, Yumin; Xie, Yi				
REFERENCE COUNT:	1	THERE ARE 1 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE			

FORMAT

L13 ANSWER 22 OF 62 CAPLUS COPYRIGHT 2002 ACS  
ACCESSION NUMBER: 2001:798457 CAPLUS  
DOCUMENT NUMBER: 135:330114  
TITLE: A reporter gene expression vector and host cell system  
for detection of HIV and monitoring HIV drug resistance  
INVENTOR(S): Dong, Jian-Yun  
PATENT ASSIGNEE(S): Musc Foundation for Research Development, USA  
SOURCE: PCT Int. Appl., 74 pp.

CODEN: PIXXD2  
DOCUMENT TYPE: Patent  
LANGUAGE: English  
FAMILY ACC. NUM. COUNT: 2  
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2001081608	A2	20011101	WO 2001-US12968	20010423
WO 2001081608	A3	20020221		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
US 6410013	B1	20020625	US 2000-559244	20000426
PRIORITY APPLN. INFO.:			US 2000-559244	A2 20000426
			US 1999-117136P	P 19990125
			US 1999-314259	A2 19990518
			WO 2000-US782	A1 20000112.
TI	A reporter gene expression vector and host cell system for detection of HIV and monitoring HIV drug resistance			
IN	Dong, Jian-Yun			
L13	ANSWER 23 OF 62 CAPLUS COPYRIGHT 2002 ACS			
ACCESSION NUMBER:	2001:705493 CAPLUS			
DOCUMENT NUMBER:	136:5216			
TITLE:	Genomic profiling of short- and long-term caloric restriction effects in the liver of aging mice			
AUTHOR(S):	Cao, Shelley X.; Dhahbi, Joseph M.; Mote, Patricia L.;			
	Spindler, Stephen R.			
CORPORATE SOURCE:	Department of Biochemistry, University of California, Riverside, CA, 92521, USA			
SOURCE:	Proceedings of the National Academy of Sciences of the United States of America (2001), 98(19), 10630-10635			
	CODEN: PNASA6; ISSN: 0027-8424			
PUBLISHER:	National Academy of Sciences			
DOCUMENT TYPE:	Journal			
LANGUAGE:	English			
TI	Genomic profiling of short- and long-term caloric restriction effects in the liver of aging mice			
AU	Cao, Shelley X.; Dhahbi, Joseph M.; Mote, Patricia L.; Spindler, Stephen R.			
REFERENCE COUNT:	58	THERE ARE 58 CITED REFERENCES AVAILABLE FOR THIS		
RECORD. ALL CITATIONS AVAILABLE IN THE RE				
FORMAT				

L13 ANSWER 24 OF 62 CAPLUS COPYRIGHT 2002 ACS  
ACCESSION NUMBER: 2001:661494 CAPLUS  
DOCUMENT NUMBER: 135:225865  
TITLE: Gene recombinant antibody and its fragment  
INVENTOR(S): Shitara, Kenya; Hanai, Nobuo; Shoji, Emi; Sakurada, Mikiko; Furuya, Akiko; Nakamura, Kazuyasu; Niwa,



Rinpei; Shibata, Kenji; Yamasaki, Motoo  
 PATENT ASSIGNEE(S): Kyowa Hakko Kogyo Co., Ltd., Japan  
 SOURCE: PCT Int. Appl., 116 pp.  
 CODEN: PIXXD2  
 DOCUMENT TYPE: Patent  
 LANGUAGE: Japanese  
 FAMILY ACC. NUM. COUNT: 1  
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2001064754	A1	20010907	WO 2001-JP1656	20010302
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
AU 2001036073	A5	20010912	AU 2001-36073	20010302
US 2002098527	A1	20020725	US 2001-796744	20010302
PRIORITY APPLN. INFO.:			JP 2000-59508	A 20000303
			JP 2000-401563	A 20001228
			WO 2001-JP1656	W 20010302

TI Gene recombinant antibody and its fragment  
 IN Shitara, Kenya; Hanai, Nobuo; Shoji, Emi; Sakurada, Mikiko; Furuya,  
 Akiko;  
 Nakamura, Kazuyasu; Niwa, Rinpei; Shibata, Kenji; Yamasaki, Motoo  
 REFERENCE COUNT: 24 THERE ARE 24 CITED REFERENCES AVAILABLE FOR  
 THIS

RECORD. ALL CITATIONS AVAILABLE IN THE RE  
 FORMAT

L13 ANSWER 25 OF 62 CAPLUS COPYRIGHT 2002 ACS  
 ACCESSION NUMBER: 2001:499783 CAPLUS  
 DOCUMENT NUMBER: 135:103329  
 TITLE: Methods of identifying G protein-coupled receptors  
 associated with the uptake of macrophage-trophic HIV,  
 and their use in diagnosis and **treatment** of  
 AIDS  
 INVENTOR(S): Littman, Dan R.; Deng, Hongkui; Ellmeier, Wilfried;  
 Landau, Nathaniel R.; Liu, Rong  
 PATENT ASSIGNEE(S): The Aaron Diamond Aids Research Center, USA; New York  
 University  
 SOURCE: U.S., 37 pp., Cont.-in-part of U.S. Ser. No. 858,660,  
 abandoned.  
 CODEN: USXXAM  
 DOCUMENT TYPE: Patent  
 LANGUAGE: English  
 FAMILY ACC. NUM. COUNT: 3  
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 6258527	B1	20010710	US 1997-861105	19970521
PRIORITY APPLN. INFO.:			US 1996-17157P	P 19960520
			US 1996-20043P	P 19960619
			US 1997-858660	B2 19970519

TI Methods of identifying G protein-coupled receptors associated with the uptake of macrophage-trophic HIV, and their use in diagnosis and **treatment** of AIDS  
IN Littman, Dan R.; Deng, Hongkui; Ellmeier, Wilfried; Landau, Nathaniel R.; Liu, Rong  
REFERENCE COUNT: 57 THERE ARE 57 CITED REFERENCES AVAILABLE FOR THIS

RECORD. ALL CITATIONS AVAILABLE IN THE RE  
FORMAT

L13 ANSWER 26 OF 62 CAPLUS COPYRIGHT 2002 ACS  
ACCESSION NUMBER: 2001:489619 CAPLUS  
DOCUMENT NUMBER: 135:71268  
TITLE: Use of locked nucleic acid-modified oligonucleotides for **treatment** of cancer and inflammation  
INVENTOR(S): Orum, Henrik; Koch, Troel; Skouv, Jan; Jakobsen, Mogen  
PATENT ASSIGNEE(S): Havsteen  
SOURCE: Exiqon A/S, Den.  
PCT Int. Appl., 50 pp.  
CODEN: PIXXD2  
DOCUMENT TYPE: Patent  
LANGUAGE: English  
FAMILY ACC. NUM. COUNT: 1  
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2001048190	A2	20010705	WO 2000-IB2043	20001222
WO 2001048190	A3	20020510		
W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM			
RW:	GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG			
US 2002068709	A1	20020606	US 2000-747913	20001222
EP 1240322	A2	20020918	EP 2000-990866	20001222
R:	AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR			
PRIORITY APPLN. INFO.:			US 1999-171873P P 19991223	
			WO 2000-IB2043 W 20001222	

TI Use of locked nucleic acid-modified oligonucleotides for **treatment** of cancer and inflammation  
IN Orum, Henrik; Koch, Troel; Skouv, Jan; Jakobsen, Mogen Havsteen

L13 ANSWER 27 OF 62 CAPLUS COPYRIGHT 2002 ACS  
ACCESSION NUMBER: 2001:293141 CAPLUS  
DOCUMENT NUMBER: 135:151353  
TITLE: Chemokines control fat accumulation and leptin secretion by cultured human adipocytes  
AUTHOR(S): Gerhardt, C. C.; Romero, I. A.; Cancelllo, R.; Camoin, L.; Strosberg, A. D.  
CORPORATE SOURCE: CNRS UPR 0415, Institut Cochin de Genetique Moleculaire, Paris, 75014, Fr.  
SOURCE: Molecular and Cellular Endocrinology (2001), 175(1-2),

81-92  
CODEN: MCEND6; ISSN: 0303-7207  
PUBLISHER: Elsevier Science Ireland Ltd.  
DOCUMENT TYPE: Journal  
LANGUAGE: English  
TI Chemokines control fat accumulation and leptin secretion by cultured human adipocytes  
AU Gerhardt, C. C.; Romero, I. A.; Cancelllo, R.; Camoin, L.; Strosberg, A. D.  
REFERENCE COUNT: 51 THERE ARE 51 CITED REFERENCES AVAILABLE FOR THIS  
RECORD. ALL CITATIONS AVAILABLE IN THE RE  
FORMAT

L13 ANSWER 28 OF 62 CAPLUS COPYRIGHT 2002 ACS  
ACCESSION NUMBER: 2001:250694 CAPLUS  
DOCUMENT NUMBER: 135:317274  
TITLE: Thymus and activation-regulated chemokine in atopic dermatitis: serum thymus and activation-regulated chemokine level is closely related with disease activity  
AUTHOR(S): Kakinuma, Takashi; Nakamura, Koichiro; Wakugawa, Motoshi; Mitsui, Hiroshi; Tada, Yayoi; Saeki, Hidehisa; Torii, Hideshi; Asahina, Akihiko; Onai, Nobuyuki; Matsushima, Kouji; Tamaki, Kunihiro  
CORPORATE SOURCE: Department of Dermatology, Faculty of Medicine, University of Tokyo, Tokyo, 113-8655, Japan  
SOURCE: Journal of Allergy and Clinical Immunology (2001), 107(3), 535-541  
CODEN: JACIBY; ISSN: 0091-6749  
PUBLISHER: Mosby, Inc.  
DOCUMENT TYPE: Journal  
LANGUAGE: English  
TI Thymus and activation-regulated chemokine in atopic dermatitis: serum thymus and activation-regulated chemokine level is closely related with disease activity  
AU Kakinuma, Takashi; Nakamura, Koichiro; Wakugawa, Motoshi; Mitsui, Hiroshi; Tada, Yayoi; Saeki, Hidehisa; Torii, Hideshi; Asahina, Akihiko; Onai, Nobuyuki; Matsushima, Kouji; Tamaki, Kunihiro  
REFERENCE COUNT: 25 THERE ARE 25 CITED REFERENCES AVAILABLE FOR THIS  
RECORD. ALL CITATIONS AVAILABLE IN THE RE  
FORMAT

L13 ANSWER 29 OF 62 CAPLUS COPYRIGHT 2002 ACS  
ACCESSION NUMBER: 2001:181821 CAPLUS  
DOCUMENT NUMBER: 134:339404  
TITLE: The CC Chemokines MDC and TARC Induce Platelet Activation Via CCR4  
AUTHOR(S): Abi-Younes, S.; Si-Tahar, M.; Luster, A. D.  
CORPORATE SOURCE: Division of Rheumatology, Allergy and Immunology, Center for Immunology and Inflammatory Diseases, Massachusetts General Hospital and Harvard Medical School, Boston, MA, USA  
SOURCE: Thrombosis Research (2001), 101(4), 279-289  
CODEN: THBRAA; ISSN: 0049-3848  
PUBLISHER: Elsevier Science Inc.  
DOCUMENT TYPE: Journal

LANGUAGE: English  
TI The CC Chemokines MDC and TARC Induce Platelet Activation Via **CCR4**  
AU Abi-Younes, S.; Si-Tahar, M.; Luster, A. D.  
REFERENCE COUNT: 55 THERE ARE 55 CITED REFERENCES AVAILABLE FOR  
THIS

RECORD. ALL CITATIONS AVAILABLE IN THE RE

FORMAT

L13 ANSWER 30 OF 62 CAPLUS COPYRIGHT 2002 ACS

ACCESSION NUMBER: 2001:125086 CAPLUS

DOCUMENT NUMBER: 134:279375

TITLE: Adenosine diphosphate strongly potentiates the  
ability

of the chemokines MDC, TARC, and SDF-1 to stimulate  
platelet function

AUTHOR(S): Gear, Adrian R. L.; Suttitanamongkol, Sudawadee;  
Viisoreanu, Delia; Polanowska-Grabowska, Renata K.;  
Raha, Sanghamitra; Camerini, David

CORPORATE SOURCE: Department of Biochemistry and Molecular Genetics and  
the Department of Microbiology/Myles H. Thaler Center  
for AIDS and Human Retrovirus Research, University of  
Virginia Health Sciences Center, Charlottesville, VA,  
22908, USA

SOURCE: Blood (2001), 97(4), 937-945  
CODEN: BLOOAW; ISSN: 0006-4971

PUBLISHER: American Society of Hematology

DOCUMENT TYPE: Journal

LANGUAGE: English

TI Adenosine diphosphate strongly potentiates the ability of the chemokines  
MDC, TARC, and SDF-1 to stimulate platelet function

AU Gear, Adrian R. L.; Suttitanamongkol, Sudawadee; Viisoreanu, Delia;  
Polanowska-Grabowska, Renata K.; Raha, Sanghamitra; Camerini, David

REFERENCE COUNT: 51 THERE ARE 51 CITED REFERENCES AVAILABLE FOR  
THIS

RECORD. ALL CITATIONS AVAILABLE IN THE RE

FORMAT

L13 ANSWER 31 OF 62 CAPLUS COPYRIGHT 2002 ACS

ACCESSION NUMBER: 2000:790144 CAPLUS

DOCUMENT NUMBER: 133:349154

TITLE: **CCR4** antagonists for treatment of  
septic shock

INVENTOR(S): Power, Christina A.; Chivatchko, Yolande

PATENT ASSIGNEE(S): Applied Research Systems ARS Holding N.V., Neth.  
Antilles

SOURCE: Eur. Pat. Appl., 20 pp.  
CODEN: EPXXDW

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
EP 1050307	A1	20001108	EP 1999-108954	19990506
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO				
WO 2000067791	A1	20001116	WO 2000-EP4018	20000504
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU,				

ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU,  
 LV, MA, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE,  
 SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA,  
 ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM  
 RW: GH, GM, KE, LS, MW, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE,  
 DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF,  
 CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG  
 EP 1176980 A1 20020206 EP 2000-927140 20000504  
 R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT,  
 IE, SI, LT, LV, FI, RO  
 PRIORITY APPLN. INFO.: EP 1999-108954 A 19990506  
 WO 2000-EP4018 W 20000504

TI CCR4 antagonists for treatment of septic shock  
 IN Power, Christina A.; Chivatchko, Yolande  
 REFERENCE COUNT: 9 THERE ARE 9 CITED REFERENCES AVAILABLE FOR THIS  
 RECORD. ALL CITATIONS AVAILABLE IN THE RE

FORMAT

L13 ANSWER 32 OF 62 CAPLUS COPYRIGHT 2002 ACS  
 ACCESSION NUMBER: 2000:756484 CAPLUS  
 DOCUMENT NUMBER: 133:329593  
 TITLE: Low adenosine anti-sense oligonucleotide,  
 compositions, kit and method for treatment  
 of airway disorders associated with  
 bronchoconstriction, lung inflammation, allergy(ies)  
 and surfactant depletion  
 INVENTOR(S): Nyce, Jonathan W.  
 PATENT ASSIGNEE(S): East Carolina University, USA  
 SOURCE: PCT Int. Appl., 1592 pp.  
 CODEN: PIXXD2  
 DOCUMENT TYPE: Patent  
 LANGUAGE: English  
 FAMILY ACC. NUM. COUNT: 1  
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2000062736	A2	20001026	WO 2000-US8020	20000324
WO 2000062736	A3	20011011		
W: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM RW: GH, GM, KE, LS, MW, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG BR 2000006019 A 20010313 BR 2000-6019 20000324 EP 1168919 A2 20020109 EP 2000-919668 20000324 R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO PRIORITY APPLN. INFO.: US 1999-127958P P 19990406 WO 2000-US8020 W 20000324				

OTHER SOURCE(S): MARPAT 133:329593  
 TI Low adenosine anti-sense oligonucleotide, compositions, kit and method  
 for treatment of airway disorders associated with bronchoconstriction,  
 lung inflammation, allergy(ies) and surfactant depletion  
 IN Nyce, Jonathan W.

L13 ANSWER 33 OF 62 CAPLUS COPYRIGHT 2002 ACS

ACCESSION NUMBER: 2000:719245 CAPLUS  
DOCUMENT NUMBER: 134:40950  
TITLE: Modulation of experimental autoimmune  
encephalomyelitis: effect of altered peptide ligand  
on  
chemokine and chemokine receptor expression  
AUTHOR(S): Fischer, F. R.; Santambrogio, L.; Luo, Y.; Berman, M.  
A.; Hancock, W. W.; Dorf, M. E.  
CORPORATE SOURCE: Department of Pathology, Harvard Medical School,  
Boston, MA, 02115, USA  
SOURCE: Journal of Neuroimmunology (2000), 110(1-2), 195-208  
CODEN: JNRIW; ISSN: 0165-5728  
PUBLISHER: Elsevier Science B.V.  
DOCUMENT TYPE: Journal  
LANGUAGE: English  
TI Modulation of experimental autoimmune encephalomyelitis: effect of  
altered  
peptide ligand on chemokine and chemokine receptor expression  
AU Fischer, F. R.; Santambrogio, L.; Luo, Y.; Berman, M. A.; Hancock, W. W.;  
Dorf, M. E.  
REFERENCE COUNT: 58 THERE ARE 58 CITED REFERENCES AVAILABLE FOR  
THIS  
RECORD. ALL CITATIONS AVAILABLE IN THE RE  
FORMAT

L13 ANSWER 34 OF 62 CAPLUS COPYRIGHT 2002 ACS

ACCESSION NUMBER: 2000:628006 CAPLUS  
DOCUMENT NUMBER: 133:217723  
TITLE: Method for validating/invalidating target(s) and  
pathways  
INVENTOR(S): Nyce, Jonathan W.  
PATENT ASSIGNEE(S): Epigenesis Pharmaceuticals, Inc., USA  
SOURCE: PCT Int. Appl., 53 pp.  
CODEN: PIXXD2  
DOCUMENT TYPE: Patent  
LANGUAGE: English  
FAMILY ACC. NUM. COUNT: 1  
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2000051621	A1	20000908	WO 2000-US5643	20000302
W:	AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM			
RW:	GH, GM, KE, LS, MW, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG			
BR 2000009247	A	20011120	BR 2000-9247	20000302
EP 1165093	A1	20020102	EP 2000-913730	20000302
R:	AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO			
JP 2002537792	T2	20021112	JP 2000-602288	20000302
PRIORITY APPLN. INFO.:			US 1999-122950P P	19990305
			WO 2000-US5643 W	20000302

OTHER SOURCE(S): MARPAT 133:217723  
TI Method for validating/invalidating target(s) and pathways  
IN Nyce, Jonathan W.  
REFERENCE COUNT: 3 THERE ARE 3 CITED REFERENCES AVAILABLE FOR THIS  
RECORD. ALL CITATIONS AVAILABLE IN THE RE

FORMAT

L13 ANSWER 35 OF 62 CAPLUS COPYRIGHT 2002 ACS  
ACCESSION NUMBER: 2000:553560 CAPLUS  
DOCUMENT NUMBER: 133:164005  
TITLE: Preparation of substituted N-heterocyclyl benzamides  
and analogs as G-protein coupled heptahelical

receptor

binding compounds  
INVENTOR(S): Shiosaki, Kazumi; Fleming, Paul  
PATENT ASSIGNEE(S): Millennium Pharmaceuticals, Inc., USA  
SOURCE: PCT Int. Appl., 80 pp.  
CODEN: PIXXD2  
DOCUMENT TYPE: Patent  
LANGUAGE: English  
FAMILY ACC. NUM. COUNT: 1  
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2000046203	A2	20000810	WO 2000-US3042	20000203
WO 2000046203	A3	20010301		
W: AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CU, CZ, DE, DK, DM, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: GH, GM, KE, LS, MW, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
EP 1150955	A2	20011107	EP 2000-907184	20000203
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO				
PRIORITY APPLN. INFO.:			US 1999-118893P	P 19990204
			WO 2000-US3042	W 20000203

OTHER SOURCE(S): MARPAT 133:164005  
TI Preparation of substituted N-heterocyclyl benzamides and analogs as  
G-protein coupled heptahelical receptor binding compounds  
IN Shiosaki, Kazumi; Fleming, Paul

L13 ANSWER 36 OF 62 CAPLUS COPYRIGHT 2002 ACS  
ACCESSION NUMBER: 2000:336392 CAPLUS  
DOCUMENT NUMBER: 133:72751  
TITLE: A key role for CC chemokine receptor 4 in  
lipopolysaccharide-induced endotoxic shock  
AUTHOR(S): Chvatchko, Yolande; Hoogewerf, Arlene J.; Meyer,  
Alexandra; Alouani, Sami; Juillard, Pierre; Buser,  
Raphaelae; Conquet, Francois; Proudfoot, Amanda E. I.;  
Wells, Timothy N. C.; Power, Christine A.  
CORPORATE SOURCE: Serono Pharmaceutical Research Institute, Geneva,  
1228, Switz.  
SOURCE: Journal of Experimental Medicine (2000), 191(10),  
1755-1763  
CODEN: JEMEAV; ISSN: 0022-1007

PUBLISHER: Rockefeller University Press  
DOCUMENT TYPE: Journal  
LANGUAGE: English  
TI A key role for CC chemokine receptor 4 in lipopolysaccharide-induced  
endotoxic shock  
AU Chvatchko, Yolande; Hoogewerf, Arlene J.; Meyer, Alexandra; Alouani,  
Sami;  
Juillard, Pierre; Buser, Raphaelaele; Conquet, Francois; Proudfoot, Amanda  
E.  
I.; Wells, Timothy N. C.; Power, Christine A.  
REFERENCE COUNT: 39 THERE ARE 39 CITED REFERENCES AVAILABLE FOR  
THIS  
RECORD. ALL CITATIONS AVAILABLE IN THE RE  
FORMAT

L13 ANSWER 37 OF 62 CAPLUS COPYRIGHT 2002 ACS  
ACCESSION NUMBER: 1999:589618 CAPLUS  
DOCUMENT NUMBER: 131:309664  
TITLE: Recombinant IFN-.alpha. (2b) increases the expression  
of apoptosis receptor CD95 and chemokine receptors  
CCR1 and CCR3 in monocytoïd cells  
AUTHOR(S): Zella, Davide; Barabitskaja, Oxana; Casareto, Luca;  
Romerio, Fabio; Secchiero, Paola; Reitz, Marvin  
S., Jr.; Gallo, Robert C.; Weichold, Frank F.  
CORPORATE SOURCE: Institute of Human Virology, University of Maryland,  
Baltimore, MD, 21201, USA  
SOURCE: Journal of Immunology (1999), 163(6), 3169-3175  
CODEN: JOIMA3; ISSN: 0022-1767  
PUBLISHER: American Association of Immunologists  
DOCUMENT TYPE: Journal  
LANGUAGE: English  
TI Recombinant IFN-.alpha. (2b) increases the expression of apoptosis  
receptor CD95 and chemokine receptors CCR1 and CCR3 in monocytoïd cells  
AU Zella, Davide; Barabitskaja, Oxana; Casareto, Luca; Romerio, Fabio;  
Secchiero, Paola; Reitz, Marvin S., Jr.; Gallo, Robert C.; Weichold, Frank  
F.  
REFERENCE COUNT: 30 THERE ARE 30 CITED REFERENCES AVAILABLE FOR  
THIS  
RECORD. ALL CITATIONS AVAILABLE IN THE RE  
FORMAT

L13 ANSWER 38 OF 62 CAPLUS COPYRIGHT 2002 ACS  
ACCESSION NUMBER: 1999:461743 CAPLUS  
DOCUMENT NUMBER: 131:241862  
TITLE: CCR5+ and CXCR3+ T cells are increased in multiple  
sclerosis and their ligands MIP-1.alpha. and IP-10  
are  
expressed in demyelinating brain lesions  
AUTHOR(S): Balashov, Konstantin E.; Rottman, James B.; Weiner,  
Howard L.; Hancock, Wayne W.  
CORPORATE SOURCE: Center for Neurologic Diseases, Brigham and Women's  
Hospital, Boston, MA, 02115, USA  
SOURCE: Proceedings of the National Academy of Sciences of  
the  
United States of America (1999), 96(12), 6873-6878  
CODEN: PNASA6; ISSN: 0027-8424  
PUBLISHER: National Academy of Sciences  
DOCUMENT TYPE: Journal  
LANGUAGE: English  
TI CCR5+ and CXCR3+ T cells are increased in multiple sclerosis and their



ligands MIP-1.alpha. and IP-10 are expressed in demyelinating brain lesions  
AU Balashov, Konstantin E.; Rottman, James B.; Weiner, Howard L.; Hancock, Wayne W.

REFERENCE COUNT: 24 THERE ARE 24 CITED REFERENCES AVAILABLE FOR THIS

RECORD. ALL CITATIONS AVAILABLE IN THE RE  
FORMAT

L13 ANSWER 39 OF 62 CAPLUS COPYRIGHT 2002 ACS

ACCESSION NUMBER: 1999:443191 CAPLUS

DOCUMENT NUMBER: 131:208638

TITLE: Anti-HIV agent trichosanthin enhances the capabilities

of chemokines to stimulate chemotaxis and G protein activation, and this is mediated through interaction of trichosanthin and chemokine receptors

AUTHOR(S): Zhao, Jian; Ben, Li-Hong; Wu, Ya-Lan; Hu, Wei; Ling, Kun; Xin, Shun-Mei; Nie, Hui-Ling; Ma, Lan; Pei, Gang  
CORPORATE SOURCE: Shanghai Institute of Cell Biology and Shanghai Research Center of Life Sciences, Chinese Academy of Sciences, Shanghai, 200031, Peop. Rep. China

SOURCE: Journal of Experimental Medicine (1999), 190(1), 101-111

CODEN: JEMEAV; ISSN: 0022-1007

PUBLISHER: Rockefeller University Press

DOCUMENT TYPE: Journal

LANGUAGE: English

TI Anti-HIV agent trichosanthin enhances the capabilities of chemokines to stimulate chemotaxis and G protein activation, and this is mediated through interaction of trichosanthin and chemokine receptors

AU Zhao, Jian; Ben, Li-Hong; Wu, Ya-Lan; Hu, Wei; Ling, Kun; Xin, Shun-Mei; Nie, Hui-Ling; Ma, Lan; Pei, Gang

REFERENCE COUNT: 64 THERE ARE 64 CITED REFERENCES AVAILABLE FOR THIS

RECORD. ALL CITATIONS AVAILABLE IN THE RE  
FORMAT

L13 ANSWER 40 OF 62 CAPLUS COPYRIGHT 2002 ACS

ACCESSION NUMBER: 1999:223049 CAPLUS

DOCUMENT NUMBER: 130:251233

TITLE: Macrophage-derived chemokine (MDC), MDC analogs, MDC inhibitor substances, and their therapeutic applications

INVENTOR(S): Gray, Patrick W.; Chantry, David H.; Deeley, Michael C.; Raport, Carol J.; Godiska, Ronald

PATENT ASSIGNEE(S): Icos Corporation, USA

SOURCE: PCT Int. Appl., 159 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 3

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9915666	A2	19990401	WO 1998-US20270	19980928
WO 9915666	A3	19990916		

W: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IS, JP, KE,

KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW,  
 MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR,  
 TT, UA, UG, US, US, US, US, US, UZ, VN, YU, ZW, AM, AZ, BY, KG,  
 KZ, MD, RU, TJ, TM  
 RW: GH, GM, KE, LS, MW, SD, SZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES,  
 FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI,  
 CM, GA, GN, GW, ML, MR, NE, SN, TD, TG  
 CN 1163635 A 19971029 CN 1996-190875 19960607  
 US 5932703 A 19990803 US 1996-660542 19960607  
 CA 2302806 AA 19990401 CA 1998-2302806 19980928  
 AU 9897778 A1 19990412 AU 1998-97778 19980928  
 EP 1017818 A2 20000712 EP 1998-951961 19980928  
 R: AT, BE, CH, DE, ES, FR, GB, IT, LI, SE, IE  
 PRIORITY APPLN. INFO.: US 1995-479620 A2 19950607  
 US 1995-558658 A2 19951116  
 US 1996-660542 A2 19960607  
 US 1997-939107 A2 19970926  
 US 1998-67447 A2 19980428  
 WO 1998-US20270 W 19980928  
 TI Macrophage-derived chemokine (MDC), MDC analogs, MDC inhibitor  
 substances, and their therapeutic applications  
 IN Gray, Patrick W.; Chantry, David H.; Deeley, Michael C.; Raport, Carol  
 J.;  
 Godiska, Ronald  
 L13 ANSWER 41 OF 62 CAPLUS COPYRIGHT 2002 ACS  
 ACCESSION NUMBER: 1999:219995 CAPLUS  
 DOCUMENT NUMBER: 130:306599  
 TITLE: Antisense oligonucleotides capable of binding to  
 multiple targets and their use in the  
**treatment** of respiratory disease  
 INVENTOR(S): Nyce, Jonathan W.  
 PATENT ASSIGNEE(S): East Carolina University, USA  
 SOURCE: PCT Int. Appl., 120 pp.  
 CODEN: PIXXD2  
 DOCUMENT TYPE: Patent  
 LANGUAGE: English  
 FAMILY ACC. NUM. COUNT: 2  
 PATENT INFORMATION:  

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9913886	A1	19990325	WO 1998-US19419	19980917
W: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, GH, GM, HR, HU, ID, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM RW: GH, GM, KE, LS, MW, SD, SZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG CA 2304312 AA 19990325 CA 1998-2304312 19980917 AU 9893951 A1 19990405 AU 1998-93951 19980917 AU 752531 B2 20020919 EP 1019065 A1 20000719 EP 1998-947089 19980917 R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, PT, IE, FI BR 9812650 A 20000822 BR 1998-12650 19980917 PRIORITY APPLN. INFO.: US 1997-59160P P 19970917 US 1998-93972 A 19980609				

WO 1998-US19419 W 19980917

TI Antisense oligonucleotides capable of binding to multiple targets and  
their use in the **treatment** of respiratory disease  
IN Nyce, Jonathan W.

REFERENCE COUNT: 2 THERE ARE 2 CITED REFERENCES AVAILABLE FOR THIS  
RECORD. ALL CITATIONS AVAILABLE IN THE RE  
FORMAT

L13 ANSWER 42 OF 62 CAPLUS COPYRIGHT 2002 ACS

ACCESSION NUMBER: 1998:783871 CAPLUS

DOCUMENT NUMBER: 130:152423

TITLE: Pivotal role of TARC, a CC chemokine, in  
bacteria-induced fulminant hepatic failure in mice  
AUTHOR(S): Yoneyama, Hiroyuki; Harada, Akihisa; Imai, Toshio;  
Baba, Masataka; Yoshie, Osamu; Zhang, Yi; Higashi,  
Hidemitsu; Murai, Masako; Asakura, Hitoshi;  
Matsushima, Kouji

CORPORATE SOURCE: Department of Molecular Preventive Medicine, School  
of  
Medicine, and CREST, The University of Tokyo, Tokyo,  
113, Japan

SOURCE: Journal of Clinical Investigation (1998), 102(11),  
1933-1941

CODEN: JCINAO; ISSN: 0021-9738

PUBLISHER: Rockefeller University Press

DOCUMENT TYPE: Journal

LANGUAGE: English

TI Pivotal role of TARC, a CC chemokine, in bacteria-induced fulminant  
hepatic failure in mice

AU Yoneyama, Hiroyuki; Harada, Akihisa; Imai, Toshio; Baba, Masataka;  
Yoshie,  
Osamu; Zhang, Yi; Higashi, Hidemitsu; Murai, Masako; Asakura, Hitoshi;  
Matsushima, Kouji

REFERENCE COUNT: 30 THERE ARE 30 CITED REFERENCES AVAILABLE FOR  
THIS  
RECORD. ALL CITATIONS AVAILABLE IN THE RE  
FORMAT

L13 ANSWER 43 OF 62 CAPLUS COPYRIGHT 2002 ACS

ACCESSION NUMBER: 1998:750309 CAPLUS

DOCUMENT NUMBER: 130:95363

TITLE: Reactions of 2-amino-1,3-butadienes and Fischer  
alkynyl carbenes: up to nine C-C bonds and seven  
stereogenic centers created in a stereoselective  
manner through a cascade process

AUTHOR(S): Barluenga, Jose; Aznar, Fernando; Barluenga, Sofia;  
Fernandez, Monica; Martin, Alfredo; Garcia-Granda,  
Santiago; Pinera-Nicolas, Alejandro

CORPORATE SOURCE: Instituto Universitario de Quimica Organometalica  
Enrique Moles, Unidad asociada al C.S.I.C., Oviedo,  
E-33701, Spain

SOURCE: Chemistry--A European Journal (1998), 4(11),  
2280-2298

CODEN: CEUJED; ISSN: 0947-6539

PUBLISHER: Wiley-VCH Verlag GmbH

DOCUMENT TYPE: Journal

LANGUAGE: English

OTHER SOURCE(S): CASREACT 130:95363

TI Reactions of 2-amino-1,3-butadienes and Fischer alkynyl carbenes: up to  
nine C-C bonds and seven stereogenic centers created in a stereoselective

manner through a cascade process  
AU Barluenga, Jose; Aznar, Fernando; Barluenga, Sofia; Fernandez, Monica;  
Martin, Alfredo; Garcia-Granda, Santiago; Pinera-Nicolas, Alejandro  
REFERENCE COUNT: 36 THERE ARE 36 CITED REFERENCES AVAILABLE FOR  
THIS

RECORD. ALL CITATIONS AVAILABLE IN THE RE  
FORMAT

L13 ANSWER 44 OF 62 CAPLUS COPYRIGHT 2002 ACS  
ACCESSION NUMBER: 1998:677839 CAPLUS  
DOCUMENT NUMBER: 129:289188  
TITLE: Methods using a monocyte chemotactic protein for the  
modulation of the growth of collateral arteries  
and/or other arteries from preexisting arteriolar  
connections  
INVENTOR(S): Schaper, Wolfgang; Ito, Wulf D.  
PATENT ASSIGNEE(S): Max-Planck-Gesellschaft Zur Forderung Der  
Wissenschaften E.V., Germany  
SOURCE: PCT Int. Appl., 45 pp.  
CODEN: PIXXD2  
DOCUMENT TYPE: Patent  
LANGUAGE: English  
FAMILY ACC. NUM. COUNT: 1  
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9844953	A1	19981015	WO 1998-EP1891	19980401
W: CA, JP, US				
RW: AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE				
EP 969877	A1	20000112	EP 1998-924093	19980401
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, FI				
JP 2001519795	T2	20011023	JP 1998-542349	19980401
PRIORITY APPLN. INFO.: EP 1997-105647 A 19970404				
WO 1998-EP1891 W 19980401				

TI Methods using a monocyte chemotactic protein for the modulation of the  
growth of collateral arteries and/or other arteries from preexisting  
arteriolar connections

IN Schaper, Wolfgang; Ito, Wulf D.

REFERENCE COUNT: 4 THERE ARE 4 CITED REFERENCES AVAILABLE FOR THIS  
RECORD. ALL CITATIONS AVAILABLE IN THE RE

FORMAT

L13 ANSWER 45 OF 62 CAPLUS COPYRIGHT 2002 ACS  
ACCESSION NUMBER: 1998:39083 CAPLUS  
DOCUMENT NUMBER: 128:139600  
TITLE: RANTES and MIP-1.alpha. activate Stats in T cells  
AUTHOR(S): Wong, Mark; Fish, Eleanor N.  
CORPORATE SOURCE: Departments of Immunology, University of Toronto,  
Toronto, ON, M5S 3E2, Can.  
SOURCE: Journal of Biological Chemistry (1998), 273(1),  
309-314  
CODEN: JBCHA3; ISSN: 0021-9258  
PUBLISHER: American Society for Biochemistry and Molecular  
Biology  
DOCUMENT TYPE: Journal  
LANGUAGE: English

TI RANTES and MIP-1.alpha. activate Stats in T cells  
AU Wong, Mark; Fish, Eleanor N.

L13 ANSWER 46 OF 62 BIOSIS COPYRIGHT 2002 BIOLOGICAL ABSTRACTS INC.

ACCESSION NUMBER: 2002:520501 BIOSIS

DOCUMENT NUMBER: PREV200200520501

TITLE: Erythrocytes serve as a reservoir for HIV-1.

AUTHOR(S): Hess, C. (1); Klimkait, T.; Schlapbach, L. (1); Del  
Zenero,

V.; Sadallah, S. (1); Balestra, G. (1); Schafer, C.;  
Battegay, M.; Schifferli, J. (1)

CORPORATE SOURCE: (1) Department of Research, Immunonephrology Laboratory,  
University Hospital Basel, Basel Switzerland

SOURCE: Abstracts of the Interscience Conference on Antimicrobial  
Agents and Chemotherapy, (2001) Vol. 41, pp. 350. print.  
Meeting Info.: 41st Annual Meeting of the Interscience  
Conference on Antimicrobial Agents and Chemotherapy  
Chicago, Illinois, USA September 22-25, 2001

DOCUMENT TYPE: Conference

LANGUAGE: English

TI Erythrocytes serve as a reservoir for HIV-1.

AU Hess, C. (1); Klimkait, T.; Schlapbach, L. (1); Del Zenero, V.; Sadallah,  
S. (1); Balestra, G. (1); Schafer, C.; Battegay, M.; Schifferli, J. (1)

L13 ANSWER 47 OF 62 BIOSIS COPYRIGHT 2002 BIOLOGICAL ABSTRACTS INC.

ACCESSION NUMBER: 2002:469443 BIOSIS

DOCUMENT NUMBER: PREV200200469443

TITLE: Chemokine responses in schistosomal antigen-elicited  
granuloma formation.

AUTHOR(S): Chiu, Bo-Chin; Chensue, Stephen W. (1)

CORPORATE SOURCE: (1) Pathology and Laboratory Medicine, 2215 Fuller Road,  
113, AAVAHs, Ann Arbor, MI, 48105: schensue@med.umich.edu  
USA

SOURCE: Parasite Immunology (Oxford), (June, 2002) Vol. 24, No. 6,  
pp. 285-294. <http://www.blackwell-science.com/pim>;  
<http://www.blackwell-science.com/pim>. print.  
ISSN: 0141-9838.

DOCUMENT TYPE: General Review

LANGUAGE: English

TI Chemokine responses in schistosomal antigen-elicited granuloma  
formation.

AU Chiu, Bo-Chin; Chensue, Stephen W. (1)

L13 ANSWER 48 OF 62 BIOSIS COPYRIGHT 2002 BIOLOGICAL ABSTRACTS INC.

ACCESSION NUMBER: 2002:449998 BIOSIS

DOCUMENT NUMBER: PREV200200449998

TITLE: IFN-gamma-inducible expression of thymus and  
activation-regulated chemokine/CCL17 and

macrophage-derived

chemokine/CCL22 in epidermal keratinocytes and their roles  
in atopic dermatitis.

AUTHOR(S): Horikawa, Tatsuya; Nakayama, Takashi; Hikita, Ichiro;  
Yamada, Hidekazu; Fujisawa, Ryuichi; Bito, Toshinori;  
Harada, Susumu; Fukunaga, Atsushi; Chantry, David; Gray,  
Patrick W.; Morita, Atsushi; Suzuki, Ryuji; Tezuka,  
Tadashi; Ichihashi, Masamitsu; Yoshie, Osamu (1)

CORPORATE SOURCE: (1) Department of Microbiology, Kinki University School of  
Medicine, Osaka, 589-8511: o.yoshie@med.kindai.ac.jp Japan

SOURCE: International Immunology, (July, 2002) Vol. 14, No. 7, pp.  
767-773. <http://www.intimm.oupjournals.org>. print.

ISSN: 0953-8178.

DOCUMENT TYPE: Article

LANGUAGE: English

TI IFN-gamma-inducible expression of thymus and activation-regulated chemokine/CCL17 and macrophage-derived chemokine/CCL22 in epidermal keratinocytes and their roles in atopic dermatitis.

AU Horikawa, Tatsuya; Nakayama, Takashi; Hikita, Ichiro; Yamada, Hidekazu; Fujisawa, Ryuichi; Bito, Toshinori; Harada, Susumu; Fukunaga, Atsushi; Chantry, David; Gray, Patrick W.; Morita, Atsushi; Suzuki, Ryuji; Tezuka, Tadashi; Ichihashi, Masamitsu; Yoshie, Osamu (1)

L13 ANSWER 49 OF 62 BIOSIS COPYRIGHT 2002 BIOLOGICAL ABSTRACTS INC.

ACCESSION NUMBER: 2002:273516 BIOSIS

DOCUMENT NUMBER: PREV200200273516

TITLE: AMD3100, a CXCR4 antagonist, attenuates allergic lung inflammation and airway hyperreactivity.

AUTHOR(S): Lukacs, Nicholas W. (1); Berlin, Aaron; Schols, Dominique; Skerlj, Renato T.; Bridger, Gary J.

CORPORATE SOURCE: (1) Department of Pathology, University of Michigan Medical

School, 1301 Catherine St., Ann Arbor, MI, 48109-0602: nlukacs@umich.edu USA

SOURCE: American Journal of Pathology, (April, 2002) Vol. 160, No. 4, pp. 1353-1360. <http://ajp.amjpathol.org/>. print. ISSN: 0002-9440.

DOCUMENT TYPE: Article

LANGUAGE: English

TI AMD3100, a CXCR4 antagonist, attenuates allergic lung inflammation and airway hyperreactivity.

AU Lukacs, Nicholas W. (1); Berlin, Aaron; Schols, Dominique; Skerlj, Renato T.; Bridger, Gary J.

L13 ANSWER 50 OF 62 BIOSIS COPYRIGHT 2002 BIOLOGICAL ABSTRACTS INC.

ACCESSION NUMBER: 2002:253817 BIOSIS

DOCUMENT NUMBER: PREV200200253817

TITLE: Serum macrophage-derived chemokine (MDC) levels are closely

related with the disease activity of atopic dermatitis.

AUTHOR(S): Kakinuma, T. (1); Nakamura, K.; Wakugawa, M.; Mitsui, H.; Tada, Y.; Saeki, H.; Torii, H.; Komine, M.; Asahina, A.; Tamaki, K.

CORPORATE SOURCE: (1) Department of Dermatology, Faculty of Medicine, University of Tokyo, 7-3-1 Hongo, Bunkyo-ku, Tokyo, 113-8655: KAKINUMAT-DER@h.u-tokyo.ac.jp Japan

SOURCE: Clinical and Experimental Immunology, (February, 2002) Vol.

127, No. 2, pp. 270-273. <http://www.blackwell-science.com/cgiilib/jnlpage.asp?Journal=cei&File=cei>. print.

ISSN: 0009-9104.

DOCUMENT TYPE: Article

LANGUAGE: English

TI Serum macrophage-derived chemokine (MDC) levels are closely related with the disease activity of atopic dermatitis.

AU Kakinuma, T. (1); Nakamura, K.; Wakugawa, M.; Mitsui, H.; Tada, Y.; Saeki, H.; Torii, H.; Komine, M.; Asahina, A.; Tamaki, K.

L13 ANSWER 51 OF 62 BIOSIS COPYRIGHT 2002 BIOLOGICAL ABSTRACTS INC.

ACCESSION NUMBER: 2001:496534 BIOSIS

DOCUMENT NUMBER: PREV200100496534

TITLE: Effects of oral steroids on blood CXCR3+ and CCR4  
+ T cells in patients with bronchial asthma.  
AUTHOR(S): Kurashima, Kazuyoshi (1); Fujimura, Masaki; Myou,  
Shigeharu; Kasahara, Kazuo; Tachibana, Hideki; Amemiya,  
Norinao; Ishiura, Yoshihisa; Onai, Nobuyuki; Matsushima,  
Kouji; Nakao, Shinji  
CORPORATE SOURCE: (1) Third Department of Internal Medicine, School of  
Medicine, Kanazawa University, 13-1 Takara-machi, Kanazawa  
City, Ishikawa, 920: kazu\_k@d2.dion.ne.jp Japan  
SOURCE: American Journal of Respiratory and Critical Care  
Medicine,  
(September 1, 2001) Vol. 164, No. 5, pp. 754-758. print.  
ISSN: 1073-449X.

DOCUMENT TYPE: Article

LANGUAGE: English

SUMMARY LANGUAGE: English

TI Effects of oral steroids on blood CXCR3+ and CCR4+ T cells in  
patients with bronchial asthma.

AU Kurashima, Kazuyoshi (1); Fujimura, Masaki; Myou, Shigeharu; Kasahara,  
Kazuo; Tachibana, Hideki; Amemiya, Norinao; Ishiura, Yoshihisa; Onai,  
Nobuyuki; Matsushima, Kouji; Nakao, Shinji

L13 ANSWER 52 OF 62 BIOSIS COPYRIGHT 2002 BIOLOGICAL ABSTRACTS INC.

ACCESSION NUMBER: 2001:412581 BIOSIS

DOCUMENT NUMBER: PREV200100412581

TITLE: Effect of cyclophosphamide pulse therapy on chemokine  
receptor expression in patients with multiple sclerosis.

AUTHOR(S): Padmanabhan, Bharani (1); Karni, Arnon (1); Hancock, Wayne  
W.; Khoury, Samia J.; Weiner, Howard L.

CORPORATE SOURCE: (1) Boston, MA USA

SOURCE: Neurology, (April 24, 2001) Vol. 56, No. 8 Supplement 3,  
pp. A226. print.  
Meeting Info.: 53rd Annual Meeting of the American Academy  
of Neurology Philadelphia, PA, USA May 05-11, 2001

American

Academy of Neurology

. ISSN: 0028-3878.

DOCUMENT TYPE: Conference

LANGUAGE: English

SUMMARY LANGUAGE: English

TI Effect of cyclophosphamide pulse therapy on chemokine receptor expression  
in patients with multiple sclerosis.

AU Padmanabhan, Bharani (1); Karni, Arnon (1); Hancock, Wayne W.; Khoury,  
Samia J.; Weiner, Howard L.

L13 ANSWER 53 OF 62 BIOSIS COPYRIGHT 2002 BIOLOGICAL ABSTRACTS INC.

ACCESSION NUMBER: 2001:185996 BIOSIS

DOCUMENT NUMBER: PREV200100185996

TITLE: The CC chemokines MDC and TARC induce platelet activation  
via CCR4.

AUTHOR(S): Abi-Younes, Sylvie; Si-Tahar, Mustapha; Luster, Andrew D.  
(1)

CORPORATE SOURCE: (1) Massachusetts General Hospital-East, 13th Street,  
Building 149, Charlestown, MA, 02129:  
luster@helix.mgh.harvard.edu USA

SOURCE: Thrombosis Research, (February 15, 2001) Vol. 101, No. 4,  
pp. 279-289. print.  
ISSN: 0049-3848.

DOCUMENT TYPE: Article

LANGUAGE: English

SUMMARY LANGUAGE: English

TI The CC chemokines MDC and TARC induce platelet activation via CCR4

AU Abi-Younes, Sylvie; Si-Tahar, Mustapha; Luster, Andrew D. (1)

L13 ANSWER 54 OF 62 BIOSIS COPYRIGHT 2002 BIOLOGICAL ABSTRACTS INC.

ACCESSION NUMBER: 2001:175535 BIOSIS

DOCUMENT NUMBER: PREV200100175535

TITLE: Thymus and activation-regulated chemokine in atopic dermatitis: Serum thymus and activation-regulated chemokine

level is closely related with disease activity.

AUTHOR(S): Kakinuma, Takashi (1); Nakamura, Koichiro; Wakugawa, Motoshi; Mitsui, Hiroshi; Tada, Yayoi; Saeki, Hidehisa; Torii, Hideshi; Asahina, Akihiko; Onai, Nobuyuki; Matsushima, Kouji; Tamaki, Kunihiro

CORPORATE SOURCE: (1) Department of Dermatology, Faculty of Medicine, University of Tokyo, 7-3-1 Hongo, Bunkyo-ku, Tokyo, 113-8655 Japan

SOURCE: Journal of Allergy and Clinical Immunology, (March, 2001) Vol. 107, No. 3, pp. 535-541. print.  
ISSN: 0091-6749.

DOCUMENT TYPE: Article

LANGUAGE: English

SUMMARY LANGUAGE: English

TI Thymus and activation-regulated chemokine in atopic dermatitis: Serum thymus and activation-regulated chemokine level is closely related with disease activity.

AU Kakinuma, Takashi (1); Nakamura, Koichiro; Wakugawa, Motoshi; Mitsui, Hiroshi; Tada, Yayoi; Saeki, Hidehisa; Torii, Hideshi; Asahina, Akihiko; Onai, Nobuyuki; Matsushima, Kouji; Tamaki, Kunihiro

L13 ANSWER 55 OF 62 BIOSIS COPYRIGHT 2002 BIOLOGICAL ABSTRACTS INC.

ACCESSION NUMBER: 2001:115423 BIOSIS

DOCUMENT NUMBER: PREV200100115423

TITLE: Adenosine diphosphate strongly potentiates the ability of the chemokines MDC, TARC, and SDF-1 to stimulate platelet function.

AUTHOR(S): Gear, Adrian R. L. (1); Suttitanamongkol, Sudawadee; Viisoreanu, Delia; Polanowska-Grabowska, Renata K.; Raha, Sanghamitra; Camerini, David

CORPORATE SOURCE: (1) Department of Biochemistry and Molecular Genetics, University of Virginia Health Sciences Center, 1300 Jefferson Park Ave, Charlottesville, VA, 22908: alg4p@virginia.edu USA

SOURCE: Blood, (February 15, 2001) Vol. 97, No. 4, pp. 937-945. print.  
ISSN: 0006-4971.

DOCUMENT TYPE: Article

LANGUAGE: English

SUMMARY LANGUAGE: English

TI Adenosine diphosphate strongly potentiates the ability of the chemokines MDC, TARC, and SDF-1 to stimulate platelet function.

AU Gear, Adrian R. L. (1); Suttitanamongkol, Sudawadee; Viisoreanu, Delia; Polanowska-Grabowska, Renata K.; Raha, Sanghamitra; Camerini, David

L13 ANSWER 56 OF 62 BIOSIS COPYRIGHT 2002 BIOLOGICAL ABSTRACTS INC.

ACCESSION NUMBER: 2001:88906 BIOSIS

DOCUMENT NUMBER: PREV200100088906

TITLE: Allodynia resulting from the activation of sensory neuron



chemokine receptors.  
AUTHOR(S): Tran, P. B. (1); Oh, S. B.; Gillard, S. E.; Bodner, A.;  
Hurley, R. W.; Hammond, D. L.; Miller, R. J.  
CORPORATE SOURCE: (1) University of Chicago, Chicago, IL USA  
SOURCE: Society for Neuroscience Abstracts, (2000) Vol. 26, No.  
1-2, pp. Abstract No.-442.18. print.  
Meeting Info.: 30th Annual Meeting of the Society of  
Neuroscience New Orleans, LA, USA November 04-09, 2000  
Society for Neuroscience  
. ISSN: 0190-5295.  
DOCUMENT TYPE: Conference  
LANGUAGE: English  
SUMMARY LANGUAGE: English  
TI Allodynia resulting from the activation of sensory neuron chemokine  
receptors.  
AU Tran, P. B. (1); Oh, S. B.; Gillard, S. E.; Bodner, A.; Hurley, R. W.;  
Hammond, D. L.; Miller, R. J.

L13 ANSWER 57 OF 62 BIOSIS COPYRIGHT 2002 BIOLOGICAL ABSTRACTS INC.  
ACCESSION NUMBER: 2001:7523 BIOSIS  
DOCUMENT NUMBER: PREV200100007523  
TITLE: Modulation of experimental autoimmune encephalomyelitis:  
Effect of altered peptide ligand on chemokine and  
chemokine

receptor expression.  
AUTHOR(S): Fischer, Falko R.; Santambrogio, Laura; Luo, Yi; Berman,  
Michael A.; Hancock, Wayne W.; Dorf, Martin E. (1)  
CORPORATE SOURCE: (1) Department of Pathology, Harvard Medical School, 200  
Longwood Ave, Boston, MA, 02115: dorf@hms.harvard.edu USA  
SOURCE: Journal of Neuroimmunology, (October 2, 2000) Vol. 110,  
No.  
1-2, pp. 195-208. print.  
ISSN: 0165-5728.

DOCUMENT TYPE: Article  
LANGUAGE: English  
SUMMARY LANGUAGE: English  
TI Modulation of experimental autoimmune encephalomyelitis: Effect of  
altered  
peptide ligand on chemokine and chemokine receptor expression.  
AU Fischer, Falko R.; Santambrogio, Laura; Luo, Yi; Berman, Michael A.;  
Hancock, Wayne W.; Dorf, Martin E. (1)

L13 ANSWER 58 OF 62 BIOSIS COPYRIGHT 2002 BIOLOGICAL ABSTRACTS INC.  
ACCESSION NUMBER: 2000:280069 BIOSIS  
DOCUMENT NUMBER: PREV200000280069  
TITLE: A key role for CC chemokine receptor 4 in  
lipopolysaccharide-induced endotoxic shock.  
AUTHOR(S): Chvatchko, Yolande (1); Hoogewerf, Arlene J.; Meyer,  
Alexandra; Alouani, Sami; Juillard, Pierre; Buser,  
Raphaelae; Conquet, Francois; Proudfoot, Amanda E. I.;  
Wells, Timothy N. C.; Power, Christine A. (1)  
CORPORATE SOURCE: (1) SeroPharmaceutical Research Institute, 14, Chemin  
des Aulx, 1228, Plan-les-Ouates, Geneva Switzerland  
SOURCE: Journal of Experimental Medicine, (May 15, 2000) Vol. 191,  
No. 10, pp. 1755-1763. print.  
ISSN: 0022-1007.  
DOCUMENT TYPE: Article  
LANGUAGE: English  
SUMMARY LANGUAGE: English  
TI A key role for CC chemokine receptor 4 in lipopolysaccharide-induced

endotoxic shock.

AU Chvatchko, Yolande (1); Hoogewerf, Arlene J.; Meyer, Alexandra; Alouani, Sami; Juillard, Pierre; Buser, Raphaele; Conquet, Francois; Proudfoot, Amanda E. I.; Wells, Timothy N. C.; Power, Christine A. (1)

L13 ANSWER 59 OF 62 BIOSIS COPYRIGHT 2002 BIOLOGICAL ABSTRACTS INC.

ACCESSION NUMBER: 1999:364216 BIOSIS

DOCUMENT NUMBER: PREV199900364216

TITLE: Anti-HIV agent trichosanthin enhances the capabilities of chemokines to stimulate chemotaxis and G protein activation, and this is mediated through interaction of trichosanthin and chemokine receptors.

AUTHOR(S): Zhao, Jian; Ben, Li-Hong; Wu, Ya-Lan; Hu, Wei; Ling, Kun; Xin, Shun-Mei; Nie, Hui-Ling; Ma, Lan; Pei, Gang (1)

CORPORATE SOURCE: (1) Shanghai Institute of Cell Biology and Shanghai Research Center of Life Sciences, Chinese Academy of Sciences, 320 Yue Yang Road, Shanghai, 200031 China

SOURCE: Journal of Experimental Medicine, (July 5, 1999) Vol. 190, No. 1, pp. 101-111.

ISSN: 0022-1007.

DOCUMENT TYPE: Article

LANGUAGE: English

SUMMARY LANGUAGE: English

TI Anti-HIV agent trichosanthin enhances the capabilities of chemokines to stimulate chemotaxis and G protein activation, and this is mediated through interaction of trichosanthin and chemokine receptors.

AU Zhao, Jian; Ben, Li-Hong; Wu, Ya-Lan; Hu, Wei; Ling, Kun; Xin, Shun-Mei; Nie, Hui-Ling; Ma, Lan; Pei, Gang (1)

L13 ANSWER 60 OF 62 BIOSIS COPYRIGHT 2002 BIOLOGICAL ABSTRACTS INC.

ACCESSION NUMBER: 1999:346650 BIOSIS

DOCUMENT NUMBER: PREV199900346650

TITLE: CCR5+ and CXCR3+ T cells are increased in multiple sclerosis and their ligands MIP-1alpha and IP-10 are expressed in demyelinating brain lesions.

AUTHOR(S): Balashov, Konstantin E.; Rottman, James B.; Weiner, Howard L.; Hancock, Wayne W. (1)

CORPORATE SOURCE: (1) LeukoSite, Inc., 215 First Street, Cambridge, MA, 02142

USA

SOURCE: Proceedings of the National Academy of Sciences of the United States of America, (June 8, 1999) Vol. 96, No. 12, pp. 6873-6878.

ISSN: 0027-8424.

DOCUMENT TYPE: Article

LANGUAGE: English

SUMMARY LANGUAGE: English

TI CCR5+ and CXCR3+ T cells are increased in multiple sclerosis and their ligands MIP-1alpha and IP-10 are expressed in demyelinating brain lesions.

AU Balashov, Konstantin E.; Rottman, James B.; Weiner, Howard L.; Hancock, Wayne W. (1)

L13 ANSWER 61 OF 62 BIOSIS COPYRIGHT 2002 BIOLOGICAL ABSTRACTS INC.

ACCESSION NUMBER: 1999:55839 BIOSIS

DOCUMENT NUMBER: PREV199900055839

TITLE: Pivotal role of TARC, a CC chemokine, in bacteria-induced fulminant hepatic failure in mice.

AUTHOR(S): Yoneyama, Hiroyuki; Harada, Akihisa; Imai, Toshio; Baba, Masataka; Yoshie, Osamu; Zhang, Yi; Higashi, Hidemitsu;

Murai, Masako; Asakura, Hitoshi; Matsushima, Kouji (1)  
CORPORATE SOURCE: (1) Dep. Molecular Preventive Med., Sch. Med., Univ.  
Tokyo,  
7-3-1 Hongo, Bunkyo, Tokyo 113-0033 Japan  
SOURCE: Journal of Clinical Investigation, (Dec. 1, 1998) Vol.  
102,  
No. 11, pp. 1933-1941.  
ISSN: 0021-9738.  
DOCUMENT TYPE: Article  
LANGUAGE: English  
TI Pivotal role of TARC, a CC chemokine, in bacteria-induced fulminant  
hepatic failure in mice.  
AU Yoneyama, Hiroyuki; Harada, Akihisa; Imai, Toshio; Baba, Masataka;  
Yoshie,  
Osamu; Zhang, Yi; Higashi, Hidemitsu; Murai, Masako; Asakura, Hitoshi;  
Matsushima, Kouji (1)

L13 ANSWER 62 OF 62 BIOSIS COPYRIGHT 2002 BIOLOGICAL ABSTRACTS INC.  
ACCESSION NUMBER: 1998:71905 BIOSIS  
DOCUMENT NUMBER: PREV199800071905  
TITLE: RANTES and MIP-1alpha activate Stats in T cells.  
AUTHOR(S): Wong, Mark; Fish, Eleanor N. (1)  
CORPORATE SOURCE: (1) Dep. Med. Genetics Microbiol., Univ. Toronto, Rm. 73,  
FitzGerald Bldg., 150 College St., Toronto, ON M5S 3E2  
Canada  
SOURCE: Journal of Biological Chemistry, (Jan. 2, 1998) Vol. 273,  
No. 1, pp. 309-314.  
ISSN: 0021-9258.  
DOCUMENT TYPE: Article  
LANGUAGE: English  
TI RANTES and MIP-1alpha activate Stats in T cells.  
AU Wong, Mark; Fish, Eleanor N. (1)